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Cortical spreading depression (CSD) is a transient propagating wave of neuronal 
and glial excitation, followed by depression, which is implicated in migraine, 
traumatic brain injury (TBI) and stroke. Yet mechanisms of these diseases 
associated with CSD are not fully understood. The transcription factor, repressor 
element-1 silencing factor (REST), plays a critical role in the processes of central 
nervous system (CNS) and REST binding to MIR137 internal promoter can be 
reduced by multiple CSD events. The first objective of this project was to explore if 
REST signalling is involved in CSD. CSD was induced by KCl and in vivo 
electrophysiology was used for recording CSD. Polymerase chain reaction (PCR) 
was applied for measuring gene expression levels. The results showed that multiple 
CSD events did not alter gene expression of REST and its truncated isoform 
REST4 in cortices of rats, although a slight but insignificant up-regulation of 
REST4 was observed. Interestingly, there was a significant reduction in NR2A 
coding gene Grin2a in the ipsilateral cortices of rats at 24 hours after multiple CSD. 
Using qPCR and western blot methods, this project further examined whether 
multiple CSD events would induce the expression of α2, the major subunit of 
gamma-aminobutyric acid A (GABAA) receptor and its coding gene. The results 
showed that both the mRNA and protein level of GABAA α2 was not altered at 3 
and 24 hours post multiple CSD, although an elevation trend of GABAA α2 protein 
level was observed. Collectively, due to small sample size, these data did not 
support the role of REST in CSD however, it would worth further investigation by 
increasing sample number to four for statistical significance. 
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Given that N-methyl-D-aspartate (NMDA) receptor plays a key role in CSD 
genesis and propagation and NMDA-receptor mediated currents and glutamate 
release can be reduced by blockade of P2X7 receptor (P2X7R); whilst inhibition of 
P2X7R channel and pore formation reduces CSD susceptibility in rats; the 2nd part 
of my project aims to study the role of C-terminal domain of P2X7R in CSD using 
an anti-P2X7R antibody. CSD was induced by KCl and was recorded using 
intrinsic optical imaging in vitro and electrophysiology method in vivo.  The 
results showed that A740003, which antagonizes the P2X7R channel and pore 
complex, suppressed CSD with a marked prolongation of CSD latency and a 
reduced magnitude in the mouse brain slice. Consistently, the anti-P2X7R antibody 
also suppressed the occurrence of CSD in the mouse brain slice and in rats. Further 
q-PCR analysis showed that the CSD-induced gene expression of key 
neuroinflammatory factors, tumor necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β) was not altered by the antibody. These data demonstrate that this 
anti-P2X7R antibody is capable of suppressing CSD and does not alter gene 
expression of TNF-α and IL-1β immediately post CSD. It is necessary to clarify the 
role of C-terminal domain of P2X7R in CSD by expressing a C-terminal truncated 
variant of P2X7R in the P2rx7 gene deficient rats/mice in future. 
In summary, this study demonstrated that multiple CSD events does not alter REST 
gene expression but can induce a slight but insignificant up-regulation of REST4 in 
ipsilateral cerebral cortices of rats. Further work by increasing sample number is 
necessary to confirm REST4 implications to TBI and stroke. The fact that the 
anti-P2X7R antibody suppresses CSD suggests a possible role of P2X7R in CSD 
involving the C-terminal domain, however, further studies using C-terminal domain 
knockout animals will help to elucidate the contribution of this domain to CSD.  
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Brief process of my PhD project 
The original aim of this thesis was to explore the role of miR-137 in migraine aura 
pathogenesis. The effect of silencing miR-137 was first examined on CSD using 
miR-137 antagomir. I had spent ~6 months to optimise the concentration and 
incubation time of miR-137 antagomir for silencing miR-137, however, the 
experiments were not successful because this antagomir and other relevant 
reagents/kits may lost their efficiency due to inappropriate storage and delivery 
resulting from the long-term custom issues encountered. Nevertheless, through this 
process, I have gained relevant background in MIR137 and laboratory techniques 
such as cell culture, transfection and PCR techniques. As a result, part of 
experimental data was included in this thesis that greatly helped my PhD training. 
Due to above reasons, the first part of my thesis shifted to REST signaling 
pathways in CSD that is relevant to MIR137 from the start of my year 2 PhD 
training. As the P2X7R project was developed at the same time whilst formulating 
the REST project, this thesis has two main topics on REST and P2X7R that are 











1.1 Cortical spreading depression 
Cortical spreading depression (CSD) is a slowly propagating wave of neuronal and 
glial depolarization across the brain surface at a slow speed of approximate 3 
mm/minute. It was firstly described as a new propagating and reversible 
electrophysiological phenomenon in the brain surface of rabbits by Leao in the 
1940s (Leao, 1944a, Leao, 1944b). CSD is accompanied by a transient negative 
direct current (DC) potential change of the electroencephalograph (EEG) depressed 
cortical surface (Leao, 1947). CSD can occur in nearly all cortical regions and is 
associated with shrinkage of the extracellular space, redistribution of ions (Hansen 
and Zeuthen, 1981), increased brain energy metabolism (Lauritzen et al., 2011), 
dilation and constriction of pial vessels (Leao, 1944a, Leao, 1947).  
1.1.1 Clinical relevance of CSD 
A large number of studies support the involvement of CSD in a range of 
neurological disorders. A single CSD is believed to be the putative cause of 
migraine aura and multiple CSD can cause secondary neuronal damage post 
traumatic brain injury (TBI) and stroke (Lauritzen, 1994, Somjen et al., 1990, 
Sunami et al., 1989, Gorji, 2001, Dreier and Reiffurth, 2015, Rogatsky et al., 1996, 
Strong et al., 2002). On the other hand, the preconditioning of CSD may also have 
neuroprotective role to subsequent ischemic insult (Shen et al., 2016, Shen et al., 
2017).  
1.1.1.1 CSD is putative cause of migraine aura 
Migraine is a disabling neurovascular disorder characterized by recurrent unilateral 
headache that is moderate to severe pain intensity with duration from hours to 2-3 
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days. Some migraine patients experience an aura, which is usually visual, but can 
also be a sensory, motor or verbal disturbance that occurs before the headache 
begins. Despite the fact that migraine affects approximately 10% of the population 
worldwide and causes marked disability, it remains under diagnosed and under 
treated.  
A variety of experimental and clinical studies have demonstrated that a single CSD 
is the electrophysiological substrate of migraine aura and a trigger for headache 
(Lauritzen, 1994, Lauritzen, 2001, Hadjikhani et al., 2001, Ayata, 2010, Smith et 
al., 2006). A number of messengers are released post CSD to sensitize or activate 
pain-signalling pathways. These messengers mainly include adenosine 
5’-triphosphate  (ATP) (Schock et al., 2007), nitric oxide (NO) (Colonna et al., 
1997, Obrenovitch et al., 2002), calcitonin gene-related peptide (CGRP) (Tozzi et 
al., 2012, Wang et al., 2016b), high mobility group protein B1 (Karatas et al., 2013), 
and gamma-aminobutyric acid (GABA) (Rodrigues et al., 1988), which are known 
to play important roles in CSD. CSD is also capable of activating trigeminal 
nociceptive neurons, as evidenced by electrophysiological recording of neurons in 
the brainstem and trigeminal ganglion (Zhang et al., 2010, Zhang et al., 2011), as 
well as promoting the pain marker, c-Fos levels by immunohistological labeling in 
the brainstem (Bolay et al., 2002). However, how CSD causes migraine headache 
still remains obscure and the contribution of some key receptors, such as 
ATP-gated P2X7 receptors, need to be further investigated. 
Another supporting evidence that CSD is the underlying cause of migraine aura is 
the discovery of similar changes in cerebral blood flow (CBF) between the two 
neurological abnormalities. There is a long lasting reduction in CBF of brain post 
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CSD (Lauritzen, 1984), and a similar change was observed in the visual area in the 
cortex of migraine patient suffering visual aura, with perfusion-weighted imaging 
(Cutrer et al., 2000). Moreover, CSD-like neuro-electric events are observed in the 
occipital cortex of patients during both spontaneous or visual stimuli triggered 
migraine aura (Bowyer et al., 2001). Additionally, CO2/O2 induced hypercapnia 
shows suppressive effects on both CSD propagation and migraine attacks 
(Gardner-Medwin, 1981).  
Causative genes for migraine were discovered to be involved in defects in calcium 
or sodium channels, or in the Na/K-ATPase (Barrett et al., 2008). The genetic form 
of migraine, identified as familial hemiplegic migraine (FHM), is a rare 
autosomal-dominant subtype of migraine with aura with strong penetrance. Mouse 
models with mutations of migraine-related genes show facilitation in the induction 
and propagation of CSD waves, supporting CSD as the underlying mechanism 
involved in the functional consequences of these mutations associated with 
migraine aura (van den Maagdenberg et al., 2004, Leo et al., 2011, Hansen, 2010, 
Unekawa et al., 2017). 
A range of studies show that many known and putative therapies for migraine 
prevention reduce the tissue susceptibility to CSD. One study found that the 
frequency of multiple CSD triggered by continuous stimulation can be reduced by 
chronic treatment with migraine preventive medications, such as valproate, 
topiramate, propranolol, methysergide and amitriptyline (Ayata et al., 2006). 
Additionally, acute treatment of topiramate was reported to block CSD (Akerman 
and Goadsby, 2005, Unekawa et al., 2012). Similar inhibition on CSD was also 
observed by the acute treatment of an acid-sensing ion channel blocker amiloride, a 
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potential migraine preventive therapy (Holland et al., 2012). These studies 
demonstrate the capacity to suppress CSD as a common, but not necessarily 
universal feature of migraine preventive therapies. 
Consistent with significant higher prevalence of migraine in women than men, 
CSD in rodents shows an increased propensity in female than male sex. Female 
mice have been reported to have a reduced threshold for CSD induction (Brennan 
et al., 2007b). Also, an increased susceptibility to CSD was observed in female 
transgenic mice expressing migraine-associated genes compared with male 
counterparts (Brennan et al., 2013, Eikermann-Haerter et al., 2009b). These may be 
caused by sex hormone: exposure to oestrogen shows higher CSD susceptibility, 
whereas exposure to testosterone shows opposite effects (Eikermann-Haerter et al., 
2009b, Eikermann-Haerter et al., 2009a).  
Collectively, CSD has become a useful tool for studying migraine aura mechanism 
and anti-CSD drugs may have potential use for migraine aura prevention. However, 
in spite of the above, there are still some arguments against the role of CSD in 
migraine aura (Borgdorff, 2018). For example, water diffusion caused cell swelling 
in CSD was not observed during or after migraine aura (Gorji, 2001, Hansen and 
Olsen, 1980, Cutrer et al., 1998); cerebral metabolism in experimental rat CSD is 
enhanced (Piilgaard and Lauritzen, 2009), while it remains unchanged in some 
migraineurs with aura (Jafarian et al., 2010). 
1.1.1.2 CSD and stroke, traumatic brain injury 
Whilst single CSD is a putative cause of migraine aura, multiple CSD events are 
associated with stroke and TBI (Somjen et al., 1990, Sunami et al., 1989). Stroke 
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occurs when the blood supply to the brain is suddenly either blocked or ruptured, 
leading to insufficient supply of oxygen and nutrients to the brain and causing brain 
cell death. Studies show that spontaneous CSD-like depolarization was observed in 
the surrounding of focal ischemic lesions (Hossmann, 1996, Dreier, 2011). 
Moreover, the spontaneous CSD surrounding the ischemic core promotes the 
progression of lesion and worsens the outcome in models of stroke (Hossmann, 
1996). The extent of ischemic damage is closely correlated with CSD number in 
focal ischemia in rats (Tatlisumak et al., 2000). The N-methyl-D-aspartate (NMDA) 
antagonists, which suppress CSD initiation and propagation, reduce the volume of 
the ischemic lesion (Tatlisumak et al., 2000, Gill et al., 1992, Iijima et al., 1992).  
In addition to ischemic stroke, multiple CSD is also implicated in TBI (Strong et al., 
2002, Rogatsky et al., 1996). TBI happens when an external force, such as bump, 
jolt and blow, injures the brain. The spontaneous occurrence of CSD in 50% to 60% 
of patients has been observed by different monitoring techniques (Mayevsky et al., 
1996, Strong et al., 2002, Fabricius et al., 2006, Hartings et al., 2009). CSD-like 
DC shifts are detected after cortical cold injury, fluid percussion injury and 
penetrating ballistic brain injury (Williams et al., 2005, Hermann et al., 1999, 
Rogatsky et al., 2003). Severe physical injuries on the cortical tissue could become 
initiation regions for CSD and seizures (Fabricius et al., 2008). The neuronal 
excitability in and around the injury area post TBI is affected with a marked 
increase of local glutamate signalling (Goodrich et al., 2013, Hosseini-Zare et al., 
2017). The elevated glutamate level post TBI may contribute to the initiation of 
CSD. 
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1.1.2 CSD models and experimental approaches 
Both whole-system and reductionist models are required for the comprehensive 
investigation of CSD. These in vitro and in vivo models can provide 
complementary approaches to study underlying ionic, neurochemical and cellular 
mechanisms.  
In vitro models, such as chick retina (RSD) (Maranhao-Filho et al., 1997, Skelton 
et al., 1983, Dahlem et al., 2003) and brain slice (Dietz et al., 2008, Tang et al., 
2014), can provide high throughput and have been widely applied to address the 
effects of pharmacological agents on CSD. Unlike conventional slices, the isolated 
retina is a complete biological circuit. Its characteristics are similar with those of 
the brain slice. The size and thickness of chick retina are comparable to brain slices. 
One key advantage of in vitro model is that it could complete control the 
oxygenation, temperature, pH and pharmacological environment. In vitro studies 
bypass the blood-brain barrier (BBB) and eliminate pharmacokinetic, 
hemodynamic, systemic physiological and anesthesia-related factors. But due to 
exposure to hypoxia, lack of vasculature and trauma during tissue preparation, the 
metabolism and tissue oxygenation differ from these in in vivo models (Galeffi et 
al., 2011, Turner et al., 2007).  
Most in vivo studies are carried out on rodents and limited on cerebral cortex due to 
ease of access. A range of species are also applied in vivo from monkeys to pigeons 
and cats (Shima et al., 1963, Van Harreveld et al., 1956). There is a fair degree of 
interspecies variability in CSD susceptibility. Although it has not been 
systematically studied the species difference in CSD susceptibility, usually, 
gyrencephalic species are less susceptible to CSD than lissencephalic species. The 
 18 
determinants for the species differences in CSD susceptibility have not been fully 
studied. The increasing ratio of astrocyte/neuron in higher species is usually cited 
as a potential cause (Tower and Young, 1973, Gardner-Medwin, 1981), but it 
seems not the only determinant. In vivo CSD models are able to provide important 
physiological information on the dynamic implications of metabolism and 
neurovascular coupling.  
CSD can be evoked by a variety of chemical (e.g. high extracellular K+, Ca2+ 
channel openers, Na+ channel activators or agonist of glutamate receptor), direct 
electrical (e.g. cathodal stimulation), and mechanical depolarizing stimulation (e.g. 
puncture of cortex) on one point of cortical surface. KCl is usually the first choice 
for concentration threshold and frequency, and is more consistent than electrical 
threshold, which usually shows large variability due to irregularities at the contact 
between electrode and tissue, such as drying and bleeding. Mechanical stimulation, 
such as needle prick, is usually less reproducible and more injurious. The CSD 
threshold is hard to be determined under mechanical stimulation. Thus the CSD 
susceptibility is an “all or none” response after being triggered by a single 
mechanical stimulus (Akerman and Goadsby, 2005). There are also some other 
ways to evoke CSD, such as focal cerebral ischemia and high-frequency afferent 
pathway (Nozari et al., 2010), but they are not suitable for experimental high 
throughput. 
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1.1.3 Key features of CSD 
1.1.3.1 Changes in cellular ionic homeostasis 
The initial depolarization of CSD wave is associated with a massive translocation 
of ions, such as a reduction in extracellular Na+ and Ca2+, a large increase in 
extracellular K+, and a significant redistribution of other ions including Cl-, Mg2+ 
and Zn2+ (Hansen and Zeuthen, 1981, Dietz et al., 2008). The changes in cellular 
ionic homeostasis usually last one to two minutes and can be spontaneously 
reversed (Kraig and Nicholson, 1978, Martins-Ferreira et al., 2000). They are 
accompanied with water entry into cells, resulting in cell swelling and therefore a 
reduction of the volume of the extracellular compartment (Martins-Ferreira et al., 
2000). The DC potential changes of CSD waves show greater correlation with 
astrocyte membrane potential than neuronal membrane potential (Sugaya et al., 
1975), demonstrating the critical role of astrocytes in the physiological process of 
CSD. Astrocytes act as a sink for extracellular K+ and a buffer for the ionic changes 
for initiating and propagating CSD. Ca2+ waves of astrocytes are associated with 
the active release of glutamate, ATP and K+ (Haydon and Carmignoto, 2006).  
1.1.3.2 Changes in brain energy metabolism 
CSD imposes a large energy demand on brain tissue both under physiological 
condition and after brain injury (Dreier, 2011, Lauritzen et al., 2011), evidenced by 
increased oxygen consumption (Mayevsky and Weiss, 1991), glucose utilization 
(Hashemi et al., 2009) and lactate production (Kraig et al., 1985, Feuerstein et al., 
2010) during CSD. The restoration of ion homeostasis is achieved by activation of 
transmembrane adenosine triphosphase (ATPase) ion pumps, which utilizes ATP to 
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transport K+ into, Na+ out of the cells. The increased ATP hydrolysis can in turn 
stimulate glycolysis and oxidative phosphorylation with high consumption of 
cellular oxygen. The early breakdown of glycogen is the first process to contribute 
to ATP formation during increased energy demand. Neuronal ATP production 
depends on increased glycolysis, followed by increased oxidation of glucose 
(Feuerstein et al., 2016).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
1.1.3.3 Release of neurotransmitters and regulation of their receptors 
CSD is associated with an efflux of a range of neurotransmitters, which mainly 
include glutamate, acetylcholine, dopamine, serotonin (5-HT), CGRP, NO, GABA 
(Rodrigues et al., 1988, Fabricius et al., 1993, Read et al., 1997, Storer and 
Goadsby, 1997, Yavich and Ylinen, 2005, Shi et al., 2010). Release of these 
transmitters and activation of their receptors play vital roles in the remarkable brain 
alterations. The synchronous release of neurotransmitters is related with dramatic 
changes in intracellular and extracellular ions during CSD, therefore it is proposed 
to have a vital role in CSD initiation. For example, extracellular glutamate is 
increased during CSD (Zilkha et al., 1995, Basarsky et al., 1999) and the activation 
of the glutamate-NMDA-receptor is required for CSD genesis (Marrannes et al., 
1988). Not only excitatory NMDA receptor, but also inhibitory neurotransmitter 
receptors mediate CSD genesis and propagation. Topiramate, a GABA-receptor 
agonist, functions to elevate CSD threshold (Green et al., 2013) and reduce CSD 
frequency and propagation (Unekawa et al., 2012). In addition, blockade of CGRP 
receptor by antagonist suppresses CSD propagation in chick retina (Wang et al., 
2016a). The genetic deletion of ATP-gated P2X7 receptor reduces the cerebral 
cortex susceptibility to CSD and suppresses subsequent activation of the 
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trigeminovascular system (Chen et al., 2017b). All above evidences indicate that 
neurotransmitters and their receptors may play crucial roles in modulating the 
transduction events of intracellular signalling, as well as the formation and 
alteration of neural circuit during CSD processes.                                         
1.1.3.4 Changes in cerebral blood flow 
CSD is also characterized by a complex pattern of alterations in regional cerebral 
blood flow (CBF). The changes of regional CBF related with CSD show a marked 
hyperemia under normal condition (Fabricius et al., 1995, Read et al., 1997, Gold et 
al., 1998, Hashimoto et al., 2000), followed by a sustained hypoperfusion in 
cortical region (Shimazawa and Hara, 1996, Lauritzen, 1984). In some studies, an 
initial brief hypoperfusion is observed prior to the hyperemia associated with CSD 
waves (Fabricius et al., 1995, Ayata and Lauritzen, 2015). While no changes of 
regional CBF are observed in subcortical region by either multiple or single CSD at 
any time (Kuge et al., 2000). 
The underlying mechanism of CSD associated hyperemia is unclear, but one 
possible mechanism may be associated with the release of vasoactive compounds, 
such as CGRP, glutamate, nitric oxide (NO), acetycholine (ACh) and cyclic GMP 
(Read et al., 1997, Read et al., 2001, Rodrigues and Martins-Ferreira, 1980, 
Basarsky et al., 1999, Wang et al., 2016a). Both topical and systemic 
administration of CGRP, a potent dilator of vessels, significantly elevates dural 
blood flow (Levy et al., 2005). Brian’s study also shows that CGRP may limit 
constriction of cerebral vessels induced by noradrenaline and contribute to 
dilatation during hypotension and CSD (Brian et al., 1996). Moreover, the inhibitor 
of CGRP receptor attenuates CSD-induced pial dilation (Colonna et al., 1994) and 
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CSD-associated hyperperfusion in rats (Reuter et al., 1998). Different with CGRP, 
endothelium-regulated dilation does not contribute to CSD-induced hyperemia in 
rats (Shimizu et al., 2002). 
Notably, the vascular response induced by CSD may proceed independently 
through its vascular conduction. This is evidenced by the following findings: (i) the 
propagation of arteriole dilation is at a faster speed than the CSD wave on the 
cortical surface and spread into the region not reached by CSD wave (Brennan et 
al., 2007a); (ii) spontaneous CBF changes can be observed in the contralateral 
cerebral cortex post multiple CSD waves (Hosseinzadeh-Nik et al., 2016). 
Moreover, the vascular response seems not essential for the process of spreading 
depression waves, as the spreading depression can proceed in the absence of the 
vascular response in isolated chick retina (Dahlem and Muller, 2000) and brain 
slice (Dietz et al., 2008).  
1.1.3.5 Gene changes 
CSD regulates a large range of genes expression clustered in following functional 
groups: (i) vasodilation, e.g. the gene expression of vasodilator atrial natriuretic 
peptide and CGRP are up-regulated post CSD, while the vasoconstrictor 
neuropeptide Y is reduced (Choudhuri et al., 2002, Wiggins et al., 2003, Wang et 
al., 2016a); (ii) inflammation, e.g. both tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) mRNA level are induced by CSD (Jander et al., 2001); (iii) 
pain, e.g. the neural maker of pain, c-fos mRNA level is significantly up-regulated 
post CSD (Tepe et al., 2015, Herrera and Robertson, 1990), (iv) oxidative stress, 
e.g. glutathione-S-transferase-5 gene expression is down-regulated by CSD, while 
major prion protein is up- regulated (Choudhuri et al., 2002) (v) neuroprotection, 
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e.g. mRNA level of brain-derived neurotrophic factor (BDNF) and heat shock 
protein 70 are both up-regulated after CSD (Kokaia et al., 1993, Medhurst et al., 
2000, Rangel et al., 2001, Faraguna et al., 2010). Some of these gene changes 
underlie the pathological process of CSD-related disease, while some are associated 
with increased adaptive tolerance induced by CSD preconditioning to further brain 
injury. 
1.2 The REST signalling pathway 
A range of gene expression is altered in response to CSD stimuli as mentioned 
above. This is modified by the changes in transcriptional repressors or enhancers, 
subsequently influencing neuronal phenotype and behavior. Repressor element-1 
silencing factor (REST), also named neuron restrictive silencing factor (NRSF), is 
one of such transcriptional regulator, which is widely known due to its function in 
modulating the expression of neuron-specific genes. REST is identified in 1995 as 
a zinc finger protein that binds to a conserved 21 bp consensus sequence termed 
neuron restrictive silencing element (NRSE) or repressor element 1 (RE1) 
(Schoenherr and Anderson, 1995, Chong et al., 1995).  
1.2.1 Regulation of REST expression 
High level of REST is expressed in non-neuronal cells in mature tissue, while much 
lower level of its expression is found in specific neuronal tissue types, 
demonstrating that the expression of REST is highly dependent on cellular types 
and physiological conditions. Moreover, increased expression of REST is observed 
in different regions of adult brains, such as cerebral cortex and hippocampus, in 
response to neuronal activation by treatment with cocaine or the glutamate 
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analogue kainic acid (Palm et al., 1998, Spencer et al., 2006, Chandrasekar and 
Dreyer, 2009).  
REST binds to its target sequences via its zinc-finger DNA binding domain, 
whereas its repressor activity is mediated by recruitment of co-repressor complexes 
to its either N-terminal or C-terminal repressor domains (Tapia-Ramirez et al., 
1997, Naruse et al., 1999). Its N-terminal can interact with mammalian homologue 
of yeast Sin3A (mSin3A) (Naruse et al., 1999, Huang et al., 1999, Grimes et al., 
2000), a transcriptional co-repressor, mediating active gene repression via its 
recruitment of histone deacetylases 1/2 (HDAC1/2) (Ballas and Mandel, 2005), 
while its C-terminal interacts with co-factor for REST, potentiating long-term gene 
silencing (Lunyak et al., 2002, Andres et al., 1999). Other chromatin modifying 
complex involved in gene repression are also recruited by cofactor for REST, such 
as HDACs, the histone methyltransferase C9a and methyl-CpG binding protein 
MeCP2 (Lunyak et al., 2002, Battaglioli et al., 2002, Roopra et al., 2004, Lee et al., 
2005), enabling REST to orchestrate a set of epigenetic signatures which change 
the chromatin structure to a condensed heterochromatin state. The co-repressor 
complex varies depending on promoter sequences and cell types, suggesting that 
REST can mediate both long-term silencing and transient repression.  
REST is more complex than its initial role of transcriptional repression within CNS. 
It may also act as a transcriptional activator or enhancer depending on isoform 
usage, genomic location, cellular types and associated co-factor binding assembly 
at the target sequence (Kallunki et al., 1998, Coulson et al., 1999, Coulson et al., 
2000, Yoo et al., 2001, Kim et al., 2008). REST has several isoforms generated via 
alternative splicing. One of the most well studied is REST4, which is a truncated 
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protein lacking C-terminal domain. This isoform arises via coding of an alternative 
N exon and produces a premature stop codon (Figure 1.1 A) (Palm et al., 1998). 
REST4 is especially expressed in neurons or certain cancer cells (Coulson et al., 
2000, Palm et al., 1998, Wagoner et al., 2010) and antagonise the effects of the full 
length REST (Figure 1.1 B) (Coulson et al., 2000, Shimojo et al., 1999). 
 
Figure 1.1 Structure and function of REST and REST4. (A) The structural organisation 
and alternative transcripts for REST and REST4 (Palm et al., 1998). Exons are shown as 
boxes and introns as lines. The respective sizes of introns are shown as above numbers. 
Vertical bars within exons indicate zinc finger motifs. Exon numbers in roman characters 
(I-VI) are shown below the respective exons. An alternative exon N introduces a premature 
stop codon, giving rise to the truncated protein variant REST4, which lacks four of the 
mine zinc fingers. (B) Regulation of REST/REST4 on the expression of target genes. 
1.2.2 The REST signalling in disease conditions 
REST signalling is implicated in variety of neurological disorders, such as epilepsy, 
ischemic stroke, schizophrenia, Alzheimer (Spencer et al., 2006, Warburton et al., 
2015, Loe-Mie et al., 2010, Noh et al., 2012, Calderone et al., 2003, Hu et al., 2011, 
Lu et al., 2014). Up-regulation of both REST and REST4 are observed in rat 
hippocampal neurons in both in vitro and in vivo epilepsy models (Spencer et al., 
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2006). This increase correlated with increased of mRNA level for the 
proconvulsant gene TAC1 (Spencer et al., 2006). Additionally, conditional deletion 
of REST in mouse forebrain neurons exhibited dramatically accelerated seizure 
progression in a epilepsy model, suggesting that REST may function as a repressor 
of epileptogenesis (Hu et al., 2011). Ischemic insults promote REST binding to 
miR-132 promoter and silencing miR-132 expression, whilst overexpression of 
miR-132 afforded protection against ischemia-induced neuronal death, suggesting a 
role of REST in the neuronal death associated with global ischemia (Hwang et al., 
2014). Also, distinct isoforms of REST mediate differential expression of miR137 
parent transcript, which is identified as a candidate gene of schizophrenia 
(Warburton et al., 2015). Collectively, these findings highlight the importance of 
REST-mediated regulation in diverse neurological disorder diseases. Yet it is 
unknown if REST and its isoforms REST4 play important roles in the context of 
CSD-linked progression of TBI, stroke and migraine aura. 
REST has an overlap role with microRNA as a negative regulator of target genes. 
In mammals, approximately 70% microRNAs are detected in primary neuronal 
cultures or in the brain (Cao et al., 2006) with a small set of brain specific and 
enriched microRNA (Landgraf et al., 2007). MicroRNAs are a large family of 
single-stranded non-coding RNAs of approximately 18-25 nucleotides in length, 
which are highly conserved through evolution (Bartel, 2004). Mature microRNA 
guides RNA-induced silencing complex (RISC) to the 3’-untranslated region of the 
target mRNAs for RNA-interference based gene regulation, which is thought to 
occur through several different mechanisms (Vimalraj and Selvamurugan, 
2013): (A) blocking of cap recognition by inhibition of joining of the large 
ribosomal subunit and inhibition of initiation factor of translation by Ago 
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protein of RISC; (B) deadenylation and degradation of target mRNA; (C) RISC 
induce proteolysis to degrade the newly synthesized polypeptides; (D) 
premature termination of ribosomes. 
Comparative sequence analysis shows that REST and its co-repressors coREST and 
MeCP2 could target several brain-enriched microRNAs, such as microRNA137 
(miR137) (Soldati et al., 2013, Warburton et al., 2015). In a mouse cell line model 
of Huntington’s disease, knock-down of REST up-regulates several microRNAs, 
including miR137, which is validated as a target of REST by chromatin 
immunoprecipitation (ChIP) (Soldati et al., 2013). Also in a human cell line 
SH-SY5Y, MIR137 gene is validated as a REST target (Warburton et al., 2015). 
Additionally, in a mouse model of Rett syndrome, miR137 expression is shown to 
be regulated by MeCP2, a core member of the REST-complex (Szulwach et al., 
2010). Notably, the NR2A subunit of NMDA receptor coding gene, Grin2a, is one 
of miR137 target genes. Reduced miR137 level in the brain tissue correlated with 
increased Grin2a level in a rat stroke model (Zhao et al., 2013). Additionally, the 
NR2A subunit of NMDA receptor contributes to CSD genesis and propagation 
(Peeters et al., 2007, Bu et al., 2016a).  
Collectively, it is likely that REST, MIR137 and their target genes may also have a 
role in CSD associated neurological disease. Yet whether REST plays an important 
role in the context of CSD-linked progression of migraine and TBI has not been 
elucidated. 
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1.3 Net-work of NMDA receptor and P2X7R in central nervous system 
1.3.1 NMDA receptor signalling  
Glutamate is one of the most important excitatory neurotransmitters that contribute 
to CSD by acting on its receptors, one of which is NMDA ionotropic receptors that 
are widely expressed in CNS. 
NMDA receptors are tetramers, which consist of different subunits: 2 mandatory 
NR1 and 2 NR2 (NR2A, 2B, 2C and 2D) and/or one NR3 (two isoforms, A and B). 
The assembly of functional NMDA receptor is usually formed by a combination of 
two mandatory NR1 subunits, two NR2 subunits and/or one NR3 subunit (Sasaki et 
al., 2002, Flores-Soto et al., 2012). The NR1 subunits are essential for receptor 
functionality, and the NR2 subunits determine the biophysical property of this 
channel conductance (Rambhadran et al., 2010). The NR2A-containing receptors 
typically mediate synaptic transmission, whereas the receptors with NR2B subunit 
are mainly expressed extrasynaptically and in astrocytes (Sanz-Clemente et al., 
2013, Dzamba et al., 2013). The activation of NMDA receptors requires membrane 
depolarization, which can remove Mg2+ present in the ion channel pore following 
the binding of ligands, such as glutamate and glycine (or D-serine).  
NMDA receptors have vital roles in the CNS development and the processes 
underlying memory, learning and neuroplasticity. Consequently, altered NMDA 
receptor expression levels or abnormal function of NMDA receptors are implicated 
in a range of pathological conditions and neurological disorders. Therefore, NMDA 
receptor is a potential therapeutic target due to its wide involvement in many brain 
disorders, such as migraine, stroke, head trauma, ischemia, neuropathic pain, 
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epilepsy, Alzheimer’s and Parkinson’s disease. (Kemp and McKernan, 2002, 
Jansen and Dannhardt, 2003, Chazot, 2004, Farlow, 2004, Wood, 2005, Cai, 2006, 
Missale et al., 2006, Brown and Krupp, 2006). NMDA receptor plays a vital role in 
excitotoxicity. During this process, excessive release of glutamate leads to 
over-activation of NMDA receptors and accumulation of intracellular calcium, 
which usually occurs during cerebral ischemia following brain trauma or stroke and 
in neurodegenerative disorders, such as schizophrenia and Parkinson (Paoletti and 
Neyton, 2007). Numerous evidences demonstrate the critical role of NMDA 
receptors in CSD mechanisms. MK801, a non-competitive inhibitor of NMDA 
receptor, appears to be one of the most effective anti-CSD compounds in rats 
(Marrannes et al., 1988, Peeters et al., 2007). However, NMDA receptor 
antagonists developed to treat these brain disorders failed in clinical trials due to 
unacceptable side effects, such as hallucinations, anesthesia, ataxia and memory 
deficits (Kristensen et al., 1992, Rockstroh et al., 1996, Huang et al., 2014). In this 
case, disruption of specific NMDA involved interaction may trigger an intense 
interest to develop new therapeutic drug targets with fewer side effects. Notably, 
inhibition of specific NR2A or NR2B subunit of NMDA receptor can suppress 
CSD, demonstrating the significant contribution of these two subunits in CSD 
generation and propagation (Shatillo et al., 2015a, Bu et al., 2016a, Wang et al., 
2012) and indicating such subtype selective drugs might have potential use for 
migraine prevention with a better safety profile. 
1.3.2 P2X7 receptor signalling 
It is well known that the activation of P2X7 receptors (P2X7R) results in increased 
release of glutamate from cerebrocortical nerve terminals and hippocampal slices 
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(Sperlagh et al., 2002, Alloisio et al., 2008, Csolle et al., 2013). The 
NMDA-receptor mediated currents and glutamate release are reduced by both 
pharmacological blockade and genetic deletion of P2X7R mice (Kovanyi et al., 
2016). The P2X7R belongs to the purinergic P2X family of ATP-gated cation 
channels (Figure 1.2). Currently, seven different P2X subtypes have been identified, 
P2X1-7 (Burnstock, 2006). P2X7R is a distinct subtype among other subforms of 
P2X receptors because of its following characters: (i) its monomeric subunit is the 
largest one and is characterized by a relative long intracellular carboxyl (C) – 
terminal tail, which plays a critical role in regulation of channel activity and 
P2X7R signal transduction (Kim et al., 2001, North, 2002); (ii) much higher ATP 
concentration is required for the activation of P2X7R, than other P2X subtypes; (iii) 
it has an essential role in inflammatory cascades. P2X7R is widely expressed in 
both central and peripheral nervous systems throughout mammals (Sperlagh et al., 
2006), involving in various of physiological and pathological processes 
(Baroja-Mazo et al., 2013).  
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Figure 1.2 Structure and signaling function of P2X7R. (A) P2X7R is a trimer. Each 
subunit possesses two transmembrane domains (TM1 and TM2), intracellular amino and 
carboxyl termini and a large extracellular loop with ATP binding site. (B) Brief stimulation 
of P2X7R by ATP (< 10 s) lead to rapid and reversible channel opening, allowing the 
passage of K+, Na+ and Ca2+, across the plasma membrane. (C) Continued 
stimulation by ATP results in the formation of a larger plasma membrane pore, 
which is permeable to molecules up to 900 Da, such as glutamate. Figure adapted 
from (Skaper et al., 2009). 
Stimulation of P2X receptor by ATP opens the channel and allows the passage of 
small cations, such as K+, Na+ and Ca2+, across the plasma membrane (Surprenant 
et al., 1996, Chessell et al., 1998, Kawate et al., 2011). P2X7R activation causes 
induction of cytosolic Ca2+ and reduction of intracellular K+ induces the activation 
of caspases-1 (Perregaux and Gabel, 1994, Ferrari et al., 1997, Kahlenberg and 
Dubyak, 2004, Perregaux and Gabel, 1998), which can further cause the release of 
pro-inflammatory cytokine IL-1β by activating IL-1β from its inactive form, pro- 
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IL-1β (Kahlenberg and Dubyak, 2004). Accumulation of IL-1β can trigger 
inflammatory cascades and induce other inflammatory mediators, such as tumor 
necrosis factor-alpha (TNF-α) (Woolf et al., 1997), nitric oxide synthase (NOS) 
(Kahlenberg and Dubyak, 2004), nuclear factor kappa-B (NF-κB) (Aga et al., 2002), 
cyclooxygenase-2 (COX-2) (Samad et al., 2001). Notably, activation of NF-κB in 
astrocytes can be promoted by pannexin 1 (Panx1) channel opening and caspase-1 
activation induced by CSD (Karatas et al., 2013). Additionally, a significant 
induction of pro-inflammatory factors, IL-1β and TNF-α, is observed post CSD 
(Jander et al., 2001). Collectively, above evidences demonstrate the potential 
contribution of P2X7R to CSD-induced inflammation cascades. 
Among all purinergic receptors, P2X7R shows functional linkage with Panx1 in 
many studies. Panx1 is a membrane channel and abundantly expressed in CNS of 
mammals in all cell types (neurons, astrocytes, microglia and oligodendrocytes). 
The synergistic activation of P2X7R and Panx1 is demonstrated in inflammation, 
calcium waves and apoptosis (Pelegrin, 2008). When activated, the P2X7R are 
highly permeable to calcium and increase the intracellular concentration of calcium, 
therefore activating Panx1 channels (Ma et al., 2009). Panx1, in turn, promote the 
release of ATP to the extracellular space, which re-activates the P2X7R as a 
positive loop. The reversible opening of P2X7R channels and the subsequent 
calcium influx into cells are associated with release of neurotransmitters, such as 
glutamate (Duan et al., 2003), GABA (Wang et al., 2002) and acetylcholine (Patti 
et al., 2006). All of these neurotransmitters are known to be released post CSD, 
indicating the potential involvement of P2X7R activation in CSD-related disorders. 
P2X7Rs have been efficacious in experimental epilepsy models (Henshall et al., 
2013, Jimenez-Pacheco et al., 2013), which may mechanistically share with 
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migraine (Davies and Panayiotopoulos, 2011, Rogawski, 2012). In fact, the critical 
role of P2X7R-Panx1 interaction in CSD is supported by a recent study that 
inhibition of P2X7R-Panx1 channel and pore formation reduces CSD susceptibility 
in rats (Chen et al., 2017b). Yet the underlying mechanism of P2X7R contribution 













The overall aim of this study is to improve our understanding on the 
pathophysiological mechanisms of neurological diseases associated with CSD by 
focusing on two factors: REST and P2X7R.  
The first part of this thesis was to explore the role of REST and MIR137 signalling 
in CSD. The second part of this thesis was to further understand the role of P2X7R 
in CSD.  








Materials and Methods 
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Multiple disciplinary methods were used for this study. CSD was induced by KCl 
both in vitro (chick retina and mouse brain slice) and in vivo (rat). Intrinsic optical 
signal (IOS) was applied in vitro (chapter 6) and electrophysiology method was 
applied in vivo for CSD recording (chapter 4, 5 & 6), PCR was applied for gene 
expression analysis (chapter 4, 5 & 6), western blot was applied for protein 
expression analysis (chapter 5). Cell culture was applied to optimise the 
concentration and incubation time of miR-137 antagomir, which functions to 
silencing miR-137 and was used to investigate the effects of silencing miR-137 on 




3.1 Animal work 
All animals were purchased from Shanghai SLAC Laboratory Animal Corporation 
Ltd and were housed in an animal unit of Soochow University for at least one-week 
before use. All animal procedures were approved by the Ethic Review Panels of 
Xi’an Jiaotong-Liverpool University and Soochow University and performed in 
accordance with the relevant national guideline.  
3.1.1 In vivo CSD induction and recording in rats 
In vivo work in rats was carried out for tissue collection to analyse how CSD would 
affect gene or protein expression (chapter 4, 5 & 6) and to investigate effects of 
specific antibodies on CSD propagation (chapter 6).  
3.1.1.1 Surgical preparation, CSD induction and recording 
Adult, male Sprague Dawley rats (280 -370 g, Shanghai SLAC Laboratory Animal 
Corporation Ltd) with food and water available ad libitum were used. Surgical 
procedures were described previously (Wang et al., 2003). Briefly, one recoding 
electrode was implanted into the rat under anaesthesia with isoflurane in O2:N2O 
(1:2, maintained at 37°C) at 3 mm anterior and 2 mm lateral to bregma 0.8-0.9 mm 
deep into the right cerebral cortex. A burr hole was also drilled with intact aura at 4 
mm posterior, 2 mm lateral to bregma at the same hemisphere for eliciting CSD 
with 3 M KCl (Figure 3.1 A). Throughout the experiment, the depth of anaesthesia 
was monitored and adjusted according to the EEG and through observation of the 
reflexes of the animal.  
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Both EEG signal and DC potential were derived from the Ag/AgCl electrode 
(Applied Neuroscience, London, UK) and the reference electrode (Applied 
Neuroscience, London, UK) placed under the scalp. EEG and DC signals were 
amplified using an AC/DC pre-amplifier (NL834, Neurolog System, Digitimer Ltd., 
Welwyn Garden City, UK) and recorded as reported previously (Wang et al., 2003). 
The alternating current component in the 1-30 Hz window provided the EEG 
(overall ×5000 amplification) and the 0-30 Hz window provided the extracellular 
DC potential (overall ×250 amplification). All the recorded variables were 
continuously digitised, displayed and recorded with Labview software (National 
Instruments, NI) via an analogue/digital-converter (USB6009, NI Instruments). 
CSD was recognized as a transient, negative shift on the extracellular DC potential 
(Figure 3.1 C). 
 40 
 
Figure 3.1 Induction of unilateral CSD in the rat ipsilateral cerebral cortex and 
representative traces in DC potential indicating CSD. A. Two bur holes were drilled 
on the right hemisphere of rat brain. KCl was applied onto the posterior hole with intact 
dura mater for CSD induction. An Ag/AgCl electrode was implanted into the anterior hole 
for CSD recording and a reference electrode placed under the scalp. Artificial cerebral 
spinal fluid (ACSF, 125 mM NaCl, 2.5 mM KCl, 1.18 mM MgCl2, 1.26 mM CaCl2; pH 
7.3), instead of KCl was used in sham group. B. In the intracerebroventricular (i.c.v.) 
based experiments, one bur hole drilled on the left hemisphere for ACSF or antibody 
i.c.v.; Two bur holes were drilled on the right: one bur hole with dura mater intact was 
used for CSD induction; the other bur hole was used for CSD recording through the 
Ag/AgCl electrode implanted into cerebral cortex. C. representative changes in the DC 
potential recorded indicating multiple CSD: area under the curve (AUC) was measured to 
determine CSD magnitude. CSD number and CSD latency were used to indicate the tissue 





3.1.1.2 In vivo protocol and tissue collection 
In order to analyse CSD effects on specific gene and protein expression, tissue was 
collected at different time points post multiple CSD. Five episodes of CSD with 40 
minute interval were induced at time points 24 hours and 72 hours post CSD. As 
some gene changes were transient, to explore the immediately effects of multiple 
CSD, tissue was collected at closer time points 15 minutes and 3 hours post 20- 
minute continuous 3 M KCl treatment.  
As single CSD has different clinical implication with multiple CSD, single CSD 
was also induced to compare with changes in some gene expression after multiple 
CSD. Cortical tissue was collection 24 hours post the single CSD. 
Both left (contralateral) and right (ipsilateral) cerebral cortex were rapidly dissected 
and snap frozen in liquid nitrogen and stored at -80°C. The frozen tissue was then 
ground into powder, which was aliquot into two parts for both RNA and protein 
extraction.  
3.1.1.3 Intracerebroventricular perfusion experiment and protocol 
In order to examine the role of P2X7R C-terminus in regulating CSD in rats 
(chapter 6) and investigate whether inhibition of P2X7R alters whether 
CSD-induced gene expression of TNF-α, IL-1β and CGRP (chapter 6), we carried 
out the following experiments. Three burr holes were drilled: (i) one with dura 
mater intact in the right parietal bone (coordinates: 5 mm posterior and 2 mm 
lateral to bregma) for CSD induction by 2 M KCl application for 30 minutes; (ii) 
one was drilled on the ipsilateral side (coordinates: 3 mm anterior and 2 mm lateral 
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to bregma) for CSD recording by Ag/AgCl electrodes; (iii) one was drilled on the 
contralateral skull (coordinates: 0.8-0.84 mm posterior and 1.7-1.9 mm lateral to 
bregma, 3.5-3.6 mm deep from the cortical surface) for artificial cerebral spinal 
fluid (ACSF, 125 mM NaCl, 2.5 mM KCl, 1.18 mM MgCl2, 1.26 mM CaCl2; pH 
7.3)/antibody perfusion into the ventricle through a stainless steel cannula (inner 
diameter: 0.38 mm, RWD Life Science, Shenzhen, China), which is held in place 
by acrylic dental cement. 
Three groups were designed (Figure 3.2): (i and ii) 0.6 µg monoclonal rabbit 
anti-P2X7R antibody (ab109246, Abcam, targeting the P2X7R C-terminus 
PKSEGQYSGFKSPY, corresponding to amino acids 582 to 595 of human P2X7R, 
n = 8) or 0.8 µg rabbit anti-IgG antibody (D110502, Sangon, n = 9) was 
intracerebroventricular (i.c.v.) perfused four days prior to the CSD induction by 30 
minute continual KCl application; (iii) ACSF was i.c.v. perfused in sham group 
(n=8). After 40 minute recording of CSD, tissue was dissected immediately and 
snaps frozen in liquid nitrogen and stored at -80°C. 
 43 
3.1.1.4 Data presentation 
For the in vivo electrophysiological data, the following parameters were analysed: 
the area under the curve (AUC, mV × minute) of each CSD wave was calculated 
and the averaged AUC was used for indicate the CSD magnitude for data 
comparison; CSD latency was calculated by the time used to elicit the first CSD 
wave in the recording site after the KCl application; CSD number induced by each 
KCl application was also counted; CSD propagation rate (mm/minute) was 
calculated by the distance between the CSD elicitation site and recording site 
dividing by the time difference. 
3.1.2 In vitro CSD model in chick retina 
In order to explore if the role of P2X7R in CSD is of non-vascular origin, in vitro 
tissue using both chick retina and mouse brain slice were applied using a P2X7R 
 
Figure 3.2 Experimental protocol for tissue collection to investigate the effect of 
pretreatment of the anti-P2X7R antibody on the CSD occurrence and CSD-induced 
expression of inflammatory factors, TNF-α, IL-1β and CGRP. In each experiment, 
0.6 µg anti-P2X7R antibody or 0.8 µg anti-IgG antibody was i.c.v. perfused four days 
KCl application for 30 minutes. ACSF was i.c.v. perfused in sham group. After 40 
minute recording of CSD, tissue was collected immediately for subsequent analysis. 
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antagonist, which blocks both P2X7R channel and pore formation (chapter 6). 
These models were validated previously in our laboratory using drugs targeting the 
NR2A subunit of NMDA receptor, which showed inhibitory effects on propagation 
rate and magnitude of RSD and CSD (Bu et al., 2016a, Bu et al., 2017).  
3.1.2.1 Chick retina preparation 
Male Hyline Brown Chicks (Wuxi poultry Ltd, Jiangsu, China) were purchased at 
one-day old. As previously described (Wang et al., 2012), chicks were killed by 
decapitation. The right eye was immediately taken off and sectioned close to the 
equator. The posterior eyecup with retina attached was placed in a tissue chamber 
and submerged in perfused Ringer’s solution (100 mM NaCl, 6 mM KCl, 1 mM 
MgSO4, 30 mM NaH2PO3, 1 mM CaCl and 20 mM glucose; adjust pH to 7.35-7.45;  
32°C) bubbled with 5% CO2 and 95% O2, at perfusion rate of 0.5 ml/min. The 
volume of perfused media was kept constant in the chamber by a suction pump 
(BT100-1L, Longer Pump Led, China) to ensure the placidity of the liquid surface. 
The tissue was initially incubated in Ringer’s solution for 30 minutes to guarantee 
recovery from preparation. 
3.1.2.2 RSD induction and intrinsic optical imaging 
Repeated CSD was elicited at the eyecup edge by 1 μl of 0.1 M KCl with 20 
minute interval for recovery. The tissue was illuminated for 5 ms per second with 2 
Hz frequency by applying a high-power LED spotlight (625 nm peak wavelength, 
SLS-0307-A, Mightex, Pleasanton, CA, USA) and the reflected light was recorded 
with a monochrome camera (QIC-F-M-12, Media Cybernetics, Marlow, UK). 
Image sequences were taken at one frame per second for 3 min. The illumination 
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and camera capture were synchronized using the same external trigger (Figure 3.3). 
Image Pro Plus software (IPP7; Media Cybernetics, UK) was applied for image 
acquisition, storage and analysis.  
 




3.1.2.3 Experimental design 
In order to examine whether the inhibitory action of P2X7R inhibition could be 
also observed in vitro, RSD model was induced in the chick retina and the receptor 
antagonist, A740003 (Tocris), which inhibit both P2X7R ion channel and pore 
formation (Honore et al., 2006) was applied. Ten repeated RSD were induced by 
KCl, with the first two recorded RSD for initial Ringer’s control (Figure 3.4). The 
perfusion medium was switched to 10 μM A740003 dissolved in 0.01% DMSO or 
DMSO vehicle group (diluted in Ringer’s solution, 0.01%, n = 3) and six RSD 
were recorded undergoing drug/vehicle conditions. Finally, after drug removal, two 




Figure 3.4 Experimental protocol to investigate effect of P2X7R antagonist 
A740003 on RSD in chick retina. Two groups were designed with DMSO control and 
A740003 drug group. In each experiment, ten repeated RSD was induced by KCl with 
20 minute interval for tissue recovery. The first two RSD were initial Ringer’s control. 
Six RSD undergoes DMSO vehicle or drug test, with the last two for post-treatment 
recording with Ringer’s control (drug removal). 
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3.1.2.4 Image analysis 
The signal of intrinsic optical imaging affects the intensity of diffusely reflected 
light and derives from characteristic physiological changes in the tissue surface. 
Changes in light scattering attributed to interstitial volume changes resulting from 
cellular swelling due to water and ion movement and neurotransmitter release. 
For all image sequences, the same area of interest (AOI) parallel to the RSD wave 
was selected and delineated manually (Figure 3.5). The recorded signal is 
synchronous with cellular depolarization, which characterizes RSD (Farkas et al., 
2008). The same AOI was selected among all sequence pictures under one 
experiment. The averaged grey level of the pixels constituting the AOI was plotted 
against time to obtain a RSD wave plot, from which the AUC was measured by 
image analysis as an index of RSD magnitude to quantify drug effects. In addition, 





Figure 3.5 Representative image (A) and plot of RSD (B) wave induced by K+ in 
the chick retina. The changes in gray level intensity within the selected area of interest 
(AOI) against time. The same AOI (rectangle within left picture) along RSD wave front 
was selected and used for all images of the sequence under study. From these plots, the 
AUC (gray level x minute) of RSD wave and propagation rate (mm/minute) were 
determined by image analysis to quantify drug effects. 
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3.1.3 In vitro CSD model in mouse brain slices 
Mouse brain slice CSD model was further applied to examine if P2X7R inhibition 
suppresses CSD can be observed in vitro as mice are mammals and more close to 
human than chick; secondly, P2X7R are also expressed in mouse cerebral cortex 
(Jimenez-Pacheco et al., 2013).  
3.1.3.1 Mouse brain slice preparation 
C57BL6 male mice (15-25 g, Shanghai SLAC Laboratory Animal Corporation Ltd) 
were killed by rapid cervical dislocation. The brain was dissected and transferred 
quickly into pre-freeze NMDG-HEPES cutting solution (93 mM NMDG, 2.5 mM 
KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 5 mM 
L-ascorbic acid, 2 mM thiourea, 3 mM sodium pyruvate, 10 mM MgSO4, 0.5 mM 
CaCl2∙2H2O; bubbled with 95% O2 and 5% CO2; pH 7.4). The cerebrum was 
sectioned along the midline. A vibratome (7000 smz-2, Campden, Leicestershire, 
UK) was applied to prepare right coronal slices at 400 µm thickness in the cortical 
visual and somatosensory regions, where are considered to be highly associated 
with migraine pain (Lauritzen and Fabricius, 1995, Hadjikhani et al., 2001). Slices 
were maintained in the NMDG-HEPES cutting solution bubbled with 5% CO2 and 
95% O2 at room temperature for 15 minutes and then transferred to Kreb’s solution.  
3.1.3.2 CSD induction in the mouse brain slice 
A cortical slice (from bregma -1 to -3 mm) was placed in a chamber and submerged 
in Kreb’s solution (25°C) at perfusion rate of 3 ml/minutes using a peristaltic pump 
(Reglo ICC, Ismatec; Wertheim, Germany) for at least 80 minutes to guarantee 
recovery from tissue dissection. CSD was induced in the IV-V layer of 
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somatosensory region of the slice by 80 second ejection of 33 µl of 260 mM KCl 
through a 200 μm diameter glass needle linked to a high-precision syringe pump 
(CMA/100, CMA/ Microdialysis; Solna, Sweden).   
3.1.3.3 Experimental design 
Series 1: To examine if blockade of the P2X7R channel and pore complex 
suppressing CSD could also be observed in the mouse brain slice, the following 
four groups were considered: (i and ii) A740003 at 0.1 and 0.3 µM (n = 6 in each 
group), at which concentration, the drug was selective for P2X7R (Honore et al., 
2006); (iii and iv) Kreb’s and 0.03% DMSO were used as the control and vehicle 
control, respectively (n = 6 in each group).  
For this series, two CSD episodes were induced with 45 minutes interval for tissue 
recovery. Corresponding drugs or vehicles were perfused 45 minutes prior to the 
2nd CSD induction for 1 hour (Figure 3.6 A). 
Series 2: To examine if blockade of the P2X7R C-terminal domain could prevent 
the occurrence of CSD, a monoclonal rabbit anti-P2X7R antibody was examined in 
the mouse brain slice. Three groups were designed by incubation of brain slices 
with (i) the anti-P2X7R antibody at 3 µg/ml (n = 6) or (ii) the anti-IgG antibody at 
3 µg/ml (n = 7) as a negative control or (iii) Kreb’s as the blank control (n = 6).  
For this series, two CSD episodes in each experiment were induced by KCl with 
2-hour interval for tissue recovery. The brain slice was incubated in the chamber 
with the Kreb’s solution or antibody for 1 hour starting from the end of the first 





Figure 3.6 Experimental protocol to investigate the role of P2X7R in CSD in the 
mouse cortical slices. A. drug protocol: four groups were designed with Kreb’s control 
group, DMSO vehicle group and P2X7R antagonist A740003 at 0.1 and 0.3 µM. B. The 
antibody protocol: three groups were designed with Kreb’s control group, anti-IgG 
antibody negative group and anti-P2X7R antibody group. 
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3.1.3.4 Intrinsic optical imaging 
The cortical slice preparation was illuminated for 50 ms at 2 Hz for 15 min, started 
as CSD was elicited, using a high-power LED spotlight (625 nm peak wavelength, 
SLS-0307-A, Mightex, Pleasanton, USA) driven by a computer controlled power 
supply (LED controller, SLC-SA04-US; Mightex, Pleasanton, USA). The reflected 
IOS changes in cortical slices were recorded with a charge-coupled device 
monochrome camera (Rolera-XR, ROL-XR-F-M-12, Qimaging, Surrey, Canada) at 
the maximum spatial resolution using Image Pro Plus software (IPP7; Media 
Cybernetics, UK). Camera exposure and illumination were synchronized by using 
an external trigger (TG1006, TTI, Cambridgeshire, UK). 
3.1.3.5 Image analysis 
Image analysis was as that was described in section 3.1.2.4 except the following: 
the AOI was selected in layers 4-6 of the somatosensory cortex that were distant 
from the site of KCl application (Figure 3.7). Additionally, CSD latency was also 
calculated and shown as the percentage relative to that of the first CSD wave to 
reflect cerebral cortex susceptibility to CSD. While CSD propagation rate was 






Figure 3.7 representative images before (A) and after (B) CSD, and plot of CSD 
wave (C) in the mouse cortical slice: the changes in gray level intensity within the 
selected area of interest (AOI) against time. The same AOI (rectangle within left picture) 
along CSD wave front was selected and used for all images of the sequence under study. 
From these plots, the area under the curve (AUC, gray level x minute) of CSD wave and 
propagation rate (mm/minute) and CSD latency (second. time interval required for 
eliciting depolarization from the start point of KCl application) were determined by 
image analysis to quantify drug effects.  
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3.2 Cell culture 
Cell culture was applied to optimise the concentration and incubation time of 
miR-137 antagomir, which is chemically engineered oligonucleotide and functions 
to silence endogenous miR-137, before exploring the effects of silencing miR-137 
on CSD and subsequent miR-137 target gene expression post CSD (chapter 4). 
3.2.1 Culture SH-SY5Y cells 
Human-derived neuroblastoma cell line SH-SY5Y was maintained in culture media 
[HAM’s F12 (Sigma) and Minimum Essential Medium Eagle (Sigma) at a ratio of 
1:1, supplemented with 10% foetal bovine serum (Sigma), 1% 100 mM sodium 
pyruvate (Sigma), 1% 200 mM L-glutamine (Sigma) and 100 U/ml penicillin/100 
μg/ml streptomycin (Sigma)] at 37°C in a humidified atmosphere 5% CO2 in T175 
flask. To passage cells, cells were cultured to 70%-80% confluent, media was 
removed and cells were washed down with pre-warmed sterile PBS. Following 
removal of PBS, cells were washed over by 5 ml of pre-warmed 1x trypsin (Sigma) 
and then removed trypsin. The cells were incubated at 37°C for 3 minutes to be 
detached from flask bottom. Cells were then washed with 10 ml of pre-warmed 
culture media to neutralize the trypsin and pipetted into single cell suspension. 
Finally, 1 ~ 2 ml of cell suspension (approximately 1-2.5 million cells) was 
transferred into a new T175 tissue culture flask with 35~40 ml of culture media. 
3.2.2 Cell counting 
A heamocytometer was applied to count cell number per ml of media. First of all, 
both the coverslip and the counting surface of the haemocytometer were washed 
with 70% ethanol. There are 5 x 5 squares each containing 5 x 5 smaller squares on 
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the centre of the counting surface of the haemocytometer. To perform the cell count, 
single cell suspension was generated as described above, 20 μl of the cell 
suspension was dropped on the centre counting surface and covered by the 
coverslip. The counting surface was visualized under a microscope with 10 x 
objective. The cells within the 25 larger squares were counted including those in 
contact with right or top borders of the 25 squares and excluding those touching left 
or bottom borders. This area corresponds to 0.1 mm3, so the number multiplied by 
1 x 104 give the cell number in 1 ml (1 cm3). Knowing the cell number per ml of 
media, the density could be calculated to seed cells as required in following 
experiments. 
3.2.3 Freezing cell for storage and defrost frozen cells 
For long time storage, cells were frozen in freezing media in liquid nitrogen. Cells 
were cultured to 70~80% confluent in T175 flask and passaged as described above, 
but instead of 10 ml culture media, 10 ml of freezing media (90% FBS and 10% 
DMSO) was used to wash cells from the flask bottom. Then the cell suspension 
split across cryovials with approximate 1.7 - 1.9 ml in each cryovial. The cryovials 
were then placed in a Mr Frosty with isopropanol at -80°C for at least 24 hours 
before transferring into liquid nitrogen for long term storage. 
To defrost frozen cells, one cryovial was taken out from liquid nitrogen, defrosted 
in 37°C water bath until only a few ice crystals present and transferred into 10 ml 
pre-warmed 37°C culture media in T25 flask. Usually after three days, cells were 
grown to 70~80% confluent and passaged into T75 flask. Similarly, when cell were 
grown to70~80% confluent in T75 flask, they were passaged into T175 flask and 
ready for further experimental use. 
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3.2.4 Optimisation transfection in SH-SY5Y cell line 
A concentration gradient of miR137 antagomir (1 nM, 10 nM, 15 nM, 50 nM and 
100 nM)) and incubation time were carried out to optimise the most efficiency of 
transfection.  
SH-SY5Y cells were seeded at 1 x 105 cells per well of a 24-well plate in 0.5 ml 
antibiotic-free media 24 hours before transfection. The transfection condition was 
listed as below: 
 
The lipofectamine 2000 (Invitrogen) was mixed with oligonucleotides (miR137 
antagomir or its negative scramble control) and incubated for 5 minutes at room 
temperature. The master mix added as list above and RNA was processed following 
24 or 72 hours incubation to analyse subsequent gene expression of miR137 
targets. 
3.3 Gene expression analysis 
3.3.1 RNA extraction 
TRIzol reagent (Sigma-Aldrich) was applied to extract RNA following the 
manufacturer’s instruction. Briefly, cortical tissue or cells was homogenized in 
TRIzol (1 ml per 50-100 mg) by tissue ruptor. 200 μl chloroform per 1 ml of 
TRIzol was added to each sample, shaken by hand vigorously for 15 seconds. After 
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5 minutes incubation at room temperature, samples were centrifuged at 12,000 xg 
for 15 minutes at 4qC, separating phase into three layers: RNA-containing 
colourless aqueous upper layer, a thin middle interphase layer and a bottom 
DNA-and-protein-containing red organic layer. The upper layer was carefully 
transferred into a new microfuge tube. 500 μl of isopropanol per 1 ml of Trizol was 
added to each sample and incubated for 10 minutes at room temperature, followed 
by centrifugation at 12,000 xg for 10 minutes at 4qC. After discarding the 
supernatant, RNA pellet was purified by adding 1 ml 75% molecular grade ethanol 
(per 1 ml TRIzol used in the initial step). Samples were shake and centrifuged at 
7,500 xg for 5 minutes at 4qC. The supernatant was discarded and the RNA pellet 
was air dried for 20 to 30 minutes at room temperature. Finally, the RNA pellet was 
re-suspended in 30-50 μl nuclease free water and incubated on a heat block at 55qC 
for 15 minutes. RNA samples were placed on ice for later quantification and cDNA 
synthesis or stored at -80qC. 
3.3.2 RNA quantification 
RNA concentration was measured by Nanodrop 2000c (Thermo Scientific). The 
sample reader was washed with nuclease free water and dried with KimWipe. 
Following the instruction of the software, the Nanodrop was set to RNA. 1 μl of 
elution nuclease free water was loaded and set as blank. Then 1 μl of sample was 
loaded and the absorbance measured. The absorbance of UV light by nucleic acid 
at 260 nm depends on their concentration. After reading completion, the RNA 
concentration in ng/μl was obtained. The quality of the RNA was also assessed by 
the Nanodrop through measuring the ratios of A260/A280 and A260/A230; 
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expected values for high RNA purity are approximately 2.0 and 2.0-2.2, 
respectively.  
3.3.3 First strand cDNA synthesis 
The GoScript Reverse Transcription System (Promega) was used for first strand 
cDNA synthesis from total RNA following the manufacturer’s protocol. Briefly, 1 
μg of RNA was used for each sample in the reverse transcriptase reaction, mixed in 
a PCR tube with the following components: 
 
The mixture was incubated at 70qC for 5 minutes, immediately cooled down on ice, 
and added the following reverse transcription mix to a final 20 μl reaction volume. 
 
The final reaction mixture was incubated as following: at 25qC for 5 minutes for 
primer annealing; at 42qC for 60 minutes for extension; finally at 70qC for 15 
minutes to inactivate the reverse transcriptase. The cDNA was stored at -20qC for 
later use. 
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3.3.4 PCR primer designing 
The online primer-designing tool Primer 3 was used to design PCR primers. A list 
of recommended PCR primers for amplification of the sequence of interest was 
generated based on appropriate GC% content, melting temperature and potential 
self-complementarity. Generally, primers were picked with 18-25 nucleotides in 
length, 58-65qC melting temperature and 40-60% GC content. The primer 
specificity was further determined by In-Silico PCR tool available from the UCSC 
Genome browser (http://genome.ucsc.edu/cgi-bin/hgPcr). Primers were ordered 
from Sangon Biotech (Shanghai) Co., Ltd and listed as below: 
 
3.3.5 Semi-quantitative PCR analysis 
PCR analysis was performed using cDNA template on Veriti 96-well Thermal 
cycler (Applied BiosystemsTM) using DNA polymerase (TaKaRa).  The DNA 
polymerase master mix is list below: 
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The amount of cDNA template used varied for each primer set depending on the 
abundance of the target for amplification. The thermal cycling conditions were as 
follows: 
 
The analysis of PCR product was performed on 1% agarose gels supplemented 
with 1:10000 dilution GelRed (Biotium). The voltage and time for gel running 
depended on the DNA fragment size to achieve adequate separation of the bands. 
The DNA was visualised using a UV transillumintor. 
3.3.6 Quantitative PCR (qPCR) 
qPCR was performed using GoTaq qPCR Master Mix (Promega) following the 
manufacturer’s instruction. The reaction component is: 
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Analysis was performed on 7500 fast Real-Time PCR system (Applied 
BiosystemsTM) with the following thermal cycling conditions: 
 
Relative gene expression was calculated using the Pfaffl method with reference 
genes, PPIA and β-actin (ACTB), which were most commonly used in CSD 
condition (Wang et al., 2016b). 




3.4 Protein expression analysis 
3.4.1 Protein extraction 
Total protein was extracted from (i) sham and CSD ipsilateral cerebral cortices of 
rats to analyse how CSD affect specific protein expression 3 hour and 24 hour post 
CSD; (ii) chick retina to test the presence of P2X7R in chick retina. The tissue was 
homogenized in the presence of protease inhibitor (Roche). The homogenate was 
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centrifuged at 13,000 rpm for 10 minutes at 4qC. The supernatant was aliquot and 
stored at -80qC.  
3.4.2 Bicinchoninic acid (BCA) assay 
Protein concentration was determined by BCA kit (Beyotime) using bovine serum 
albumin (BSA) as standard curve. Briefly, a series of dilution BSA standard and 
protein extract with TBS were prepared to a total 20 μl/well in a 96-well plate with 
duplicates. BCA working solution was prepared with solution A and B at 50/1 ratio 
and 200 μl was added into each well. The plate was sealed and incubated in water 
bath at 37qC for 20 minutes. The absorbance was measured by a spectrophotometer 
with wavelength at 562 nm. The standard curve was prepared by plotting the mean 
blank-corrected 562 nm measurement for each BSA standard versus its 
concentration. The protein concentration of each sample was calculated according 
to this standard curve.  
3.4.3 Western blot  
Western blot was applied to (i) determine the protein level of NR2A and GABAA 
α2; (ii) determine the presence of P2X7R in chick retina with rat cortex as a 
positive control, as P2X7R was reported to be expressed in rat cortex (Franke et al., 
2004). Protein samples are separated by 10% SDS-PAGE and transferred onto 
nitrocellulose membrane. 5% non-fat milk in TBST (20 mM Tris, 150 mM NaCl, 1‰ 
Tween 20; pH 7.6) was applied to block non-specific binding. The membrane was 
then incubated with rabbit anti-NR2A antibody (1 in 2000 dilution, ab124913, 
abcam) or anti-GABAA receptor α2 antibody (1 in 500 dilution, ab72445, abcam) 
or anti-P2X7R antibody (1 in 1000 dilution) overnight at 4qC with gentle rocking. 
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Excess primary antibody was washed three times by TBST and then incubated with 
IRDye 800CW Donkey anti-Rabbit IgG secondary antibody (1 in 5000 dilution, 
926-32213, LI-COR) at room temperature for 1 hour with gentle rocking. The 
membrane was then washed three times by TBST for later detection. The 
membrane was then scanned by the Odyssey scanner with selection of channel 800. 
The membrane was then stripped by 0.2 M NaOH for 15 minutes at room 
temperature to further detect β-actin, which was used as a reference. Then the 
membrane was washed out by TBST and the same process was carried out was 
described above starting from non-specific blocking with 5% non-fat milk in TBST. 
Finally, the membrane was scanned and saved as a tif format. The density and 
volume of signal each band was analysed quantified using Image J software. 
3.5 Data presentation and statistical analysis 
All data was shown as mean ± SEM. For the image data and the in vivo 
electrophysiological data relevant P2X7R project, abnormal distribution of the data 
was confirmed using Shapiro-Wilk test and one-tailed Mann-Whitney U test was 
applied to compare each parameter between two independent groups within each 
data set, as previous publication has showed suppressive effects of blockade of 
P2X7R on CSD (Chen et al., 2017b).  
Correlation between CSD parameters was analysed. Abnormal/normal distribution 
of these data was checked using Shapiro-Wilk test. Abnormal distribution data was 
analysed by Spearman’s correlation, while normal distribution data was analysed 
by Pearson’s correlation, with an “r” value ranging from +1 to -1. A value of 0 
indicates that there is no association between the two variables. A value greater 
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than 0 indicates a positive association. A value less than 0 indicates a negative 
association. *p < 0.05, **p < 0.01 ***p < 0.001, and ****p < 0.0001 indicate 
statistical significance. 
All qPCR data were analysed using relative fold change (Pfaffl method). If data 
obeys normal distribution, two-tailed unpaired t-test was used for comparison 
between sham and CSD groups, and two-tailed paired t-test was used for 
comparison between ipsilateral and contralateral hemispheres within each group. 
While, if data doesn’t obey normal distribution, unpaired two-tailed Mann-Whitney 
U-test and paired two-tailed Wilcoxon test were used respectively. Both PCR gel 
bands and western blot bands were quantified using Image J software and 
normalised to β-actin. Abnormal distribution of these data was confirmed using 
Shapiro-Wilk test. Unpaired two-tailed Mann-Whitney U-test and paired two-tailed 
Wilcoxon test were used as described above for different comparison. *p < 0.05, 
**p < 0.01 ***p < 0.001, and ****p < 0.0001 indicate statistical significance. 
Power analysis was finally carried out using GPower 3.1.9.2 to estimate the 
minimum number of samples required to detect trends with a given degree of 
confidence. The input parameters were set as the following: the significance level α 
0.05 and power (the likelihood of rejecting null hypothesis) 0.8; the effect size was 
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4.1 Introduction  
CSD is associated with alterations of gene expression (Shen and Gundlach, 1999, 
Shen et al., 2003, Faraguna et al., 2010), which can be modified by the changes in 
transcriptional repressors or enhancers, subsequently influencing neuronal 
phenotype and behavior. Altered REST expression is associated with physiological 
brain functions, but it is also highly responsive to brain injuries (Qureshi and 
Mehler, 2011, Warburton et al., 2016, Zhao et al., 2016). In such scenarios, 
differential spliced isoforms of REST are observed and distinct properties have 
often been attributed to the individual isoforms (Chen and Miller, 2013). Similarly, 
expression of REST truncated isoform REST4 is also reported to be associated with 
disease progression, such as epilepsy (Spencer et al., 2006, McClelland et al., 2014), 
which has moderate co-morbidity with migraine (Deprez et al., 2007, Sowell and 
Youssef, 2016).  
In vitro, in human cells, REST has been demonstrated to regulate MIR137 
expression, a microRNA involved in schizophrenia, in part via an internal promoter 
termed Imir137 (Warburton et al., 2014). A second promoter utilized by human 
MIR137 is upstream of MIR137 host gene (MIR137HG), which encodes for the 
full-length precursor mRNA. The mature miRNA-137 (miR-137) is implicated in 
several neurological disorders and regulates the dynamics between neuronal 
proliferation and differentiation during the different stages of neural development 
(Silber et al., 2008, Szulwach et al., 2010). Reduction in miR-137 expression leads 
to deregulation of genes involved in synaptogenesis and neuronal transmission 
(Strazisar et al., 2015). Variants within or upstream of genes regulated by miR-137, 
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in combination with MIR137HG risk variants, influence grey matter concentration 
in schizophrenia-related central nervous system regions (Wright et al., 2016).  
REST and miR-137 target genes have been previously associated with epilepsy, 
schizophrenia, stroke and migraine (McClelland et al., 2014, Spencer et al., 2006, 
Wright et al., 2016, Zhao et al., 2016, Bu et al., 2016a). These include genes 
encoding for the P/Q type calcium channel (Antoniotti et al., 2016), 
N-methyl-D-aspartate (NMDA) receptor (Noh et al., 2012, Zhao et al., 2013) and 
neuropeptides, such as substance P (Quinn et al., 2002), which are implicated in 
migraine pathogenesis (Martins et al., 2017) and traumatic brain injury (TBI) (Vink 
et al., 2017); whilst inhibition of NMDA receptors and its major NR2 subtypes 
have been shown to suppress the genesis and propagation of CSD (Bu et al., 2016a, 
Peeters et al., 2007, Shatillo et al., 2015b). There are several putative REST target 
genes. RELN (Reelin), JUN (Jun oncogene) and GAD1 (glutamate decarboxylase 1) 
contained a predicted REST binding site and were regulated in response to sodium 
valproate (Warburton et al., 2015), which was an anticonvulsant drug applied in 
migraine treatment and reported to suppress the frequency of CSD in vivo (Ayata et 
al., 2006). Other putative REST target genes include VIP (vasoactive intestinal 
peptide), Tac 1 (substance P) and NKB (neurokinin B), which are clinically 
associated with migraine or epilepsy (Fusayasu et al., 2007, Nakano et al., 1993).  
REST signalling pathway is important to modulate neuronal function and is 
implicated in neurological dysfunctions. Most importantly, my UoL supervisor 
Professor John Quinn’s lab found that the binding of REST to the internal MIR137 
(rImir137) promoter is markedly reduced 24 hours post multiple CSD in rats (see 
Appendix 1, Figure A) (Warburton, 2015 pp 277-281), suggesting REST/MIR137 
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signals may be involved in the process of multiple CSD. In this chapter, whether 
REST is involved in CSD was examined.  
4.2 Objectives  
(i) To address whether multiple CSD events alter the gene expression of REST and 
its truncated REST isoform REST4, as well as MIR137HG in rat cortex. 
(ii) To investigate whether the reduced REST binding to rImir137 promoter affect 
subsequent miR137 target gene Grin2a expression. 
(iii)To investigate whether silencing miR-137 by antagomir regulate CSD. 
(iv) To address whether the change of REST variants in response to multiple CSD 
affect subsequence expression of its target genes. 
4.3 Results 
4.3.1 Successful induction of CSD by KCl 
CSD was induced by KCl application in the rat cerebral cortex in order to explore if 
multiple CSD alters mRNA levels of REST, REST4, in rats. Changes in the DC 
potential were observed in ipsilateral motor cortices of all rats, indicating 
successful CSD induction at the somatosensory cortex (Figure 3.1 A & C). In the 3 
hour series, 4 or 5 CSD waves were observed in all rats with 20 minutes KCl 
application. In the 24 and 72 hour series, typically one CSD wave was induced by 
each KCl application for all the 5 episodes, however two CSD waves were 
occasionally observed in 2/8 rats due to individual variation in cortical 
susceptibility to KCl stimuli. In the sham control groups, ACSF application did not 
induce CSD in any rats at any time point.  
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4.3.2 Multiple CSD effect on the mRNA levels of REST, REST4 and MIR137HG 
in ipsilateral cortices of rats at 3 hours 
In order to address if multiple CSD alters gene expression of REST, REST4 and 
MIR137HG, I generated cDNA from both contralateral and ipsilateral cortices of 
sham and CSD rats and measured the respective mRNA levels at different time 
points post-CSD. Expression of REST, REST4 and MIR137HG were first 
identified by both RT-PCR and qPCR at 3 hour post CSD.  
The RT-PCR gel data showed that there were no significant changes between the 
contralateral and ipsilateral cortices of sham group for all of the three genes (Figure 
4.1A & B), indicating that surgery did not affect their mRNA levels. Also no 
changes were observed between sham contralateral and CSD contralateral group 
(Figure 4.1A & B), suggested that the CSD did not alter mRNA levels of REST, 
REST4 and MIR137HG on contralateral side. Compared to the sham ipsilateral 
group, CSD did not alter the gene expression of these three genes (Figure 4.1A & 
B), although there was a slight but insignificant increase of REST4 mRNA level in 
CSD ipsilateral group (Figure 4.1A & B).  
Consistent with RT-PCR data, the increase trend of REST4 mRNA level by CSD 
were observed by qPCR (2.73 fold change when compared to the sham group) 
(Figure 4.1C). Also, no changes were observed by qPCR in the mRNA level of 
both REST and MIR137HG at 3 hour post CSD. 
Based on the power analysis for REST4 gene expression at 3 hours, it could be able 





Figure 4.1 CSD increased mRNA level of REST4, but not REST and MIR137HG in 
ipsilateral cortices of rats at 3-hour post CSD. (A) RT-PCR analysis of REST, REST4 
and MIR137HG in the rat from both contralateral and ipsilateral cerebral cortex of 
sham and CSD group; (B) Image J semi-quantitative analysis of RT-PCR data 
normalised to ACTB in CSD group compared with sham group. (C) qPCR analysis of 
REST, REST4 and MIR137HG in the rat ipsilateral cerebral cortex from sham and 
CSD group. Comparisons between sham and CSD groups were done using unpaired 
two-tailed Mann-Whitney U-test; Comparisons between ipsilateral and contralateral 
hemispheres within each group were done using paired two-tailed Wilcoxon test. 
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4.3.3 Multiple CSD effect on the mRNA levels of REST, REST4 and MIR137HG 
in ipsilateral cortices of rats at 24 and 72 hours 
The mRNA level of REST, REST4 and MIR137HG were also identified by 
RT-PCR at 24 and 72 hour post CSD. Similar as 3 hour post CSD, the surgery also 
did not alter the gene expression of these three genes 24 and 72 hour post CSD, as 
no significant difference was observed between sham contralateral and ipsilateral 
group (Figure 4.2). The increase trend of REST4 mRNA was returned to basal level 
at 24 and 72 hour post CSD (Figure 4.2 A, B & C). Additionally, no significant 
changes in ipsilateral REST and MIR137HG mRNA levels were observed when 
compared to the sham group at both 24 hours and 72 hours post-CSD (Figure 4.2 A, 
B & C). 
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Figure 4.2 CSD did not alter the mRNA level of REST, REST4 and MIR137HG in 
ipsilateral cortices of rats at 24 and 72 hour post CSD in rats. RT-PCR analysis of REST, 
REST4 and MIR137HG in the rat both contralateral and ipsilateral cerebral cortex from 
sham and CSD group 24 (A) and 72 hours (B) post CSD in responsive order. (C) Image J 
semi-quantitative analysis of RT-PCR data normalised to ACTB in CSD group compared 
with sham group. Comparisons between sham and CSD groups were done using unpaired 
two-tailed Mann-Whitney U-test; Comparisons between ipsilateral and contralateral 
hemispheres within each group were done using paired two-tailed Wilcoxon test. 
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4.3.4 Reduction of Grin2a gene expression by multiple CSD 
As REST binding over the rImir137 promoter was modulated in response to 
multiple CSD in rat cortical tissue (Figure A1), I further investigated if there is any 
change in the expression of miR-137 target gene, Grin2a. This was examined in 
both contralateral and ipsilateral cortices of sham and CSD treated rats (Figure 4.3). 
There was no significant change in Grin2a mRNA level between contralateral and 
ipsilateral cortices of sham rats at all time points analysed post ACSF application, 
indicating surgery did not alter Grin2a gene expression (Figure 4.3). Grin2a gene 
expression was not altered 3 hours post-CSD; However, a significant reduction of 
ipsilateral Grin2a mRNA levels was observed at 24 hours after CSD when 
compared to that of the sham ipsilateral cerebral cortex (p = 0.0357) and a 
reduction trend when compared with CSD contralateral cerebral cortex (p = 0.0625) 
(Figure 4.3). This reduction was no longer apparent at 72 hours post-CSD. 
 
Figure 4.3 Gene expression of miR-137 target gene, Grin2a, at 3, 24 and 72 hour 
post-CSD in rat ipsilateral cerebral cortex of sham and CSD rats. CSD reduced Grin2a 
mRNA expression in ipsilateral cerebral cortex of rats 24 hours, but not 3 and 72 hours 
post-CSD (n = 3 in each group except n = 5 in 24 hours CSD group), Comparisons 
between sham and CSD groups were done using unpaired two-tailed Mann-Whitney U-test; 
Comparisons between ipsilateral and contralateral hemispheres within each group were 
done using paired two-tailed Wilcoxon test. *p < 0.05. 
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4.3.5 Optimisation of mir137 antagomir  
Mir137 antagomir was applied to explore the effects of inhibition of miR-137 on 
CSD. Before application to our CSD model, the cell line SH-SY5Y was used to 
address the potential time points and concentration of the mir-137 antagomir as 
described in section 3.2.4 that could be used to optimise the study in CSD. 
Unfortunately, this antagomir did not work at all concentration and incubation 
times in cell line. Also, the level of miR-137 failed to be examined. All the relevant 
reagents were delivered from Liverpool to Suzhou. Due to some custom issues on 
the import of biological samples and reagents, there was a 2-month delay. All of 
the dry ice, which was used for keep reagents cold, was used up and this is likely to 
have affected the loss of efficacy of the reagents. This experiment was not pursued 
further.   
4.3.6. Multiple CSD effect on REST potential target genes 
PCR was carried out to investigate how multiple CSD alter subsequent expression 
of a panel of REST putative target genes, Tac 1, NKB, VIP, GAD1, RELN and 
c-JUN.  
To align our data with our collaborator Alix Warburton for paper publication 
purpose, RT-PCR was carried out to analyse Tac 1, NKB and VIP gene expression 
at time points post 15 min, 3 hour, 24 hour and 72 hour post CSD. For all of these 
genes, there was no difference between sham contralateral and ipsilateral group 
(Figure 4.4), indicating that the surgery did not affect their gene expression. Their 
gene expressions were also not altered in response to multiple CSD compared with 
sham ipsilateral cerebral cortex at all time points I tested (Figure 4.4).  
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To complement this data, qPCR was also used to analyse the effects of CSD on 
other REST putative targets, GAD1, RELN and c-JUN at time points 3 hour and 24 
hours. Similar with above target genes, surgery did not affect their gene expression 
by comparing sham contralateral and ipsilateral cerebral cortex (Figure 4.5). The 
gene expression of both RELN and C-JUN were not altered at 3 hour and 24 hour 
post CSD (Figure 4.5 B & C). However, CSD slightly increased (1.5 fold) GAD1 
gene expression in the ipsilateral group at 24 hours, compared with sham ipsilateral 




Figure 4.4 Gene expression profiling of REST target genes at different time points post 
CSD. RT-PCR analysis of Tac1, NKB and VIP in the rat contralateral and ipsilateral 
cerebral cortex from sham and CSD group 15 minutes (A) 3 (E), 24 (I) and 72 hours (M) 
post CSD in responsive order. (B-D, F-H, J-L, N-P) showed the relative image J 
semi-quantitative analysis of RT-PCR data nomalised to ACTB in each group compared 
with sham contralateral group. (n = 3 in each group except n = 5 in 24 hours CSD group). 
Comparisons between sham and CSD groups were done using unpaired two-tailed 
Mann-Whitney U-test; Comparisons between ipsilateral and contralateral cortex within 
each group were done using paired two-tailed Wilcoxon test. 
 
Figure 4.5 Gene expression profiling of REST target genes 3 & 24 hrs post CSD. Q-PCR 
analysis of putative NRSF target genes in rat cerebral cortex following CSD. Data were 
analysed by unpaired t-test between sham and CSD group (n = 3 in each group except n = 
5 in 24 hours CSD group), Comparisons between sham and CSD groups were done using 
unpaired two-tailed Mann-Whitney U-test; Comparisons between ipsilateral and 
contralateral hemispheres within each group were done using paired two-tailed Wilcoxon 
test. *p < 0.05. 
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4.4 Discussion 
Our results did not support the role of REST or REST4 in CSD, as multiple CSD 
events did not alter gene expression of REST and REST4 in cerebral cortices of 
rats, although a slight but insignificant up-regulation of REST4 was observed. 
Combining with the fact that CSD reduced REST binding to the rImir137 promoter 
in the ipsilateral cerebral cortex of rats (Figure A1) (Warburton, 2015 pp 277-281), 
further studies on increasing sample number are required for statistical significance 
to confirm the role of REST4 in multiple CSD-associated TBI and stroke. 
Although did not reach significant, up-regulation trend of ipsilateral REST4 gene 
expression was observed in all the 3 rats at 3 hours after CSD, which was 
disappeared at 24 hours and 72 hours. This apparent elevation trend in ipsilateral 
cortices is unlikely to be related to the direct effect of KCl because using the same 
protocol, our lab previously showed that CGRP mRNA levels were similarly 
increased in multiple cortical regions (frontal, motor, somatosensory, and visual 
cortices) (Wang et al., 2016b), indicating that the elevated expression is attributed 
to CSD, rather than depolarization in the immediate area of KCl application. 
Monitoring changes in gene expression at the 3 specific time points may have 
missed some of the transient changes following CSD, which may at least partially 
account for that the transient elevation trend of REST4 at 3 hours post-CSD did not 
reach significance. It is clear from the literature that the time course of transient 
expression in vivo in the brain for many genes is quite distinct from that in tissue 
culture (Spencer et al., 2006). Another possibility account for this insignificance is 
due to small sample number (n = 3). Further power analysis of REST4 gene 
expression at 3 hours shows that it should be able to reach significance with a 
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sample size of four. Increasing sample number needs to be considered in the further 
work. Nevertheless, these data does allow us to follow the temporal expression in 
vivo after multiple CSD events. 
Unlike REST4, REST mRNA levels did not show change trend in response to 
multiple CSD episodes. This is contrast to that reported previously that REST 
expression is highly responsive to epilepsy (Spencer et al., 2006). It is possible that 
REST gene expression is less dynamic than REST4 as previously observed in an 
epilepsy model (Spencer et al., 2006). The mechanism to account for the 
differential changes of these gene expression is unknown, however both 
transcriptional and post transcriptional mechanisms have been postulated.  
As a potential consequence of reduced REST binding to rImir137 promoter (Figure 
1A) (Warburton, 2015 pp 277-281), miR-137 target gene, Grin2a was significantly 
reduced 24 hours post-CSD. Grin2a encoded protein NR2A is an important subunit 
of NMDA receptor that is widely expressed in the brain, which functions in a 
variety of neurological diseases such as memory and post-stroke depression (Zhao 
et al., 2013, Allyson et al., 2010, Ali and Meier, 2009). Increasing evidence 
supports promising clinical use of drugs that selectively inhibit NR2A containing 
receptors with a lesser neurotoxicity than those fully block NMDA receptors and 
drugs antagonizing NR2A-containing NMDA receptors have been proven as 
effective CSD suppression compounds both in vitro and in vivo (Wang et al., 2012, 
Bu et al., 2016a). The fact that Grin2a mRNA expression was down-regulated at 24 
hours post-CSD suggests multiple CSD suppresses Grin2a transcriptional activity. 
The Grin2a has been predicted as a miR-137 target gene (Wright et al., 2013, 
Strazisar et al., 2015) and the reduction of Grin2a corresponds with reduced REST 
 80 
binding to rImir137 promoter, this finding suggests the potential involvement of 
REST/MIR137/Grin2a pathway in pathophysiology of CSD associated 
neurological diseases such as TBI and stoke (Figure 4.6). In a rodent model of 
stroke, reduced level of miR-137 in rat brain tissue correlated with increased 
Grin2a (Zhao et al., 2013). The depressive behavioural effects associated with 
increased levels of Grin2a in the post-stroke depression model were alleviated by 
injection of a miR-137 mimic, suggesting a neuroprotective role for this miRNA 
(Zhao et al., 2013). 
 
Figure 4.6 Schematic depiction of the potential involvement of REST/MIR137/Grin2a 
pathway in CSD processes. Blue lines indicate the pathway in normal condition. Red lines 
indicate the pathway in CSD condition. T-bars indicate the inhibitory effect. Arrow-bars 
indicate promote effect or increase/decrease expression. Dotted lines indicate a (predicted) 
change trend, which need to be further confirmed. Abbreviations: CSD, cortical spreading 
depression; REST, repressor element-1 silencing transcription factor; RE1, repressor 
element 1. NMDA, N-methyl-D-aspartic acid. 
Gene expression analysis of cortical samples from sham ipsilateral and CSD 
ipsilateral groups showed that multiple CSD was able to induce GAD1 gene 
expression in our model (Figure 4.5). The mRNA level of Tac1, NKB, VIP, RELN 
and c-JUN were not changed at time points analysed. However we cannot rule out 
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the possibility that this may reflect the time-course used in our experiment not 
being appropriate to identify any transient changes in their expression at other time 
points. The induction of GAD1 may be related to the potential increase of REST4 
mRNA level after multiple CSD, as REST4 can antagonise the function of 
full-length REST protein (Tabuchi et al., 2002, Coulson et al., 2000). GAD1 
encodes one of several isoforms of GAD, which is a key enzyme during the 
synthesis of GABA. GABA is an inhibitory neurotransmitter and is known to be 
released post CSD (Clark and Collins, 1976). Topiramate, a GABA-receptor 
agonist, functions to elevate CSD threshold (Green et al., 2013) and reduce CSD 
frequency and propagation (Unekawa et al., 2012). It is necessary to further study 
whether these changes influence subsequent GABA protein synthesis.  
In summary, although this study found that multiple CSD did not change the gene 
expression of REST and REST4, a slight but insignificant up-regulation of REST4 
was observed. Considering the subsequent reduction of both REST binding to the 
rImir137 promoter and the downstream miR137 target of NR2A coding gene 
expression, and induction of REST target gene GAD1 post CSD, it cannot deny the 
potential involvement of REST or REST4 in CSD processes. Future study should 
be carried out to confirm the statistically significance of REST4 by increasing 
sample number and to examine if overexpression or knockout of REST would 








Regulation of GABAA α2 and NR2A gene and protein 




5.1 Introduction  
NMDA receptor is known to be contribute to CSD genesis and propagation and the 
receptor antagonism have been proven as effective CSD suppression compounds 
(Gill et al., 1992). Of the NR2 subunits of the receptor, NR2A subunit has a 
dominant role relative to NR2B in CSD elicitation and propagation (Wang et al., 
2012). Further, not only the excitatory, but also the inhibitory neurotransmitter 
receptor mediates CSD genesis and propagation. These were supported by that 
topiramate, a GABA-receptor agonist, can elevate CSD threshold (Green et al., 
2013) and reduce CSD frequency and propagation (Unekawa et al., 2012). The 
suppressive effect on RSD is attributed to GABAA receptor α2 (Wang et al., 2015). 
The data in chapter 4 demonstrate that reduction of NR2A coding gene Grin2a in 
response to multiple CSD stimulation (Figure 4.3). How CSD would alter 
inhibitory neurotransmitter receptor subunits and whether CSD alter their protein 
expression remains unclear and these questions will be addressed in this chapter. It 
is generally considered that single CSD is more clinical relevant with migraine aura 
and is considered as the potential trigger for migraine headache (Ayata, 2010, 
Hadjikhani et al., 2001, Smith et al., 2006). Whether single CSD shows different 
effects on their gene expression is also explored in this chapter. 
5.2 Objectives 
(i) To address whether multiple CSD alters GABAAα2 coding gene expression at 
15 min, 3 hours, 24 hours and 72 hours post CSD. 
(ii) To address whether multiple CSD alters NR2A and GABAAα2 protein level at 
3 hours and 24 hours post CSD. 
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(iii) To address whether single CSD alters NR2A and GABAAα2 coding gene 
expression. 
5.3 Results  
5.3.1 GABAAα2 gene expression is not altered post multiple CSD 
The mRNA level of Gabra2, encoding for GABAAα2 subunit, there was no 
significant difference between contralateral and ipsilateral in the sham group at all 
time points (Figure 5.1), indicating that the surgery procedure did not affect Gabra2 
gene expression. Different from Grin2a shown in chapter 4 (Figure 4.3), ipsilateral 
Gabra2 mRNA level is not altered between sham and CSD group at all time points 
I tested, indicating that multiple CSD did not influence the gene expression of 





Figure 5.1 mRNA level of Gabra2 was not altered at 15 minutes, 3, 24 and 72 hours 
post-multiple CSD. The gene expression of Gabra2 at different time points post CSD was 
analysed by qPCR among both contralateral and ipsilateral groups of sham and CSD. 
There was no significant difference among all groups. (n=3 in each group, except n = 5 in 
CSD 24 hours group). Comparisons between sham and CSD groups were done using 
unpaired two-tailed Mann-Whitney U-test; Comparisons between ipsilateral and 




5.3.2 Multiple CSD effect on the protein levels of NR2A and GABAAα2 
How multiple CSD alters the protein level of NR2A and GABAAα2 was explored 
by western blot analysis. Comparing with sham ipsilateral group, both NR2A and 
GABAAα2 protein level were not altered at 3 and 24 hours post CSD (Figure 5.2). 
But there was a reduction trend of GABAAα2 protein level in the ipsilateral 
cerebral cortex 3 hours post CSD and this reduction trend was returned to normal 
level 24 hours post CSD (Figure 5.2 D-F). Based on the power analysis for 
GABAAα2 protein level at 3 hours, it should be able to reach significance with a 
sample size of four. 
 
Figure 5.2. Multiple CSD reduced GABAAα2, but not NR2A protein level. The 
translational changes of NR2A (A & B) and GABAAα2 (D & E) were determined by 
western blot. Bands intensity was measured by Image J (C & F). Data was shown as mean 
± SEM. Unpaired two-tailed Mann-Whitney U-test was used for comparison between sham 
ipsilateral and CSD ipsilateral groups.  
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5.3.3 Single CSD did not alter the gene expression of Grin2a and Gabra2 
To explore whether single CSD shows different effect on their gene expression, the 
mRNA level of Grin2a and Gabra2 was detected by qPCR at 24 hours post single 
CSD. There were no significant changes in both Grin2a and Gabra2 mRNA levels 
between CSD contralateral and CSD ipsilateral (Figure 5.3). Sham samples were 
not included in this study, as it was shown in Figure 4.3 and Figure 5.1 that the 
mRNA levels of Grin2a and Gabra2 were not altered by surgery during the multiple 
CSD tests.  
 
Figure 5.3 Ipsilateral Grin2a and Gabra2 gene expression was not altered 24 hours post 
single CSD. Comparison of Grin2a and Gabra2 mRNA between CSD contralateral (contra) 
cortices normalized to CSD ipsilateral (ipsi) cortices. There was no significant difference. 
(n = 3 in each group). Data was shown as mean ± SEM. Paired two-tailed Wilcoxon test 




One main finding of this chapter is that the protein level of GABAAα2 showed a  
reduced trend, but insignificant, post multiple CSD in ipsilateral cortices in rats 
(Figure 5.2), suggesting that GABAAα2-containing inhibitory receptors may be 
involved in multiple CSD-associated TBI and stroke. This finding is in line with 
down-regulation of the GABAAα2 subunit observed in the lesioned cortex 
associated with a stroke (Sacco et al., 2009). This reduced trend of GABAA α2 adds 
new evidence supporting the vital role of GABAA receptors in the pathophysiology 
of stroke as there are increased expression of GABAA α3 subunit and a reduction in 
GABAA α1, α2, α5 and γ2 subunits in a range of animal studies (Redecker et al., 
2002, Kharlamov et al., 2008, Schwartz-Bloom and Sah, 2001). In particular, 
GABAA α2 subtype activation suppresses retinal spreading depression (Wang et al., 
2015). Collectively, it is proposed that GABAA α2-containing receptors play a key 
role of in CSD associated with diseases. 
The reduction of GABAAα2 protein level 3 hours post CSD may not be associated 
with its reduced synthesis as mRNA levels of Gabra2 were not altered after 
multiple CSD at all the time points tested (Figure 5.1). The reduction of GABAA α2 
after CSD may be associated with its internalization as a previous study showed 
that an internalization of GABAA receptors by endocytosis was observed in status 
epilepticus (Goodkin et al., 2005), which may share similar mechanisms with  
cortical spreading depolarisation (Kramer et al., 2017). It should be noted that 
given that activation of GABAA receptor in response to GABA leads to reduction 
of CGRP release (Bourgoin et al., 1992), a key target for migraine prevention, 
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suggesting that GABAAα2-containing receptor may contribute to multiple 
CSD-induced CGRP elevation.  
Differently from Gabra2, NR2A expression was not altered post multiple CSD at 
all the points tested in ipsilateral cortices of rats (Figure 5.2). This data is consistent 
with a previous study that the immunoreactivity of NR2A was not changed on 
mouse cerebral cortex 24 hours post CSD (Chazot et al., 2002). However, a 
reduction of Grin2a expression at 24 hours, but not at 3 hours and 72 hours, post 
multiple CSD, was observed (Figure 4.3), suggesting multiple CSD led to a 
transient mRNA reduction of Grin2a. This transient reduction may not have 
affected NR2A levels post CSD as NR2A was not altered (Figure 5.2). Notably, 
inhibition of NR2A-containing NMDA receptors prevents the occurrence of CSD 
both in chick retina (Wang et al., 2012) and rats (Bu et al., 2016a). Taken together, 
it is possible that there is a negative feedback that NR2A activation contributes to 
CSD genesis and propagation, which may in return lead to down regulation of 
Grin2a expression. Further studies on a more extensive template changes of NR2A 
post multiple CSD will help to elucidate this notion. A relevant study is that in 
combined striatum-hippocampus-cortex slices, there is a local and remote increase 
of NMDA receptor binding sites was observed 1 hour post CSD induction (Haghir 
et al., 2009), which supports the important involvement of NR2A in CSD.  
Unlike multiple CSD, Grin2a level was not altered by single CSD in rat ipsilateral 
cerebral cortices at 24 hour post CSD (Figure 5.3). This data are in line with the 
induction of CGRP gene expression was observed by multiple but not single CSD 
(Wang et al., 2016b). The single CSD event is associated with human migraine 
aura; whilst multiple CSD events are more commonly associated with TBI. This 
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data support that multiple CSD has more pronounced impacts on altering gene 
expression involved in pathogenesis of TBI or stroke associated with CSD. Taken 
together that antagonism of NR2A-containing NMDA receptors show protective 
effects against TBI (Katayama et al., 1990, LaPlaca and Thibault, 1998, Merchant 
et al., 1999). These results that the reduction of NR2A mRNA level post multiple, 
not single CSD, suggested the protective role of NR2A-containing NMDA 
receptors in the pathological processes of TBI.  
In summary, multiple CSD events does not alter GABAA α2 gene expression but 
can cause a slight but insignificant down-regulation of its protein level in ipsilateral 
cerebral cortices of rats. Further work by increasing sample number is necessary to 











P2X7R contributes to CSD  
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6.1 Introduction  
The endogenous nucleotide, ATP, has been known to be involved in migraine 
(Burnstock and Ralevic, 2014) and can be released in response to both CSD 
(Schock et al., 2007) and CGRP in meninges (Yegutkin et al., 2016). The 
ATP-gated P2X7R is of particular interest as in a nitroglycerin (NTG)-induced 
mouse model of migraine, a selective P2X7R antagonist, brilliant blue G, 
completely prevented the effect of NTG in wild-type, but not in knockout mice 
(Goloncser and Sperlagh, 2014). Additionally, Panx1 is considered to either 
regulate P2X7R pore formation or form the pore itself by tightly coupling with the 
P2X7R after activation (Pelegrin and Surprenant, 2006). Indeed, inhibition of the 
P2X7R-Panx1 complex suppresses spreading depolarization (Chen et al., 2017b). 
Furthermore, P2X7R deficient mice were found to have reduced CSD (Chen et al., 
2017b) and lack of hypersensitivity to mechanical and thermal stimuli (Chessell et 
al., 2005). Blockade of P2X7R attenuates post-ischemic damage 
(Cisneros-Mejorado et al., 2015) and shows seizure suppressive and 
neuroprotective effect in epilepsy models (Henshall et al., 2013, Jimenez-Pacheco 
et al., 2013, Engel et al., 2012), which shows moderate co-morbidity with migraine 
(Deprez et al., 2007, Farkas et al., 2008). Notably, the C-terminus of P2X7R is 
implicated in regulating receptor function, such as pathway activation and 
protein-protein interaction (Costa-Junior et al., 2011). 
In light of this evidence, this part of the thesis studied whether the suppressive 
effects on CSD by inhibition of both P2X7R ion channel and the pore formation 
could be also observed in the mouse slice and the role of P2X7R in CSD is of 
non-vascular origin. Then this project further explored if an anti-P2X7R antibody 
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acting on the C-terminus of this receptor could inhibit the occurrence of CSD using 
both in vitro and in vivo models. Knowing that CSD can increase the mRNA levels 
of proinflammatory cytokines, such as IL-1β and TNF-α at 4 hours and CGRP at 24 
hours post multiple CSD waves (Jander et al., 2001, Wang et al., 2016b), this study 
also examined whether C-terminus of P2X7R would lead to an induction of IL-1β, 
TNF-α and CGRP gene expression induced by CSD in the rat cerebral cortex. 
6.2 Objectives  
(i) To determine whether the action of P2X7R ion channel and P2X7R- Panx1 
pore complex on CSD is of non-vascular origin using chick retina and 
mouse brain slice.  
(ii) To examine whether blockade of P2X7R C-terminal domain by an antibody 
could prevent CSD occurrence. 
(iii) To investigate whether an anti-P2X7R antibody would alter the gene 
expression of IL-1β, TNF-α and CGRP in cerebral cortex of rats 
immediately after CSD. 
6.3 Results 
6.3.1 P2X7R is expressed in chick retina 
Before determining effects of P2X7R antagonism on RSD genesis and propagation, 
P2X7R protein expression was tested on chick retina by western blot. As P2X7R 
protein is expressed in the rat cerebral cortex (Franke et al., 2004), rat cortex was 
also tested as the positive control. Abundant protein expression was observed in 
chick retina, which shows similar levels as those of rat cerebral cortex (Figure 6.1), 
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indicating that chick retina is a suitable tissue for P2X7R pharmacological study 
and indicating an important functional role of P2X7R in chick retina.  
  
Figure 6.1 Expression of P2X7R in the chick retina. The P2X7R protein expression in 
chick retina was detected by western blot. The rat cerebral cortex was used as a positive 
control (left column). 
6.3.2 P2X7R antagonist A740003 did not suppress RSD in chick retina 
A740003, a competitive P2X7R antagonist inhibiting both P2X7R ion channel and 
pore formation (Honore et al., 2006), was used to investigate the role of P2X7R in 
RSD genesis and propagation. In the DMSO control group, RSD magnitude 
slightly reduced over 10 repeated RSD and the propagation rate was not altered 
throughout experiment (Figure 6.2). A740003 at concentration 10 μM showed no 
suppressive effects on both the RSD magnitude and propagation rate, when 
compared with the DMSO control group (Figure 6.2).  
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Figure 6.2 Effects of A740003 on the magnitude (AUC) (A) propagation rate (B) of 
RSD induced by 0.1 M KCl in the chick retina. P2X7R antagonist A740003 (dissolved 
in DMSO) treatment group and one vehicle DMSO group were tested (n=3 in each group). 
Ten RSD in total were induced with 20 minute interval and three perfusion media were 
tested in each experiment: initial two RSD in perfused ringer’s solution, six RSD in 10 μM 
A740003 drug perfused solution and final two RSD in Ringer’s solution. Data (mean ± 
SEM) were plotted as percentage of initial control value. Unpaired two-tailed 
Mann-Whitney U-test was used for comparison between DMSO and A740003 group at 
each time point.  
6.3.3 P2X7R antagonist A740003 suppress CSD in the mouse brain slice 
Whether blockade of the P2X7R channel and pore complex could suppress CSD 
was further examined in mouse brain slice. In the 2nd CSD of the Kreb’s control 
group, CSD latency and magnitude were 128.7% ± 67.3% and 108.8% ± 13.4% 
and relative to their respective baselines (the 1st CSD) (Figure 6.3 A and C) and the 
propagation rate was 5.9 ± 2.4 mm/minute (Figure 6.3 B). Neither 0.03% DMSO 
nor A740003 at 1 μM changed these parameters when compared with respective 
Kreb’s control group (Figure 6.3). Notably, A740003 at 3 μM increased the CSD 
latency to 3.3-fold relative to its initial control value and this prolongation was 
significant when compared with that of the Kreb’s control and DMSO vehicle 
controls (p = 0.0011 and p =0.0043 respectively, Figure 6.3 A and D). Additionally, 
the drug at 3μM also markedly reduced the CSD magnitude to 55.8% relative to its 
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initial control value and this reduction was significant when compared with that of 
both Kreb’s control and 0.03% DMSO vehicle group (p = 0.013 and p = 0.0076, 
respectively, Figure 6.3 C and D). Conversely, unlike the CSD magnitude and 
latency, A740003 at both concentrations applied did not alter CSD propagation rate 
(Figure 6.3 B). 
  
Figure 6.3 Inhibitory effects of the P2X7R antagonist, A740003, on the latency (A), 
propagation rate (B), magnitude (C) of CSD induced by 260 mM KCl ejection onto mouse 
brain slices and representative traces showing CSD waves in each group (D). Four groups 
were designed including Kreb’s as the control, DMSO as the vehicle control, 1 µM and 3 
µM of A740003 drug (n = 6 in each group). Data was shown as mean ± SEM. Unpaired 
one-tailed Mann-Whitney U-test was used for comparison between each group. *p < 0.05; 
**p < 0.01. 
  
 97 
6.3.4 Suppression of CSD by an anti-P2X7R antibody in the mouse brain slice 
Whether blockade of the C-terminus of P2X7R by an anti-P2X7R antibody 
suppress CSD was further examined in the mouse brain slice. In the Kreb’s control 
group, the CSD latency and magnitude were 170.1% ± 38.9% and 72.1% ± 6.0% 
relative to their respective baseline (Figure 6.4 A and C) and the propagation rate 
was 5.0 ± 1.1 mm/minute (Figure 6.4 B). The anti-IgG antibody had no effects on 
CSD when compared to that of Kreb’s control. The CSD latency, magnitude and 
propagation rate were 162.1% ± 33.4%, 72.4% ± 7.1% and 5.6 ± 1.6 mm/minute in 
respective order in the anti-IgG antibody group (Figure 6.4). Consistent with the 
P2X7R antagonist, pre-incubation of the brain slice with the anti-P2X7R antibody 
at 3 µg/ml markedly prolonged CSD latency to 451.0% ± 120.0% (Figure 6.4 A), 
which was significant when compared to that of the Kreb’s group (p = 0.0465) and 
anti-IgG antibody control (p = 0.0206). CSD magnitude was also slightly reduced 
by the antibody, but this reduction did not reach significance (Figure 6.4 C) and it 
showed no effect on CSD propagation rate (Figure 6.4 B). 
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Figure 6.4 Effects of the anti-P2X7R antibody on the latency (A), propagation rate (B), 
magnitude (C) of CSD induced by 260 mM KCl onto the somatosensory cortex of mouse 
and representative traces of CSD wave in each group (D). Four groups were designed 
including Kreb’s as control, glycerol (n = 6) as the vehicle control, anti-IgG antibody was 
negative control, 3 µg/ml of anti-P2X7R antibody (n = 6). Data was shown as mean ± SEM. 
Unpaired one-tailed Mann-Whitney U-test was used for comparison between each group. 
*p < 0.05. 
6.3.5 Correlation analysis of CSD latency with magnitude in mouse brain slices 
I further carried out correlation analysis of CSD latency with CSD magnitude in 
mouse brain slices. The results showed that after treatment of 0.3 µM A740003 and 
anti-P2X7R antibody, reduced CSD magnitude showed a negative correlation with 
the increased CSD latency (r = -0.507, p = 0.0006, Figure 6.5). 
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Figure 6.5 Correlation analysis of CSD latency with magnitude (AUC) in mouse brain 
slices. The reduced CSD magnitude negatively correlated with the increased of CSD 
latency after treatment of 0.3 µM A740003 and anti-P2X7R antibody. Two-tailed 
Spearman’s correlation analysis. 
6.3.6 Suppression of CSD by an anti-P2X7R antibody in vivo in rats 
Whether the anti-P2X7R antibody could suppress the occurrence of CSD was 
further explored in rats. In the sham group, no CSD could be induced when 
glycerol was perfused into the i.c.v. in the absence of KCl application. Topical 
application of 2M KCl for 30 minutes induced multiple CSD waves in anti-IgG and 
anti-P2X7R antibody. In the anti-IgG group, the CSD latency, magnitude, 
propagation rate and number were 149.6 ± 9.0 seconds, 3.3 ± 0.2 mm/minute, 7.0 ± 
0.9 mV× minute and 5.8 ± 0.4 in respective order (Figure 6.6 A-D). Similar as that 
in the mouse brain slice, perfusion of 0.6 μg of the anti-P2X7R antibody into the 
contralateral i.c.v. significantly prolonged the CSD latency to 272.9 ± 9.4 seconds 
(p = 0.0013 Figure 6.6 A). Corresponding to this, the anti-P2X7R antibody 
markedly reduced the propagation rate to 1.9 ± 0.2 mm/minute (p = 0.0013, Figure 
6.6 B) and CSD number to 4.2 ± 0.2 (p = 0.0058, Figure 6.6 D) compared with the 
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anti-IgG antibody group. The anti-P2X7R antibody did not alter the CSD 
magnitude (p = 0.2317, Figure 6.6 C). 
 
Figure 6.6 Inhibitory effects of the anti-P2X7R antibody on the CSD latency (A) 
propagation rate (B) magnitude (C), number (D) in rats. Two groups were designed 
including anti-IgG antibody (n = 8) as the negative control and anti-P2X7R antibody (n = 
8). Data was shown as mean ± SEM. Unpaired one-tailed Mann-Whitney U-test was used 
for comparison between the two groups. *p < 0.05 ; **p < 0.01. 
 
6.3.7 Correlation analysis of CSD latency with CSD number in vivo  
Correlation of CSD parameters in vivo was also analysed in rats. As the CSD 
propagation rate was calculated by the distance (5 mm) between the two holes 
dividing the CSD latency, the negative correlation ship between CSD latency and 
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propagation rate was caused by calculation method. In this case, only correlation of 
CSD latency with CSD number was analysed. The reduced CSD number negatively 
correlated with the increased of CSD latency, but this correlation did not reach 
significant (r = -0.3536, p = 0.2148, Figure 6.7). 
 
Figure 6.7 Correlation analysis of CSD latency with CSD number in rats. Two-tailed 
Pearson’s correlation analysis. 
6.3.8 The anti-P2X7R antibody did not alter the rapid induction of IL-1β and 
TNF-α mRNA level by CSD 
Whether multiple CSD could immediately induce rapid induction of IL-1β, TNF-α 
and CGRP gene expression and whether P2X7R contributes to the CSD-induced 
induction of TNF-α, IL-1β and CGRP gene expression was examined. As described 
above, anti-P2X7R antibody or anti-IgG antibody was pre-perfused into 
contralateral i.c.v 4 days prior to CSD induction by KCl in rats. Compared with the 
sham group, the gene expression of IL-1β and TNF-α, but not CGRP, were 
significantly induced immediately after multiple CSD induction in the anti-IgG 
antibody group and the mRNA levels increased to 9.94 ± 1.63 (10-fold, p < 0.001) 
and 2.99 ± 0.21 (3-fold, p < 0.0001) respectively (Figure 6.8). 
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Pretreatment of the anti-P2X7R antibody into i.c.v. did not alter the CSD-induced 
rapid induction of ipsilateral IL-1β and TNF-α gene expression in rats compared 
with anti-IgG antibody group. The mRNA levels were maintained at the same 
levels as those of the anti-IgG antibody group (Figure 6.8 A &.B). The antibody 
also did not alter the basal level of CGRP gene expression maintained immediately 
post-CSD (Figure 6.8 C). 
Figure 6.8 Effects of the multiple CSD and anti-P2X7R antibody on the gene expression 
of TNF-α, IL-1β and CGRP in rat cortices. CSD rapidly induced ipsilateral IL-1β and 
TNF-α gene expression, but not CGRP. Anti-P2X7R antibody did not alter the rapid 
induction of IL-1β and TNF-α gene expression by CSD (n = 8 in sham and anti-P2X7R 
antibody group, n = 9 in anti-IgG antibody group).. Data was shown as mean ± SEM. 
Two-tailed unpaired t-test was used for comparison between each group. ***p < 0.001; 
****p < 0.0001. Abbreviation: Ab, antibody. 
 
6.4 Discussion  
This chapter showed that both P2X7R antagonist, A740003, and anti-P2X7R 
antibody are capable of suppressing CSD. First, pharmacological blockade of the 
P2X7R channel and pore complex by antagonist A740003 suppressed CSD with a 
significant prolongation of CSD latency and a reduced magnitude in the mouse 
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brain slice (Figure 6.3). These data suggest that mouse brain slice CSD is valid for 
the pharmacological study of P2X7R and P2X7R plays a key role in regulating 
CSD. Second, consistent with the mouse brain slice data, pretreatment of the 
anti-P2X7R antibody also suppressed CSD with a reduced cerebral cortex 
susceptibility to CSD in rats as evidenced by the extended CSD latency and 
reduced propagation rate and number of CSD waves (Figure 6.6). Finally, these 
data are consistent with a previous finding that inhibition of P2X7R-Panx1 channel 
and pore formation reduces CSD susceptibility in rats (Chen et al., 2017b). 
Collectively, these results support the critical role of P2X7R in the underlying 
mechanism of CSD-associated neurological diseases, such as migraine, TBI and 
stroke. 
It was noted that unlike in the mouse brain slice (Figure 6.3), rat cortex in vivo 
(Figure 6.6) and a previous study in rats (Chen et al., 2017b), the suppressive effect 
of P2X7R antagonist was not observed in the RSD model (Figure 6.2). The reason 
to account for these differences is not known. It was demonstrated that the presence 
of P2X7R was detected in the tissue (Figure 6.1), which complements previous 
findings that P2X7R was expressed on chick embryo retina cells (Anccasi et al., 
2013). Therefore, the negative results on suppressing RSD in the chick retina 
cannot be due to the lack of receptor. It is possible that there are marked species 
differences leading to functional difference in antagonist pharmacology for P2X7R. 
Isoquinolone derivatives such as KN-04 and KN-62 block human P2X7R with low 
nanomolar concentration, but little effects at rodent P2X7R, even at high 
micromolar concentration (Humphreys et al., 1998, Baraldi et al., 2004). 
Conversely, Brilliant Blue G is twenty times more potent at rat P2X7R than human 
(Jiang et al., 2000). Another possibility may be due to the small sample number (n 
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= 3 only) used in chick retina as preliminary data. As the drug concentration used 
in chick retina is quite high, to save the drug, I did not further increase sample 
number. Whether the negative data in the chick retina is associated with the lack of 
blood vessels in the chick retina is uncertain as the fact that inhibition of P2X7R by 
A740003 suppressed CSD was observed in the mouse brain slice argues this 
possibility. The finding that mouse brain slice lacks blood vessels and the 
suppressive effect on CSD was observed in this tissue suggest the neuronal/glial 
action and unlikely to involve the blood vessels. 
The anti-P2X7R antibody is capable of suppressing CSD both in vitro and in vivo. 
This finding extends to the previous publication that blockade of the receptors ion 
channel and pore formation as well as genetic deletion of P2X7R suppressed CSD 
(Chen et al., 2017b). Notably, the CSD propagation rate and magnitude were 
distinct between in vitro and in vivo studies using anti-P2X7R antibody. Also, the 
negative correlation of CSD latency with magnitude in vitro was not observed in 
vivo. These may result from the lack of blood vessels in the mouse brain slice 
model compared that of the rat, in the former relevant signalling molecules released 
from these cells after CSD being removed by the continuous Kreb’s perfusion. It’s 
not clear how the antibody enters the cells, acting on the intracellular C-terminus of 
P2X7R. Perhaps there was a change of the membrane property in response to CSD 
allowing the antibody to cross the membrane. This is possible as increased 
permeability of neuronal membranes to large molecules is observed following 
experimental TBI in vivo (Pettus et al., 1994, Pettus and Povlishock, 1996). 
Nevertheless, it assumes that the mechanism of the anti-P2X7R antibody in 
suppressing CSD elicitation and propagation may be related to the function of the 
receptor C-terminus for several reasons. First, the pore formation of P2X7 receptor 
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is regulated by a distal C-terminal region (Smart et al., 2003), whilst blockade of 
the pore formation suppresses CSD. Second, the Src homology 3 (SH3) domain of 
the C-terminus of the P2X7R functions to interact with Src family kinase (SFK) 
(Iglesias et al., 2008, Suadicani et al., 2009); whilst SFK activation is required for 
CSD propagation as a single CSD can induce SFK activation and its inhibitor 
suppresses CSD in rats (Bu et al., 2017). Third, the arginine and lysine residues at 
positions R578 and K579 within the C-terminus of the P2X7R are essential to 
locate P2X7R on the cell surface (Denlinger et al., 2003); It is likely that blocking 
the vicinity region of the C-terminus would have an influence on the P2X7R cell 
surface expression thus controlling receptor trafficking and modulating the channel 
activity, which may subsequently alter CSD (Chen et al., 2017a). The suppressive 
effects on CSD by this antibody may due to function loss of C-terminus or the 
function changed of P2X7R channel and pore complex which is caused by complex 
conformation change due to combination of anti-P2X7R antibody. Another 
possibility is that this antibody did not work selectivity as the antibody also 
recognised an unspecific protein (70 kDa), which was close to P2X7R (75 kDa) in 
negative control HEK293 cells (Communications with Abcam), for which reason, 
the manufacture of anti-P2X7R antibody applied was discontinued by Abcam after 
completion of all the experiments. Therefore, the major limitation of this study is 
that there is no direct evidence showing the blockade of P2X7R C-terminus by the 
antibody. In the future, it is necessary to confirm the role of C-terminal domain of 
P2X7R in CSD by expressing a C-terminal truncated variant of P2X7R in the 
P2rx7 gene deficient rats/mice. 
The possibilities to account for the suppression of CSD by blockade of P2X7R may 
be associated with a range of signaling pathways (Figure 6.9). As CSD induces 
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ATP release (Schock et al., 2007), partially acting on P2X7R (Yegutkin et al., 
2016), which activation in return mediates cerebral cortex susceptibility to CSD, 
we therefore propose a possible positive feedback loop of P2X7R during CSD 
associated neurological disease. Another possibility may link to glutamate receptor 
signalling. P2X7R activation leads to glutamate release from rat cortical nerve 
terminals (Marcoli et al., 2008, Di Cesare Mannelli et al., 2015); whereas the 
NMDA receptor of glutamate and its major NR2 subunits (NR2A and 
NR2B)-containing receptors are known to contribute to the initiation and 
propagation of CSD (Bu et al., 2016a, Obrenovitch et al., 1996, Peeters et al., 2007, 
Wang et al., 2012, Deuchars et al., 2001). Moreover, SH3 domain of the P2X7R 
C-terminus is involved in the initial step of the signal transduction events causing 
the activation of Panx1 channel, the latter of which is induced following multiple 
CSD (Karatas et al., 2013). In fact, blockade of the interaction between P2X7R and 
Panx1 was recently reported to suppress CSD depolarization in rodents (Chen et al., 
2017b). Furthermore, Both P2X7R antagonists and Panx1 inhibitors can revert 
oxaliplatin-induced neuropathic pain (Di Cesare Mannelli et al., 2015). Moreover, 
P2X7R channels are highly permeable to Ca2+ and calcium influx accelerates CSD 
propagation in rats (Torrente et al., 2014). Collectively, the underlying mechanism 
underlying the role of P2X7R in CSD is therefore multifactorial. 
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Figure 6.9 Schematic depiction of the potential underlying mechanisms of P2X7R 
contribution to CSD. First, the C-terminus of P2X7R can interact with SFK, while SFK 
activation is required for CSD induction. Second, The C-terminus of P2X7R is involved in 
Panx1 activation, which can be induced by multiple CSD. Third, CSD can induce ATP 
release, which activates P2X7R. Moreover, P2X7R activation leads to glutamate release 
whereas its NMDA receptors are known to contribute to the CSD initiation and 
propagation. Finally, P2X7R channels are highly permeable to Ca2+ and calcium influx 
accelerates CSD propagation in rats. 
 
We explored if our antibody model not only modulated CSD but the associated 
differential gene expression observed. Gene expression of pro-inflammatory 
cytokines can be induced within 4 hours post CSD in the rat brain (Jander et al., 
2001) and their protein levels can also be increased by CSD (Kunkler et al., 2004, 
Grinberg et al., 2013). The present study extends these findings demonstrating a 
rapid induction of TNF-α and IL-1β gene expression in the ipsilateral cerebral 
cortex of rat immediately after multiple CSD. The immediate induction of IL-1β 
and TNF-α mRNA level by CSD is unlikely to result from the action of the 
anti-IgG antibody, because our preliminary experiments examined that CSD 
glycerol i.c.v significantly induced IL-1β and TNF-α mRNA level compared with 
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sham glycerol i.c.v. group. The brain inflammatory response is likely to occur as a 
consequence of microglia activation, which is related to astrocytosis during CSD in 
rat brain tissues (Ghaemi et al., 2017). Given that IL-1β can exacerbate ischaemic 
brain damage in middle cerebral artery occlusion models in rats (Yamasaki et al., 
1995), the CSD-induced IL-1β and TNF-α upregulation may become a therapeutic 
target for preventing stroke and TBI associated with multiple CSD. 
Different from a marked elevation of CGRP mRNA level at 24 hours post multiple 
CSD (Wang et al., 2016b), the induction of CGRP gene expression was not 
observed immediately post CSD and anti-P2X7R antibody also did not alter its 
gene expression in our study. This may reflect the time course used in this 
experiment. Although qPCR analysis of CGRP gene did not show any significant 
changes, it does provide a negative control for gene expression changes in response 
to CSD and provides support that the observed induction of TNF-α and IL-1β was a 
specific response to CSD rather than an experimental artifact.  
P2X7R activation is known to promote release of TNF-α (Suzuki et al., 2004) and 
IL-1β in hippocampus slice (Verhoef et al., 2003, Bernardino et al., 2008). 
Additionally, a significant down-regulation of IL-1β mRNA level after 30 minutes 
pretreatment of a P2X7/Panx1 pore inhibitor, A438079, was observed 4 hours post 
CSD (Chen et al., 2017b). On contrary, in this study, pretreatment of the 
anti-P2X7R antibody 4 days before the CSD induction did not influence 
CSD-induced rapid induction of ipsilateral cortical IL-1β and TNF-α gene 
expression. It is possible that changes of these gene expression have temporal 
profile. Such mRNA level change may have not been picked up at the time point 
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immediately post CSD. Extensive time points may help to address this result in 
future. 
In conclusion, the data demonstrates that the anti-P2X7R antibody is capable of 
suppressing CSD, which may attribute to the C-terminal domain of P2X7R, or the 
non-specific binding of this antibody.. This data may offer a novel therapeutic 
strategy for CSD associated neurological disease, such as migraine, TBI and stoke, 
as antibodies have been increasingly used to prevent CSD associated diseases, 
















The key findings of this thesis have two folds: (i) A slight but insignificant 
up-regulation of REST4 was observed post CSD. This statistically insignificance 
mainly attribute to the small sample number. The potential involvement of REST4 in 
CSD processes cannot be ruled out as power analysis suggests a significance can be 
reached when the sample size increases to four. (ii) Blockade of P2X7R by both the 
receptor antagonist and an antibody was capable of suppressing CSD, although 
studies on the latter using an alternative monoclonal antibody requires further 
clarification. These data suggest P2X7R as potential target for the therapy of 
CSD-associated neurological disease, such as TBI, stroke and migraine aura.  
One key finding is that REST4 may be involved in the progression of CSD by 
influencing subsequent targets and the target-associated genes as the mRNA level of 
transcriptional regulator REST4 showed a transient up-regulation, although 
insignificant, in the ipsilateral cerebral cortex of rats post 3 hours of multiple CSD. 
The mechanism to account for this change has not been well explored. It is known 
that REST4 functions as antagonism of full-length REST (Tabuchi et al., 2002). 
Whilst CSD-induced transient elevation trend of REST4 (Figure 4.1) is associated 
with the reduced binding of full-length REST to rImir137 promoter after CSD in 
ipsilateral cerebral cortices of rats (Warburton, 2015 pp 277-281). Given that a 
significant reduction of Grin2a was observed in ipsilateral cerebral cortices of rats 24 
hours post multiple CSD (Figure 4.3), it is possible that the reduced binding of REST 
to rImir137 promoter by CSD may cause increased miR-137 level, whilst miR-137 
functions to suppress its target genes Grin2a.  
It is proposed that the transient up-regulation trend of the REST4 transcript after 
multiple CSD may confer an adaptive neuroprotective effect, providing ischemic 
tolerance against subsequent insults after TBI. This notion was proposed based on the 
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following facts: Activation of Grin2a encoding NR2A-containing NMDA receptor is 
required for the CSD initiation (Bu et al., 2016a, Wang et al., 2012); whilst, the 
altered expression of Grin2a corresponds with the time frame in which increased 
tolerance to subsequent neuronal attacks induced by various preconditioning methods 
(Yanamoto et al., 2004). Additionally, the REST target GAD1 mRNA level was 
slightly increased by multiple CSD. GAD1 encodes a key enzyme during the 
synthesis of GABA, which is released post CSD (Clark and Collins, 1976). Whilst, 
activation of GABAA receptor is known to suppress the initiation and propagation of 
CSD (Akerman and Goadsby, 2005). Collectively, we propose that up-regulation of 
the REST4 transcript after multiple CSD may confer an adaptive neuroprotective 
effect, providing ischemic tolerance against subsequent insults after TBI. 
There are several main limitations of REST study, which are as follows: (i) The data 
for REST4 gene expression lacks statistical significance, which may be caused by the 
small sample number, increasing sample number need to be considered in further 
work. (ii) These three specific time points may have missed some of the transient 
changes of REST and MIR137HG mRNA levels following CSD. Extensive time scale 
and other brain regions are necessary to explore their gene expression under both 
multiple and single CSD condition. (iii) Due to the lack of commercial specific 
anti-REST4 antibody, further studies are necessary to develop anti-REST4 specific 
antibody to explore specific REST4 binding over rImir137 promoter, as well as the 
effects of CSD on the protein expression of REST and REST4. (iv) Other MIR137 
parent transcripts, as well as the mature miR-137 level are necessary to be explored to 
address the consequences of the increased REST4 mRNA levels. (v) Future study 
should be carried out to examine if overexpression or knockout of REST would 
influence the initiation of CSD, as well as its subsequent gene expression. 
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Another key finding of this thesis is that the C-terminal domain of P2X7R may play a 
pivotal role of CSD genesis and propagation. The anti-P2X7R antibody targeting its 
C-terminus suppresses CSD both in vitro mouse brain slices and in vivo rats. Its 
C-terminal domain functions to regulate the pore formation of this receptor (Smart et 
al., 2003). Pharmacological inhibition of the P2X7R channel and pore complex 
suppressed CSD in mouse brain slices, which are in line with previous findings in rats 
(Chen et al., 2017a). The molecular mechanism by which P2X7R modulate cortical 
susceptibility to CSD has not been studied previously, but P2X7R signal is divergent 
involving multiple pathways. One plausible explanation is that P2X7R C-terminus 
functions to interact with SFK, while, the activation of this receptor is required for 
CSD genesis and propagation (Bu et al., 2017). Secondly, P2X7R activation leads to 
glutamate release (Marcoli et al., 2008, Di Cesare Mannelli et al., 2015). The NMDA 
receptor of glutamate is known to contribute to the initiation and propagation of CSD 
(Bu et al., 2016b, Obrenovitch et al., 1996, Peeters et al., 2007, Wang et al., 2012, 
Deuchars et al., 2001). Moreover, the function of P2X7R on CSD may attribute to its 
highly permeable property to Ca2+ and calcium influx accelerates CSD propagation in 
rats (Torrente et al., 2014). These data offers a novel antibody therapeutic strategy for 
CSD-associated neurological disease to increase the efficacy to toxicity window for 
the therapy, as well as lower the dosage needed, as drugs usually need to be dosed at, 
or very near, their maximum tolerated dose in order to achieve the desired therapeutic 
efficacy. 
The main limitation of P2X7R study is lack of direct evidence showing the blockade 
of P2X7R C-terminus by the antibody. Further in vivo experiments are necessary to 
expresses a C-terminal truncated variant of P2X7R in the P2rx7 gene deficient 
rats/mice to confirm the role of specific C-terminal region of P2X7R in CSD. Also, 
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the potential underlying mechanisms mentioned above are worth to be explored in 
future studies. 
In conclusion, this project focused on two factors in CSD as follows: (i) This study 
does not support the truncated isoform of transcriptional regulator REST, REST4, is 
implicated in CSD progression. However, the transient but insignificant increase by 
CSD may be associated with changes of subsequent target gene expression, such as 
GAD1 and Grin2a; (ii) P2X7R plays a pivotal role in CSD. Whether C-terminal 
domain is involved in regulating CSD requires further clarification. These studies 
provide insight into the genetic and molecular mechanisms of CSD and offers novel 
therapeutic strategy for preventing CSD-associated neurological diseases, such as 
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Appendix 1:  ChIP analysis of REST binding to the two MIR137 promoters 
 
Figure A. Differential REST binding over the rImir137 and rMIR137HG promoter 
in rat cerebral cortex. (A) Illustrates predicted transcription factor binding for 
REST over the MIR137 locus from human ENCODE ChIP-seq data (March 2012 
release), as well as primers spanning the MIR137HG and Imir137 promoters. (B). 
Multiple CSD reduced REST binding over the rImir137 promoter, but not 
rMIR137HG promoter, in ipsilateral cortex of rats at 24 hours post-CSD. ChIP 
analysis of chromatin extracted from both contralateral and ipsilateral cortices of 
rats 24-hour post-CSD (n = 3) was performed using antibodies against the C-REST 
and the N-REST, with histone H3 as a positive control. Abbreviation: IP: 
immunoprecipitation; C-NRSF: the C-terminal of NRSF; N-NRSF the N-terminal of 
NRSF; No Ab: no antibody control. 
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Abstract
Objective: The neuropeptide calcitonin gene-related peptide (CGRP) has now been established as a key player in
migraine. However, the mechanisms underlying the reported elevation of CGRP in the serum and cerebrospinal fluid of
some migraineurs are not known. A candidate mechanism is cortical spreading depression (CSD), which is associated
with migraine with aura and traumatic brain injury. The aim of this study was to investigate whether CGRP gene
expression may be induced by experimental CSD in the rat cerebral cortex.
Methods: CSD was induced by topical application of KCl and monitored using electrophysiological methods.
Quantitative PCR and ELISA were used to measure CGRP mRNA and peptide levels in discrete ipsilateral and contra-
lateral cortical regions of the rat brain 24 hours following CSD events and compared with sham treatments.
Results: The data show that multiple, but not single, CSD events significantly increase CGRP mRNA levels at 24 hours
post-CSD in the ipsilateral rat cerebral cortex. Increased CGRP was observed in the ipsilateral frontal, motor, somato-
sensory, and visual cortices, but not the cingulate cortex, or contralateral cortices. CSD also induced CGRP peptide
expression in the ipsilateral, but not contralateral, cortex.
Conclusions: Repeated CSD provides a mechanism for prolonged elevation of CGRP in the cerebral cortex, which may
contribute to migraine and post-traumatic headache.
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Introduction
Migraine is a complex, multifactorial neurological dis-
order that is conservatively estimated to affect !12% of
Americans (1). The most prominent characteristic of
migraine is the disabling headache, which manifests as
a throbbing, unilateral pain made worse with routine
activity, and coincident with nausea/vomiting and/or
photophobia/phonophobia. Approximately one-third
of migraineurs experience a premonitory aura, which
typically manifests as a disruption in the ipsilateral
visual hemifield (2). The pathophysiological substrate
of the visual aura is cortical spreading depression
(CSD), a transient wave of neuronal and glial depolar-
ization, followed by a sustained depression of electrical
activity (3,4). CSD is associated with a massive trans-
location of ions and release of nitric oxide, arachidonic
acid, glutamate, and ATP (5,6). The sudden rise in
extracellular Kþ, arachidonic acid and nitric oxide is the
likely trigger for CSD-induced activity in meningeal noci-
ceptors (7) and central trigeminovascular neurons (8).
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CSD may also lead to migraine by potentiation of an
inflammatory response in the dura (9).
In addition to the connection between migraine and
CSD, it is well accepted that CSD also occurs following
acute brain injuries, such as traumatic brain injury
(TBI) and strokes (10–12). Whereas the pattern of
brain injury-triggered CSD is heterogeneous and influ-
enced by many factors, a common feature is that there
are multiple CSD events, often about every 30 minutes
for many hours to days (11). For example, 72% of sub-
arachnoid hemorrhage patients experience clusters of
repetitive CSD events (13), and 56% of TBI patients
experience repeated spreading depression events
(mostly CSD), with a total of 1328 events observed in
58 patients over 67 hours (14). Hence, brain injury in
humans can lead to tens to hundreds of CSD events
over days. Repeated CSD events have also been
observed for hours to days in some, but not all,
animal TBI models (12).
It has been shown that multiple CSD events can
modulate many genes at early (hours) and late (days
to weeks) time points across a variety of gene ontol-
ogies (15,16). A potential candidate for regulation by
CSD is calcitonin gene-related peptide (CGRP).
CGRP is a vasoactive neuropeptide that is
widely distributed in the central and peripheral ner-
vous systems. Clinical and preclinical studies have
established CGRP as a key player in migraine (17).
Intravenous CGRP administration to migraineurs is
sufficient to elicit a migraine-like headache (18,19),
and CGRP levels have been reported to be elevated
in both the serum and CSF of migraineurs (20).
Importantly, CGRP receptor antagonists and
CGRP-blocking antibodies can ameliorate migraine
symptoms (21,22).
In this report, we have asked whether CSD is suf-
ficient to alter CGRP expression. Such a link would fit
in the context of interesting, but limited, evidence of
CGRP involvement in CSD (17,23). In particular, a
calcium-dependent release of CGRP was observed
during CSD and inhibition of CGRP receptors
reduced the magnitude of CSD in rat neocortical
slices (24). Elevated CGRP may modulate neurotrans-
mission and possibly contribute to sensory hypersen-
sitivity (17,25). For this scenario, we reasoned that the
elevated synthesis, if it occurred, would likely be main-
tained for a relatively long time (24 hours). Similar
prolonged times were also required for activation of
CGRP gene expression in trigeminal ganglia organ
cultures (26), and by epigenetic reprogramming of
glial cells (27). We therefore proposed that CSD
might be a mechanism by which cortical levels of
CGRP become elevated for a prolonged period in
migraine and TBI patients.
Materials and methods
Animals
Adult male Sprague–Dawley rats (n¼ 36, 240–440 g;
Shanghai SLAC Laboratory Animal Corporation,
Ltd.) with food and water ad libitum were used.
Experimental procedures were performed in the
animal unit of Soochow University. All rats were
healthy, with no drug treatments or previous tests car-
ried out prior to experimentation. Animals were housed
two per cage in specific pathogen-free conditions with
standard bedding material and rat special synthetic
feed. Animals were allowed to acclimate to the housing
room for 7 days prior to the experiment, then matched
by body weight into experimental groups of sham and
CSD, which were performed randomly on different
days using one rat per day at various times during the
day. No animals were excluded from the analysis.
During the experiment, rats were given isoflurane anes-
thesia, which was monitored by absence of whisker
movements and lack of reaction to brief tail pinches.
After surgeries, animals were given an antibiotic and
anti-inflammatory, as described below, and outwardly
appeared healthy. Euthanasia was by excess isoflurane
exposure. All procedures were approved by the Ethic
Review Panel of Soochow University under agreement
with XJTLU, and performed in accordance with
Chinese national guidelines and in adherence to
ARRIVE guidelines.
CSD induction
Animals were anesthetized with isoflurane (5% induc-
tion, 2.5–3.5% during surgery, 1.0–1.5% maintenance)
in O2: N2O (1:2). A small incision was made and two
small burr holes were drilled carefully in the skull right
frontoparietal region (1mm i.d.; Figure 1). The poster-
ior hole (4mm posterior, 2mm lateral to bregma) was
prepared with extra care to minimize damage to the
underlying dura. A silver chloride recording electrode
was implanted through the anterior hole (3mm anterior,
2mm lateral to bregma) for recording of CSD waves. A
reference electrode was placed under the scalp. Both
holes were moisturized with artificial cerebrospinal
fluid (ACSF; 125mM NaCl, 2.5mM KCl, 1.18mM
MgCl2, 1.26mM CaCl2, pH 7.3). Rectal temperature
was maintained at 37"C. Upon completion of surgery,
rats were maintained under anesthesia for at least 1 hour
to allow for stabilization and tissue recovery.
For the multiple CSD group (n¼ 14), 1 ml of 3 M
KCl was carefully dropped into the posterior hole for
single CSD wave elicitation. As soon as the first CSD
wave was detected at the recording site, KCl was
removed using a tissue, followed by washout with
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ACSF and placement of ACSF-moistened cotton over
the hole. For the sham group (n¼ 12), 1 ml ACSF was
used. In both groups, five repeated CSD or sham epi-
sodes were elicited at 40-minute intervals. Both electro-
encephalogram (to monitor depth of anesthesia) and
direct current potentials (to monitor CSD events)
were recorded and analyzed using LabVIEW. The elec-
trode was removed and wound sutured after the fifth
CSD episode. Ibuprofen (5–10mg) and mupirocin oint-
ment (0.4–0.8mg) were applied. At 24 hours after the
fifth CSD episode, the rat was re-anesthetized for
euthanasia and tissue removal.
For the single CSD group (n¼ 5), CSD induction,
CSD recording, and post-surgery care were the same as
that for the repeated CSD, except that only one CSD
episode was elicited by 1 ml of 3 M KCl. For the sham
group (n¼ 5), 1 ml ACSF was used. At 24 hours, the rat
was re-anesthetized for euthanasia and tissue removal.
qPCR
All quantitative polymerase chain reaction (qPCR)
assays on multiple CSD tissue samples were performed
blinded at the University of Iowa using coded samples
shipped from XJTLU. Some of those samples were also
tested at XJTLU as an internal control for measure-
ments on the single CSD samples, which were done at
XJTLU. In both locations, the same protocols and
reagents were used. Whole cortex or cortical regions
(50–100mg) were homogenized in 1ml TRIzol
(Sigma-Aldrich) and RNA concentration and purity
measured by Nano-Drop (Thermo Scientific); 1 mg
total RNA was reverse transcribed into cDNA using
the GoScriptTM RT system (Promega). qPCR was per-
formed in duplicate using 1/20th of the cDNA reaction
on a Bio-Rad CFX Connect using SYBR-Green
Master Mix (Takara Clontech), except for 18S rRNA,
which used 1/20,000th of the cDNA. Primers (forward,
reverse) were: CGRP (NM_001033953.2)
50AACCTTGGAAAGCAGCCCAGGCATG30, 50GT
GGGCACAAAGTTGTCCTTCACCA30; and three





18S rRNA (NR_046237.1) 50ATGGCCGTTCTTA
GTTGGTG30, 50AACGCCACTTGTCCCTCTAA30.
All qPCR data from multiple CSD samples were ana-
lyzed using both absolute quantification of CGRP
mRNA (with standard curves) and relative fold
change (2"!!Cq method) normalized to each contralat-
eral hemisphere. The single CSD samples were analyzed
only by the relative fold change (2"!!Cq method) nor-
malized to the sham tissue. Standard curves were gen-
erated using plasmids containing PCR products in
pCR2.1 (Invitrogen) (confirmed by sequence). CGRP
mRNA levels were normalized to the product-based
geometric mean of the three reference genes (28), calcu-
lated as the cube-root of the product of the reference
genes (PPIA# b-actin# 18S)1/3 divided by 10,000.
Similar results were observed when CGRP levels were
normalized to each individual reference gene. CGRP
levels are mean$ SEM.
ELISA
Protein extraction and detection from cortex homogen-
ates followed the manufacturer’s instructions using the
CSD induction
(AP: –4 mm, L: 2 mm)
CSD recording
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Figure 1. Cortical spreading depression (CSD) induction and
propagation in the rat cortex. (A) CSD was induced with topical
application of 1ml 3 M KCl (or artificial cerebrospinal fluid for
sham) onto the dura via a posterior burr hole. An anterior hole
was used for CSD recording. A total of 36 rats were used. Of
these, 26 rats were used for multiple CSD experiments including
14 for CSD induction and 12 for sham. To minimize the animal use,
three of 14 rats in the CSD group and three of 12 in the sham
group were also used for measuring calcitonin gene-related pep-
tide (CGRP) levels in addition to CGRP mRNA. In the single CSD
group, 10 rats were used with five for CSD and sham, respectively.
(B) A representative trace showing CSD propagation and magni-
tude (indicated as area under the curve, AUC, grey lines).
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rat CGRP enzyme-linked immunosorbent assay
(ELISA) kit (Bertin Pharma). To minimize the
number of animals, cortical regions were snap frozen,
pulverized, and split to allow both protein and RNA
extractions. Due to the small amounts of tissue, it was
necessary to combine motor, somatosensory, and visual
cortices for protein, and set aside cingulate and frontal
cortices for only RNA. All protein samples were rap-
idly homogenized within 15 seconds in 2 N acetic acid
at 2ml/100mg tissue, then heated at 90!C for 10 min-
utes, centrifuged at 10,000 g for 30 minutes, dried for 1
hour, and stored at "80!C. Immediately before assay,
samples were reconstituted with enzyme immunoassay
(EIA) buffer, and analyzed using a microplate reader.
CGRP levels are mean#SEM.
Data analysis
For qPCR data, statistical analyses were performed
using GraphPad Prism software as follows: compari-
sons across groups were done using an ordinary one-
way analysis of variance (ANOVA) Kruskal–Wallis
test; comparisons between ipsilateral versus contralat-
eral hemispheres within the group were done using one-
tailed Wilcoxon –t-test; comparisons between CSD and
sham groups were done using one-tailed Mann–
Whitney t-test. For ELISA data, normal distribution
was confirmed by SPSS 16.0 software, and statistical
analyses were performed using GraphPad Prism soft-
ware with comparisons across groups using one-way
ANOVA; comparisons between ipsilateral versus
contralateral hemisphere within the group using one-
tailed paired t-test; comparisons between CSD and
sham groups using one-tailed unpaired t-test.
Results
Detection of experimentally induced CSD in rats
In the sham group, ACSF administration was insuffi-
cient to elicit CSD. In the CSD group, 1 ml of topical
3 M KCl onto the dura resulted in a CSD wave that
began $2–3 minutes after administration (Figures 1A
and 1B). CSD propagation was identified by a transi-
ent, negative shift of the direct current–potential, which
was observed in all CSD rats monitored by this means.
For the rats that underwent multiple CSD events, the
magnitude of each event was approximately 9mV%
minutes and there was no significant difference in the
number or magnitude of CSD episodes over the 5 KCl
applications (p¼ 0.89) (not shown). When summed up,
the mean accumulative magnitude of CSD for each rat
was 53.0# 10.2mV%minutes in the multiple CSD
group (n¼ 14) and 5.9# 1.8mV%minutes (n¼ 5) in
the single CSD group. Generally, only a single CSD
wave was observed after each of the applications;
although in four rats a second wave was observed
after one of the applications in the multiple CSD group.
Increased cortical CGRP gene expression
at 24 hours post-multiple CSD
In the sham group, the copy number of contralateral
and ipsilateral CGRP mRNA was 13.5# 2.9 and
14.1# 2.2, respectively (p¼ 0.69), indicating that the
surgical procedure did not significantly change CGRP
gene expression (Figure 2A).
In the CSD group, the copy number of CGRP
mRNA in the contralateral hemisphere was 18.6# 2.2,
which is not significantly different from that of contra-
lateral hemisphere in sham rats (p¼ 0.14; Figure 2A),
demonstrating that repeated unilateral CSD does not
affect CGRP gene expression in the contralateral
hemisphere. In contrast, repeated CSD events in the ipsi-
lateral hemisphere significantly increased the CGRP
mRNA copy number to 79.1# 22.7 at 24 hours post-
CSD (p< 0.001; Figure 2A). Comparison of relative
ipsilateral CGRP levels normalized to the contralateral
hemisphere of each rat agrees with the measured abso-
lute levels. The sham group showed a 1.3# 0.4-fold
increase between hemispheres, whereas the CSD group
had a significantly greater 3.8# 0.8-fold increase
(p¼ 0.004; Figure 2B).
No increased CGRP gene expression
at 24 hours post-single CSD
In the single CSD group, CSD ipsilateral cortex did not
show a significant change in CGRP mRNA levels.
There was a 1.28# 0.06-fold change compared with
that in sham ipsilateral group (p¼ 0.11; Figure 3).
Contralateral samples were not included in this test,
as it was shown that surgery did not significantly alter
CGRP gene expression during the multiple CSD tests
(Figure 2). Thus, it is very unlikely an elevation of
CGRP gene expression in the contralateral cortex
would be observed with single CSD.
Regional induction of CGRP in the cortex
We then examined CGRP mRNA levels in discrete
regions of the cortex. In the sham group, CGRP
mRNA levels in the contralateral and ipsilateral fron-
tal, motor, somatosensory, and visual cortices were
similar (Figure 4A). The cingulate had slightly higher
CGRP mRNA levels in the sham contralateral
(16.7# 4.0) and ipsilateral (32.9# 12.0) cortices
(Figure 4A), which is consistent with a previous
report that the rat cingulate has elevated CGRP relative
to other cortical regions (29). There was no significant
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change in CGRP mRNA content between contralateral
and ipsilateral hemispheres of sham frontal, cingulate,
or somatosensory cortices (p¼ 0.16, 0.11, and 0.22, in
respective order), indicating that the surgery does not
alter CGRP mRNA expression in these regions.
However, a slight, but significant, increase in CGRP
mRNA was observed in the motor and visual cortices
of sham rats (p¼ 0.016 and 0.031, respectively;
Figure 4A).
Following CSD, CGRP mRNA levels were signifi-
cantly increased in the ipsilateral frontal, motor, som-
atosensory, and visual cortices when compared with
sham (p¼ 0.013, 0.001, 0.001, and 0.001, respectively;
Figure 4A). In contrast, CSD did not alter CGRP
mRNA levels in the ipsilateral cingulate cortex com-
pared with sham (p¼ 0.45; Figure 4A). As with the
whole cortex, comparison between CSD and sham
cohorts of the relative CGRP levels normalized to the
contralateral hemisphere of each rat agreed with the
absolute levels. In the CSD rats, there were significant
increases in the ipsilateral compared with contralateral
hemispheres of the frontal cortex (8.0" 1.8, p¼ 0.013),
motor cortex (9.5" 3.1, p¼ 0.013), somatosensory
cortex (15.3" 4.0, p¼ 0.001), and visual (14.5" 5.4,
p¼ 0.001) compared with sham rats (Figure 4B).
Also, as seen with absolute expression data, the nor-
malized cingulate cortex did not exhibit a CSD-induced
increase over sham (1.6" 0.3, p¼ 0.45; Figure 4B).
Increased CGRP peptide expression
at 24 hours post-multiple CSD
Aliquots of somatosensory, motor, and visual cortices
used for RNA analyses were combined and used for
parallel peptide measurements (see Methods). In the
sham group, CGRP peptide levels were 1.4" 0.5 ng/g
tissue in the ipsilateral hemisphere and 1.8" 0.1 ng/g
tissue in contralateral (p¼ 0.27), indicating that surgi-
cal procedures do not alter overall CGRP expression





















































Figure 2. Ipsilateral calcitonin gene-related peptide (CGRP) mRNA is upregulated 24 hours post-multiple cortical spreading
depression (CSD). (a) Absolute levels of CGRP mRNA were significantly elevated in the ipsilateral (ipsi), but not contralateral (contra),
cortex post-CSD. There was no significant increase in the sham-treated rats. Data for individual rats are shown with lines connecting
the paired cortices. (b) Comparison of CGRP mRNA levels between contralateral and ipsilateral cortices shown for individual rats
(left panel) and as the fold change (right panel). Increased relative expression of CGRP mRNA in the ipsilateral normalized to
contralateral cortex. In both (a) and (b), sham (n¼ 6), CSD (n¼ 8), **p< 0.01; ***p< 0.001.























Figure 3. Ipsilateral calcitonin gene-related peptide (CGRP)
mRNA is not altered 24 hours post-single cortical spreading
depression (CSD). Comparison of CGRP levels between ipsilat-
eral (ipsi) cortices of CSD rats (n¼ 5) normalized to sham rats
(n¼ 5). There was no significant difference (p¼ 0.11).
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under these conditions (Figure 4). In the CSD ipsilat-
eral cortex, the CGRP level was 4.0! 0.6 ng/g tissue,
which was about 2.9-fold higher than sham ipsilateral
cortex (p¼ 0.014; Figure 5).
Discussion
In this study, we have shown that unilateral multiple
CSD is sufficient to upregulate CGRP mRNA and pep-





















































































(AP: +3 mm, L: 2 mm)
CSD induction
(AP: –4 mm, L: 2 mm)
Figure 4. Multiple cortical spreading depression (CSD)-induced calcitonin gene-related peptide (CGRP) mRNA expression shows
regional specificity. (a) Top view of rat brain cortical regions used for dissections. Cortical regions are designated as 1¼ frontal,
2¼ cingulate, 3¼motor, 4¼ somatosensory, and 5¼ visual. The CSD recording and induction sites are also indicated. (b) Absolute
levels of CGRP mRNA were significantly elevated in ipsilateral (ipsi) frontal, motor, somatosensory (SS), and visual cortices, but not in
the cingulate (Cing) cortex, or the contralateral (contra) hemispheres, 24 hours post-multiple CSD. (c) Significant increases in relative
ipsilateral CGRP mRNA were observed in the frontal, motor, somatosensory, and visual cortices, but not in the cingulate cortex, at 24
hours post-multiple CSD. In both panels, sham (n¼ 6), CSD (n¼ 6), *p< 0.05; **p< 0.01; ***p< 0.001.
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induction was widespread across much of the cerebral
cortex: in the frontal, motor, somatosensory, and visual
cortices, but not in the cingulate cortex. The lack of
induction in the cingulate is consistent with reports
that CSD propagation is less efficient in this region
(30). Importantly, the fact that CGRP mRNA levels
were similarly increased in multiple cortical regions
indicates that the elevated expression is attributed to
CSD, rather than depolarization in the immediate
area of KCl application. These data extend an earlier
in vitro study showing that CSD induced CGRP release
in rat neocortical slices (24). Thus, CSD might contrib-
ute to the elevated CGRP in the CSF of some migraine
patients. However, it is very unlikely that cortical
CGRP contributes to the elevation of CGRP in the
external jugular vein during migraine. Indeed, Piper
et al. (31) clearly documented that CGRP release into
the external jugular vein was not increased by experi-
mental CSD in the cat. Whether CSD increases synthe-
sis in the trigeminal ganglia remains to be determined.
A recent study reported that CSD increases the number
of CGRP-positive cells in rat trigeminal ganglia (32),
which may point to increased synthesis. Overall, these
data provide evidence linking CSD and CGRP expres-
sion that may contribute to migraine pathogenesis.
A key finding of our study was that multiple CSD
events were required for robust induction of the CGRP
gene. The experimental protocol we used was designed
to elicit multiple CSD events similar to that used in
other laboratories (9,23,33–35), but which also likely
differs from human migraine. Indeed migraine aura is
believed to involve only a single CSD event. On the
other hand, TBI is commonly associated with up to
hundreds of CSD waves that can occur over days fol-
lowing the injury (10–12). To our knowledge, the pos-
sibility that individuals with a history of head trauma
and spreading depression exhibit elevated CGRP levels
has not been investigated. However, in a recent study,
Elliott and colleagues observed a sustained elevation of
CGRP in the brainstem (most likely from the trigeminal
nerve) for at least 4 weeks in rodents exposed to con-
trolled cortical impact injury (36). This injury can cause
one to four CSD events over several hours (37). More
limited studies have also reported elevated CGRP in
other rodent TBI models (38,39). Whether from TBI
or migraine, there is increasing evidence that CSD
affects behavior and likely potentiates nociception that
may in part involve CGRP. CSD activates meningeal
nociceptors and central trigeminovascular neurons
(7,8,40), and an immediate effect of CSD is reduced
movement and freezing responses (41,42). Nonetheless,
a limitation of animal CSD studies remains extrapola-
tion to humans, especially as CSD propagation is lim-
ited by prominent sulci in the human brain that are
absent in the lissencephalic rodent brain. Within this
limitation, we predict that TBI may increase CGRP
levels to alter brain plasticity and predispose patients
to migraine-like post-traumatic headaches.
How might CSD increase cortical CGRP gene
expression? While speculative, one mechanism may be
generation of reactive oxygen species (ROS).
Migraineurs have elevated plasma levels of a ROS-
induced lipid peroxidation products (43). In rats,
CSD produces ROS in the cortex and trigeminal
nerve (44,45). Likewise, the ROS-responsive COX2
gene has been reported to be upregulated by CSD
(16). Moreover, ROS-induced CGRP gene expression
can be inhibited with antioxidant treatment in rat tri-
geminal ganglia (26). In light of these observations, we
speculate that CSD-induced ROS production can lead
to pro-inflammatory cascades that upregulate the
CGRP gene. Interestingly, a recent analysis of the lit-
erature concluded that oxidative stress is a shared fea-
ture of most migraine triggers (43).
We have provided evidence showing that CSD upre-
gulates CGRP gene expression in the cortex. Given the
promising potential of CGRP-based therapeutics for
treating and preventing migraine, a link between CSD
and CGRP further emphasizes the importance of CSD
as a target for migraine drug development (46,47). The
significance of our finding is that CSD may be a mech-
anism by which CGRP levels become elevated for a
prolonged period in some migraine patients. While
there are multiple mechanisms that can potentially
increase CGRP expression, including nitric oxide (48)
























Figure 5. Ipsilateral calcitonin gene-related peptide (CGRP)
peptide levels are upregulated post-multiple cortical spreading
depression (CSD). CGRP peptide levels are significantly elevated
in ipsilateral (ipsi) cortex 24 hours post-CSD (n¼ 3), but not the
contralateral (contra) hemispheres, nor in sham rats (n¼ 3),
*p< 0.05.
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physiological in vivo mechanism that may elevate
cortical CGRP gene expression in migraine and post-
traumatic headache. Given CGRP’s role as a
neuromodulator (17), this elevation may potentially
contribute to cortical hyperexcitability and sensory
abnormalities in migraine.
Article highlights
. Multiple CSD events can trigger CGRP gene expression in discrete regions of the rat cerebral cortex.
. This is the first in vivo evidence for a mechanism to initiate and maintain elevated CGRP levels in migraine
and post-traumatic headache.
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Original Article
Sarcoma family kinase activity is required
for cortical spreading depression
Fan Bu1,2, Yan Wang2, Liwen Jiang1,2, Dongqing Ma1,2,
John P Quinn3 and Minyan Wang1,2
Abstract
Objectives: Sarcoma family kinase activity is associated with multiple diseases including ischemia and cancer; however,
its role in the mechanism of migraine aura has been less well characterised. This study aims to investigate whether
sarcoma family kinase is required for cortical spreading depression.
Methods: Cortical spreading depression was induced by topical application of Kþ to the cerebral cortex and was
monitored using electrophysiology in rats, and intrinsic optical signal in mouse brain slices. Drugs were perfused into the
contralateral cerebral ventricle for pharmacological manipulations in rats. Western blot analysis was used for detecting
the level of phosphorylated, and total, sarcoma family kinase in the ipsilateral cortex of rats.
Key results: The data demonstrate that a single cortical spreading depression in rats induced ipsilateral cortical sarcoma
family kinase phosphorylation at the Y416 site. Deactivation of sarcoma family kinase by its inhibitor (3-(4-chlorophenyl)
1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-dpyrimidin-4-amine) suppressed the elevated enzyme activity and cortical suscep-
tibility to cortical spreading depression. Interestingly, the inhibitory effect of the N-methyl-D-aspartate receptor antag-
onist NVP-AAM077 on cortical spreading depression was reversed by the sarcoma family kinase activator pYEEI
(EPQY(PO3H2)EEEIPIYL), suggesting a link between this enzyme and N-methyl-D-aspartate receptors. Similarly, after
deactivation of sarcoma family kinase, a reduction of sarcoma family kinase phosphorylation and cortical susceptibility to
cortical spreading depression was observed with NVP-AAM077.
Conclusions: We conclude that activation of sarcoma family kinase is required for cortical spreading depression, and
this process is regulated by recruiting N-methyl-D-aspartate receptors. This study provides novel insight for sarcoma
family kinase function in the mechanism of migraine aura.
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Introduction
Sarcoma family kinases (SFK) are a family of non-
receptor protein tyrosine kinases. Five members of
SFK are expressed in the mammalian central nervous
system: Src, Fyn, Yes, Lck and Lyn (1). SFK phosphor-
ylation acts as a regulatory hub converging multiple
intracellular signaling cascades and membrane proteins
including N-methyl-D-aspartate (NMDA) and neur-
onal purinergic P2X7 receptors (2–6). SFK is asso-
ciated with multiple diseases including neuropathic
pain (7), stroke (2) and cancer (8). A recent study
shows that a SFK selective inhibitor, 3-(4-chlorophe-
nyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyri-
midin-4-amine (PP2), reduces the frequency of
multiple cortical spreading depression (CSD) in mice.
However whether the SFK activity is involved in a
single CSD, the putative underlying mechanism of
migraine with aura (9) has not been elucidated.
The link between SFK and NMDA receptors is well
documented. SFK can couple to the NMDA receptor,
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forming a complex in a rat stroke model (4), and the
activated SFK and NMDA receptor interaction is
thought to be via the adapter protein, NADH dehydro-
genase subunit 2 (ND2) (10). During anoxia/ischemia,
SFK can be recruited by the activation of the NMDA
receptor, leading to the opening of the neuronal hemi-
channel pannexin 1 (Panx1) (2); this correlates with the
fact that Panx1 channels can be opened after CSD
induction in mice (11). It was reported that NMDA
receptor coupling with Src and the sustained neuronal
depolarization during ischemia can be suppressed by
the competitive NMDA receptor antagonist, (2R)-
amino-5-phosphonopentanoate acting on the ligand-
binding site for glutamate (4). Given that competitive
antagonists targeting the NMDA receptor NR2 major
subunit suppress CSD genesis and propagation (12–14),
NR2A and NR2B may be key subunits of the receptor
involved in any potential SFK activity in CSD.
In this report, we have investigated whether cortical
SFK can be activated by a single CSD in rats. We sub-
sequently examined whether deactivation of SFK phos-
phorylation reduces the likelihood of CSD occurrence
and if it correlates with a reduction of SFK phosphor-
ylation. To complement that model, we investigated a
functional link between SFK activity and NMDA
receptors during CSD. We reason that SFK phosphor-
ylation, if it occurred, would likely be increased after
CSD, which in turn is required for CSD propagation.
SFK signaling during CSD is regulated, at least in part,
by activation of NMDA receptors.
Materials and methods
Animals
A total of 34 adult male Sprague Dawley rats
(328.1! 30.8 g, mean! SD) and 20 adult male
C57BL6 mice (21.4! 1.5 g, mean! SD) were purchased
from Shanghai SLAC Laboratory Animal Corporation
Ltd. The sample size of animals was estimated based on
previous studies on cortical spreading depression sus-
ceptibility. Animals were housed in the Experimental
Animal Centre of Soochow University under agreement
with Xi’an Jiaotong-Liverpool University (XJTLU) for
at least 1 week with food and water available ad libitum
before use. Animal procedures were approved by the
Ethical Review Panels of Soochow University and per-
formed during the light phase of the cycle in accordance
with relevant national and provincial guidelines.
In vivo experiment
Animal surgery and CSD induction. Rats were anaesthetized
with isoflurane (5% for induction, 2.5-3.5% during sur-
gery, 1–1.5% for maintenance) in O2:N2O, with the
animal breathing spontaneously as previously reported
(14). The depth of anesthesia was monitored and
adjusted through examination of the electroencephalo-
gram (EEG) signal and by absence of whisker move-
ments and lack of reaction to brief tail pinches. Rectal
temperature of animals was maintained at 37"C.
Three burr holes were drilled in the parietal bone.
One of these burr holes (1mm, i.d, coordinates: 0.8mm
posterior and 1.8mm lateral to bregma) was drilled in
the left side, which was used for implanting a stainless
steel cannula (0.38mm i.d, RWD Life Science) into the
intracerebral ventricle (i.c.v., 3.5mm deep from the cor-
tical surface) which was used for drug perfusion
(Figure 1(a)). The other two burr holes were drilled in
the right side (Figure 1(a)): The posterior one (1mm,
i.d, coordinates: 5mm posterior and 2mm lateral to
bregma) with dura intact for CSD induction; and the
anterior one (0.8mm, i.d, coordinates: 3mm anterior
and 2mm lateral to bregma) was used for the implant-
ation (0.9mm deep from the cortical surface) of an Ag/
AgCl electrode (0.1mm, i.d, Applied Neuroscience).
The EEG and direct current (DC) potential were
derived between the Ag/AgCl electrode and a reference
electrode placed under the scalp. The subsequent
experimental procedure was carried out after at least
one hour of stabilization.
As described previously (14), a single CSD was
induced by topical application of 1 ml of 3M KCl
(Sigma-Aldrich) for 5 minutes, although occasionally
two CSD waves were observed. After CSD induction,
KCl was quickly replaced by artificial cerebrospinal
fluid (ACSF) (composition in mM: 2.5 NaCl, 250
KCl, 1.18 MgCl2, 1.26 CaCl2; pH 7.3 adjusted with
1M NaOH, not buffered) for 5 minutes to enable
CSD propagating across the ipsilateral cortex (14).
Recording of EEG and extracellular DC potential. As reported
previously (14), EEG and DC signals were amplified
using an AC/DC pre-amplifier (NL834, Digitimer
Ltd). The alternating current component in 1–30Hz
provided the EEG (#5000 overall amplification) (15).
The DC component in 0–30Hz provided the DC poten-
tial (#250 overall amplification). All the recorded vari-
ables were continuously displayed and recorded by
Labview 11.0 (NI Instruments) during the experiment.
The spreading depolarization wave of CSD was recog-
nized as a transient negative shift (Figure 1(b)), demon-
strating successful CSD induction.
In vivo experimental design. Series 1: Our previous study
shows that the NR2A-preferring NMDA receptor antag-
onist, NVP-AAM077 (NVP), perfused through micro-
dialysis probes suppresses CSD in rats (14). In this
study, we investigated whether the drug perfused i.c.v.
also suppresses CSD and cortical SFK phosphorylation
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induced by CSD in rats. Three groups were designed: (i)
the known anti-CSD drug, NVP (synthesized by Yi Li
from XJTLU) (n¼ 5) with a total 0.3 nmol NVP applied.
(ii) ACSF was used for both the CSD group (n¼ 7); and
(iii) the sham group (n¼ 5).
Series 2: We examined whether CSD could induce
SFK activation, and if so, whether the activation of
SFK after CSD and the cortical susceptibility to CSD
could be suppressed by SFK inhibition. Four groups
were designed: (i) The SFK selective inhibitor, PP2
(#1407, Tocris) (16) with final 2.5 nmol used (n¼ 7);
(ii) the negative control for PP2, PP3 (1-Phenyl-1H-
pyrazolo[3,4-d]pyrimidin-4-amine, #2794, Tocris) with
total 2.5 nmol used as the negative control (n¼ 7);
(iii) ACSF was perfused for CSD group (n¼ 7) and
(iv) sham group (n¼ 5) where no KCl was applied. In
order to minimize animal use, both the CSD and sham
groups from series 1 were also used in this series.
In the above two series, each drug or ACSF was
perfused i.c.v. using a syringe pump (CMA100, CMA/
Microdialysis) at 0.5ml/minute for 10 minutes starting
at 120 minutes before CSD induction. Rats in each
group were immediately sacrificed as soon as CSD
recordings were completed. Rat cortices were dissected
for subsequent detection of levels of SKF phosphoryl-
ation in order to address whether CSD induced SFK
phosphorylation, and if so, whether this elevation was
altered with SFK or NMDA receptor inhibition.
Protein preparation
Ipsilateral cortices from rats were homogenized in the
presence of protease inhibitor (04693116001, Roche)
and phosphatase inhibitor (#5870, CST) for subsequent
detection of SFK phosphorylation. Total protein was
harvested from supernatant after tissue lysate was cen-
trifuged at 13,000 rpm for 10 minutes at 4"C. Protein
concentration was determined using Bicinchoninic Acid
Protein Assay Kit (P0010, Beyotime).
Western blotting
Proteins were denatured with 4#NuPAGE! LDS
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Figure 1. Effects of the NMDA receptor antagonist, NVP, perfused into contralateral ventricle on CSD in rats. (a). CSD was induced
by topical application of 1 ml of 3 M KCl for 5 minutes onto cortex with dura intact via the posterior burr hole on the right parietal
bone. The ipsilateral anterior hole was used for CSD recording. NVP (i) or ACSF (ii) was perfused through a cannula implanted in the
contralateral ventricle (i.c.v.) at 120 minutes prior to CSD induction. In the sham group (iii), only ACSF was perfused in the absence of
KCl application as the control. The whole ipsilateral cortical tissue was subsequently used for detecting SFK activity after the in vivo
experiment. (b). A representative trace showing CSD propagation wave after i.c.v. perfusion of ACSF. CSD magnitude (mV # minute,
dashed area) and latency (L, minute) were used for quantifying CSD. The effect of 0.3 nmol NVP on CSD magnitude are shown in panel
(c) and latency in panel (d). All the values shown are median (range). *p< 0.05, **p< 0.01, Mann-Whitney test with one-tailed
calculation was used for comparison of ACSF and NVP groups.
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5 minutes, separated on a 10% sodium dodecyl sulfate–
polyacrylamide gel and subsequently transferred onto
nitrocellulose membranes. Non-specific binding of anti-
body was blocked with 5% milk in Tris-Buffered
Saline with Tween-20 (TBST) for 1 hour at room tem-
perature (RT).
The level of SFK (!60 kDa) phosphorylation at
Y416 amino acid (PY416 SFK), a strong indicator of
SFK activation (17), and b-actin (!45 kDa) as the ref-
erence under CSD condition (18) were detected using
western blot analysis. Each membrane was cut into two
parts horizontally, which were incubated with anti-
PY416 monoclonal SFK antibody (anti-rabbit, #6943,
CST, 1:500) and b-actin monoclonal antibody (anti-
rabbit, #4970, CST, 1:1000) separately overnight at
4"C. Excess primary antibody was removed by TBST,
membranes and the membranes incubated with horse-
radish peroxidase-labeled secondary antibody
(AB10058, Sangon Biotech) at 1:5000 for 1 hour at
RT. Proteins were detected by Western bright enhanced
chemiluminescence working solution (K-12045-D50,
Advansta). In order to further detect the level of total
SFK (! 60 kDa), the anti-PY416 SFK antibody on the
nitrocellulose membrane was stripped away using 0.2M
NaOH for 15 minutes at 37"C. The membrane was then
washed using TBST and the same process repeated,
starting from non-specific binding blocking except
that anti-SFK monoclonal antibody (anti-rabbit,
#2109, CST) at 1:1000 but not anti-PY416 SFK anti-
body was used. Protein expression level was subse-
quently quantified using ImageJ software, and data
was normalized to b-actin for comparison.
In vitro experiment
Mouse brain slice preparation. The mouse brain slice
model of CSD was established by referencing those
reported previously in the mouse brain slice (19,20),
rat brain slice (21) and chick retina (22) with modifica-
tions as below. Briefly, the mouse brain was removed
and the cerebrum was cut along the midline and cor-
onal sections (400 mm) were prepared using a vibratome
(7000 smz-2, Campden, UK) with coordinates between
1 to 3mm posterior to bregma, each containing som-
atosensory and visual cortices that are highly associated
with migraine aura (9,23). Brain slices were quickly
transferred into ice-cold oxygenated NMDG-HEPES
cutting solution (24) with minor modifications to main-
tain osmolality around 300 mOsm and improve tissue
survival time. Of these, HEPES was added into the
modified cutting solution (composition in mM:
93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20
HEPES, 25 glucose, 5 L-ascorbic acid, 2 thiourea,
3 sodium pyruvate, 10 MgSO4, 0.5 CaCl2#2H2O;
bubbled with 95% O2 and 5% CO2; pH 7.4) in order
to prevent tissue edema (25). After 15min stabilization
at room temperature, brain slices were transferred into
Kreb’s solution (composition in mM: 126 NaCl, 2.5
KCl, 2.4 CaCl2#2H2O, 1.3 MgCl2#6H2O, 18 NaHCO3,
1.2 NaH2PO4, 10 Glucose; bubbled with 95% O2 and
5% CO2; pH 7.4) and maintained for 80 minutes prior
to carrying out further procedures. In order to reduce
the animal use, at least two brain slices from each
mouse were used and they were assigned to different
experimental groups.
CSD induction and imaging of mouse cortical slice. Each
brain slice was placed in a chamber and submerged in
Kreb’s solution with a perfusion rate of 3ml/minute
using a peristaltic pump (Reglo ICC, Ismatec). Unless
otherwise stated, CSD was induced in the somatosen-
sory region by ejection of 33 ml of 260mM KCl at 25 ml/
minute using a syringe pump (CMA/400, CMA/
Microdialysis). The coronal slice was illuminated for
50ms, starting when CSD was elicited, using a high-
power LED spotlight (625 nm peak wavelength,
SLS-0307-A, Mightex) driven by a computer-controlled
power supply (LED controller, SLC-SA04-US,
Mightex). For each KCl application, changes in the
reflected intrinsic optical signal in each cortical slice
were recorded for 15minutes at 2Hz with a charge-
coupled device monochrome camera (Rolera-XR,
ROL-XR-F-M-12, Qimaging) using Image Pro Plus
software (IPP7; Media Cybernetics) (22). Camera
exposure and illumination were synchronized using an
external trigger (TG1006, TTI).
Intrinsic optical imaging of CSD was captured from
each 1800-frame sequence, in which an area of interest
(AOI) parallel to the CSD wave front was delineated
manually in layers 4 to 6 of the somatosensory cortex
that were distant from the site of KCl application. For
each picture within the sequence, gray levels of the pixel
constituting the AOI were corrected by subtracting the
respective dark background. Changes in this value were
plotted against time (i.e. 1800 data points over 15min-
utes), providing the dynamic changes within the AOI.
This signal is synchronous with the sudden cellular
depolarization that characterizes the excitation phase
of CSD (26).
In vitro experimental design. Series 3: In order to explore a
functional link between SFK and NMDA receptor
during CSD, we investigated whether the inhibitory
effect of NVP on CSD could be altered by co-applica-
tion of an SFK activator in the mouse brain slice. Four
groups were designed: (i) Kreb’s control (n¼ 6);
(ii) NVP, at 0.1 mM (n¼ 7); (iii) NVP and the SFK
activator, pYEEI (27) (sequence: EPQY(PO3H2)
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EEEIPIYL, APeptide Ltd, China) at 0.3 mM (n¼ 7);
and (iv) NVP and the negative analog of SFK activa-
tor, YEEI (sequence: EPQYEEEIPIYL, APeptide Ltd,
China) at 0.3mM (n¼ 8). Two CSD episodes were eli-
cited in each experiment with a 45-minute interval for
tissue recovery. The drug or vehicle was perfused
45minutes prior to the second CSD induction for
1 hour, that is, the first CSD was under Kreb’s perfu-
sion in both the control and drug groups; however, the
drug replaced Kreb’s solution in the drug group prior
to the second CSD.
Data presentation and statistical analysis
For in vivo data analysis, electrophysiological data on
CSD was quantified as described previously (14) using
the Labview program. The following parameters were
defined: (i) Area under the curve (AUC, mV"minute)
of CSD waves was used to reflect CSD magnitude.
Although very occasionally, in the case where more
than one CSD wave was elicited, the AUC of the first
CSD wave in each rat was used for comparison; and
(ii) latency (minute), the time difference between the
start of KCl application to the starting point of the
rising phase of the first CSD wave. Both CSD magni-
tude and latency were used to reflect cortical suscepti-
bility to CSD.
For the image analysis, intrinsic optical imaging of
CSD was quantified as reported previously (22), for
each CSD wave. Latency was calculated by the time
interval between the starting point of KCl ejection
and that of CSD elicitation. AUC was calculated by
gray levels"minute. In each image sequence related
to a given CSD, the distance of 1mm between two
images in the same CSD wave, divided by the differ-
ence in their exposure time, allowed the calculation
of CSD propagation rate (mm/minute). In order to
eliminate variations of AOI chosen in each individual
experiment, CSD magnitude and latency within each
different test were given in delta intensity between the
second CSD and the first CSD episode relative to
that of the first CSD wave (i.e. initial control)
respectively.
The abnormal distribution test using Shapiro-Wilk
was confirmed using Prism software. All values were
given in median (range). The Mann-Whitney test was
used for comparing two independent groups with two-
tailed calculation, except for one-tailed calculation for
investigating the effects of NVP on CSD in rats.
Significant differences are shown as *p< 0.05 and
**p< 0.01. Correlation analysis was carried out
between CSD characteristics and levels of SFK phos-
phorylation of individual experiments with NMDA
receptor inhibition or SFK deactivation.
Results
NMDA receptor inhibition suppressed CSD in rats
We investigated whether the NMDA receptor antagon-
ist, NVP, perfused i.c.v suppresses CSD in rats. In the
ACSF group, topical application of 3M KCl for 5 min-
utes typically elicited one CSD wave that was identified
by a transient negative shift of DC potential
(Figure 1(b)); however, two CSD waves were observed
in two out of seven rats. The CSD magnitude and
latency was 20.99 (10.82) mV"minute (n¼ 6) and
1.98 (1.00) minutes (n¼ 4), respectively (Figure 1(c),
(d)). Compared with the CSD group, 0.3 nmol NVP
perfused into contralateral i.c.v. markedly reduced
CSD magnitude to 17.10 (3.42) mV"minute (n¼ 4,
p¼ 0.009, Figure 1(c)). In addition, CSD latency was
significantly prolonged to 4.86 (3.04) minutes (n¼ 4,
p¼ 0.014, Figure 1(d)). Overall, these data are consist-
ent with that reported previously in the chick retina
(22,28) and rat (14).
CSD-induced ipsilateral cortical SFK activation
Results regarding whether CSD could induce SFK
phosphorylation demonstrate that both phosphory-
lated SFK at amino acid Y416 and total SFK were
detected in the ipsilateral cortex of rats with a molecu-
lar weight of 60 KDa (Figure 2(a)). In the sham group,
the relative intensity of PY416 SFK and total SFK was
0.27 (0.22) (n¼ 5) and 0.95 (0.18) (n¼ 4) respectively
(Figure 2(b)). In the CSD group, the relative intensity
of PY416 SFK was 0.97 (0.7) (n¼ 5), which was signifi-
cantly increased compared with that of the sham group
(p¼ 0.008), demonstrating that a single CSD is suffi-
cient to induce SFK phosphorylation. In contrast, the
level of total SFK was not different to that of the sham
group CSD (n¼ 6).
SFK inhibition suppressed CSD-induced SFK
activation
We examined whether SFK phosphorylation induced
by CSD could be suppressed by the SFK selective
inhibitor, PP2. When 2.5 nmol PP3, the negative con-
trol for PP2, was perfused into i.c.v, the level of phos-
phorylated SFK in the ipsilateral cortex was 0.98 (0.45),
which is similar to that of the CSD-only group (n¼ 4,
Figure 2(b)). Similarly, total SFK level with 1.09 (0.21)
was not altered (n¼ 3). However, 2.5 nmol PP2 perfused
into the i.c.v markedly reduced the level of phosphory-
lated SFK to 0.44 (0.28) (n¼ 5). This reduction was sig-
nificantly different from that of either the PP3 group
(p¼ 0.016) or CSD group (p¼ 0.032). In contrast, the
level of total SFK was not altered by PP2 (n¼ 4).
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SFK inhibition suppressed CSD
To further our analysis, we addressed whether inhib-
ition of SFK activity by PP2 could suppress cortical
susceptibility to CSD in rats. In the ACSF group, the
CSD magnitude and latency were 20.99 (10.82)
mV!minute (n¼ 7), 1.98 (1) minutes (n¼ 4) respect-
ively (Figure 3). PP3 at 2.5 nmol perfused into i.c.v. did
not alter all these parameters (Figure 3). In contrast to
PP3 but similar to NVP (Figure 1), PP2 at 2.5 nmol
markedly suppressed the magnitude of CSD to 13.68
(4.93) mV!minute (n¼ 7) compared with either the
PP3 group (n¼ 7, p¼ 0.011) or ACSF group (n¼ 7,
p¼ 0.002, Figure 3(a)). In addition, PP2 also prolonged
CSD latency to 3.05 (3.06) minutes (n¼ 7), which was
significantly different to that of the PP3 group (n¼ 6,
p¼ 0.014, Figure 3(b)).
The inhibitory effect of NMDA receptor antagonist
on CSD was reversed by SFK activation
The mouse brain slice CSD model was validated using
NVP. In the Kreb’s group, changes in CSD magnitude
and latency in the second episode over the first CSD
were #5.30 (32.58) (n¼ 5) and 29.0 (90) (n¼ 6) respect-
ively (Figure 4(c), (d)). The propagation rate was 6.29
(4.07) mm/minute (n¼ 5) (Figure 4(e)). Compared with
the Kreb’s group, perfusion of NVP at 0.3 mM signifi-
cantly suppressed the magnitude of CSD and CSD
propagation rate with the reduction to #35.89 (20.89)
(n¼ 5, p¼ 0.008) and 4.55 (3.33) mm/minute (n¼ 7,
p¼ 0.018) (Figure 4(c) and (e)). These results are con-
sistent with the previous studies in chick retina (22) and
rats (14), suggesting the mouse brain slice CSD model is










































Figure 2. Detection of SFK activity after CSD and effects of
PP2 on SFK activation induced by CSD in the ipsilateral cortex of
rats. (a) Representative immunoblotting of PY416 SFK and total
SFKs treated with i.c.v. perfusion of ACSF, PP3 or PP2 in response
to CSD. Equal loading of samples was indicated by the b-actin
intensity. Phosphorylation at Y416 amino acid (PY416) levels
indicated activated SFK and total SFK levels indicated SFK
expression. Samples without CSD induction from the sham
group are used as control. (b) Quantitative analysis of relative
intensity of PY416 SFK and total SFK normalized to b-actin.
All the values shown are median (range). *p< 0.05, **p< 0.01,
Mann-Whitney test, two-tailed calculation, was used for the
comparison of PY416 SFK or total SFK levels between sham vs.













































Figure 3. Effects of SFK inhibition on the magnitude (a) and
latency (b) of CSD in rats. The SFK inhibitor PP2 at 2.5 nmol, its
negative analog PP3 at 2.5 nmol or ACSF was perfused into the
contralateral i.c.v. 2 hours prior to CSD induction. All the values
shown are median (range). *p< 0.05, **p< 0.01, Mann-Whitney
test, two-tailed calculation, was used for the comparison of CSD
latency and magnitude between ACSF vs. PP3, ACSF vs PP2, and
PP3 vs PP2 groups.
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In contrast to that reported previously in rats (14), the
CSD latency was not altered by NVP compared with
the Kreb’s group (Figure 4(d)). The mechanism for this
difference is not known, but may be associated with
different tissues used in these studies, that is, the rat
cortex in vivo versus the mouse brain slice in this
experiment.
We utilized this model to address whether the inhibi-
tory effect of NVP on CSD could be reversed by the
SFK activator. The brain slice treated with the negative
control, YEEI, at 0.1 mM in the presence of NVP,
resulted in changes in the magnitude and latency of
CSD, which were !23.25 (34.62) (n¼ 7, Figure 4(c))


































































































Figure 4. Effects of SFK activation on the suppression of CSD by NVP in the mouse brain slice. (a) Representative images of mouse
cortical slice before ((a), upper) and after ((a), lower) Kþ-induced CSD in the mouse coronal slice. CSD was plotted by the kinetic
changes in gray level intensity within the selected area of interest (AOI, area within the red rectangle). The same AOI along CSD wave
front (indicated by the short arrow) was selected and used for all images of the sequence under study. (b) Representative traces shows
CSD wave treated with bath perfusion of Kreb’s. All the averaged gray levels within the AOI were plotted against time to generate the
CSD wave showing a biphasic pattern. CSD magnitude was indicated by the area under the curve of CSD wave. CSD latency is the
time interval required for eliciting depolarization from the start point of KCl application. Propagation rate of CSD (mm/minute)
reflects the velocity of CSD wave propagating across cortex. Panels (c)–(e) show effects of the SFK activator, pYEEI, at 0.1 mM on the
CSD magnitude (c), latency (d) and propagation rate (e) in the presence and absence of NVP at 0.3 mM. YEEI at 0.1 mM was set as the
scramble control of pYEEI. In order to minimize data variation, CSD magnitude (c) and latency (d) were presented as changes in
reflected difference in light intensity between CSD2 and CSD1 (i.e. delta CSD magnitude and latency) relative to the initial control. All
the values shown are median (range). *p< 0.05, **p< 0.01, Mann-Whitney test, two-tailed calculation, was used for the comparison
between two independent groups.
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The propagation rate was 4.05 (3.18) mm/minute
(n¼ 5, Figure 4(e)). These results were similar to the
result of the NVP group. Interestingly, exposing a cor-
tical slice to pYEEI at 0.1 mM (n¼ 5) reversed the sup-
pressive effect of NVP on CSD magnitude, which was
significant compared with the NVPþYEEI group
(p¼ 0.018) or NVP alone group (p¼ 0.008, Figure 4(c)).
However, neither the CSD latency (Figure 4(d)) nor CSD
propagation rate (Figure 4(e)) was altered by pYEEI.
The NMDA receptor antagonist suppressed
CSD-induced cortical SFK activation
Whether CSD-induced elevation of SFK phosphoryl-
ation was suppressed by NMDA receptor inhibition
was further examined. In the sham group, the relative
intensity of phosphorylated SFK and total SFK of the
ipsilateral cortex were 0.31 (0.22) (n¼ 5) and 0.84 (0.25)
respectively (n¼ 5, Figure 5(b)). As described above,
CSD significantly increased the level of phosphorylated
SFK to 0.59 (0.67) (n¼ 8, p¼ 0.002), but it did not alter
the level of total SFK (n¼ 8, Figure 5(b)). Compared
with that of the CSD group, 0.3 nmol NVP perfused
into i.c.v. significantly reduced the level of phosphory-
lated SFK induced by CSD to 0.32 (0.27) (n¼ 5,
p¼ 0.006, Figure 5(b)). However, the level of total
SFK was not altered by application of NVP (n¼ 5,
Figure 5(b)).
Reduced cortical susceptibility to CSD correlates
with a lower level of SFK phosphorylation by
PP2 and NVP
We further carried out correlation analysis of CSD
latency and magnitude with levels of ipsilateral cortical
SFK phosphorylation with and without NMDA recep-
tor inhibition or SFK deactivation in rats. The results
showed that after PP2 perfusion i.c.v at 120 minutes
prior to CSD induction, lower levels of SFK phosphor-
ylation showed a tendency for negative correlation with
the increased CSD latency (Figure 6(a)) and a positive
correlation with the reduced magnitude (Figure 6(c)).
Similarly, after perfusion of NVP at 120 minutes prior
to CSD induction, the lower levels of SFK phosphor-
ylation also showed a strong negative correlation with
the increased CSD latency (Figure 6(b)), whereas its
correlation with the reduced CSD magnitude was not
pronounced relative to the control (Figure 6(d)).
Discussion
In this study, we used in vivo and in vitro approaches to
show that a single CSD rapidly promotes SFK phos-
phorylation while deactivation of SFK reduces the like-
lihood of CSD occurrence, which coincides with the
lower level of SFK phosphorylation. Further investiga-
tion shows that this can be regulated by NMDA recep-
tors. This finding provides novel insight into SFK
signaling in the mechanisms underpinning migraine
aura, indicating that SFK may be a potential target
for migraine prophylaxis.
A key finding of our study is that SFK activity is
required for CSD propagation. A single CSD rapidly
promoted the ipsilateral cortical SFK phosphorylation
at its active Y416 site, and this elevation of SFK phos-
phorylation was prevented by the SFK inhibitor
perfused into the contralateral i.c.v. of rats (Figure 2).
Consistent with this, SFK inhibition also reduced cor-
tical susceptibility to CSD as PP2 suppressed CSD
magnitude and prolonged CSD latency in rats
(Figure 3). We conclude that a single CSD induces
rapid SFK activation, which in turn contributes to
CSD propagation. Further correlation analysis demon-





































Figure 5. Effects of NMDA receptor inhibition on CSD-
induced SFK activation in the ipsilateral cortex of rats. (a)
Representative immunoblotting of PY416 SFK and total SFKs
treated with i.c.v. perfusion of NVP at 0.3 nmol (i) or ACSF (ii) in
response to CSD. Samples without CSD induction (iii) from the
sham group were used as control. Equal loading of samples was
indicated by the b-actin intensity. PY416 levels indicated activated
SFK and total SFK levels indicated SFK expression. (b)
Quantitative analysis of relative intensity of PY416 SFK and total
SFKs normalized to b-actin. All the values shown are median
(range). **p< 0.01, Mann-Whitney test, two-tailed calculation,
was used for the comparison of PY416 SFK or total SFK levels
between ACSF groups with vs. without CSD; and ACSF vs. NVP
groups with CSD.
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CSD showed stronger positive correlation with a lower
level of SFK phosphorylation after PP2 was perfused 2
hours prior to CSD induction than after PP3 applica-
tion (Figure 6(a) and (c)). These data suggest that
deactivation of SFK was able to reduce the likelihood
of CSD occurrence, which coincides with a lower level
of SFK phosphorylation. Given that migraine aura is
believed to involve only a single CSD event (29), the
critical role of SFK activity in CSD suggests that SFK
activation is involved in the pathophysiology of
migraine aura. These data extend a recent study in
mice showing that intraperitoneal injection of PP2
inhibited the frequency of multiple CSD (6). The find-
ing is also consistent with SFK activation being
induced by multiple cell stresses (30) and tissue
damage (31).
SFK activity is a known regulatory hub at which
multiple signaling pathways converge, for example,
coupling intracellular and membrane proteins including
P2X7 and NMDA receptors (2,3,32). One explanation
to account for a key role of SFK activity in CSD is
a link with the P2X7 receptors, as tyrosine kinase
plays a pivotal role in P2X7 receptor-mediated cellular
responses and is involved in the initial steps leading to
Panx1 channel opening (33), which can be opened by
CSD (11). Alternatively, SFK activity in CSD could be
regulated by the activation of NMDA receptors.
Firstly, SFK is known to couple with the NMDA
receptor, forming an SFK-NMDA receptor complex
(4). Secondly, in this study, we demonstrated a func-
tional link between SFK and NMDA receptors during
CSD. The reduced CSD magnitude in the mouse brain
slice with NVP was no longer observed when the SFK
activator was co-applied (Figure 4). Additionally, ele-
vation of SFK phosphorylation at Y416 amino acid
induced by a single CSD was prevented by NMDA
receptor inhibition by NVP (Figure 5), which is consist-
ent with that observed with the SKF inhibitor, PP2
(Figure 3). Interestingly, the increase in CSD latency
showed a strong negative correlation with a lower
level of SFK phosphorylation after NVP was perfused
2 hours prior to CSD induction (Figure 6(b)). This indi-
cates that NMDA receptor inhibition reduces the like-
lihood of CSD occurrence, which subsequently further
reduces SFK phosphorylation. Collectively, these data,
together with the fact that NMDA receptor and its
major subunits, NR2A and NR2B, contribute to CSD
genesis and propagation in vivo (13,14,22), supports the
model that we propose, that SFK activity contributing
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Figure 6. Correlation analysis of CSD characteristics with levels of ipsilateral cortical SFK phosphorylation at Y416 site with and
without SFK deactivation or NMDA receptor inhibition in rats. ((a), (b)). The increased CSD latency strongly negatively correlated with
the reduction of SFK phosphorylation after PP2 (a) or NVP (b) perfusion i.c.v at 120 minutes prior to CSD induction. ((c), (d)); the
reduced CSD magnitude positively correlated with a lower SFK phosphorylation after perfusion of PP2 (c) or NVP (d) at 120 minutes
prior to CSD induction. Black lines show correlation between each CSD parameter and respective level of SFK phosphorylation of
individual experiments. Red dotted lines indicate the averaged correlation between CSD latency and SFK phosphorylation. Green
dotted lines indicate the averaged correlation between CSD magnitude and SFK phosphorylation.
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receptors. This is consistent with the previous finding
that SFK can be recruited by activation of NMDA
receptors leading to Panx1 channel opening during
anoxia/ischemia (2).
The mechanism by which SFK activity is regulated
by NMDA receptors in CSD is not known, but one
candidate might be a Ca2þ influx as the synaptic
NMDA receptor contributes to Kþ-triggered CSD via
calcium entry (34); and accumulation of cytoplasmic
calcium can activate SFK through multiple signaling,
including the NMDA receptor (3,35). Alternatively,
SFK may directly act on the NMDA receptor by phos-
phorylation of NR2A/B subunits (1), which are known
key players in CSD genesis and propagation (12–14).
Interestingly, the fact that uncoupling Src from the
ND2-NMDA receptor by Src40-49 (10) did not alter
CSD magnitude or the cortical susceptibility to CSD
in the mouse brain slice (data not shown) does not sup-
port any involvement of Src (10). It is possible that
Fyn might be involved in this process, as PP2 preferen-
tially inhibits Fyn, but not Src, at nanomolar concen-
trations (36).
In summary, our data provides strong evidence that
a single CSD is sufficient to induce SFK phosphoryl-
ation, which in turn regulates cortical susceptibility to
CSD. This positive feedback loop associated with CSD
can be regulated by NMDA receptors. It remains to be
resolved if elevation of SFK activity by CSD would
subsequently trigger Panx1 channel opening. Given
that CSD is the accepted underlying cause of migraine
with aura, our finding gives new clues about the
molecular and cellular mechanism of migraine with
aura and may constitute a new strategy for migraine
prophylaxis.
Article highlights
. A single CSD is sufficient to rapidly increase SFK phosphorylation, which in turn facilitates CSD
propagation.
. Deactivation of SFK reduces the likelihood of CSD occurrence, which coincides with lower level of SFK
phosphorylation.
. SFK activity required for CSD propagation is regulated by activation of NMDA receptors.
. This is the first in vivo evidence showing SFK activity may play a pivotal role in the mechanism of migraine
aura.
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The Transient Receptor Potential Ankyrin Type 1 Plays a Critical Role
in Cortical Spreading Depression
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Abstract—The transient receptor potential ankyrin type-1 (TRPA1) channels have been proposed as a potential
target for migraine therapy. Yet the role of cortical TRPA1 channels in migraine mechanism has not been fully
understood. Cortical spreading depression (CSD) is known as an underlying cause of migraine aura. The aim
of this study is to investigate if cortical TRPA1 activity is required for CSD genesis and propagation. A mouse
brain slice CSD model with intrinsic optical imaging was applied for TRPA1 signaling pharmacology. The results
showed that the TRPA1 agonist, umbellulone, facilitated the propagation of submaximal CSD. Correspondingly,
an anti-TRPA1 antibody and two selective TRPA1 antagonists, A967079 and HC-030031, prolonged the CSD
latency and reduced magnitude, indicating a reduced cortical susceptibility to CSD under TRPA1 deactivation.
Furthermore, the TRPA1 agonist, allyl-isothiocyanate (AITC), reversed the suppression of CSD by HC-030031,
but not by A967079. Interestingly, the inhibitory action of A967079 on CSD was reversed by exogenous
calcitonin-gene-related peptide (CGRP). Consistent to TRPA1 deactivation, the prolonged CSD latency was
observed by an anti-CGRP antibody in the mouse brain slice, which was reversed by exogenous CGRP. We con-
clude that cortical TRPA1 is critical in regulating cortical susceptibility to CSD, which involves CGRP. The data
strongly suggest that deactivation of TRPA1 channels and blockade of CGRP would have therapeutic benefits
in preventing migraine with aura. ! 2018 IBRO. Published by Elsevier Ltd. All rights reserved.
Key words: cortical spreading depression, migraine, the transient receptor potential ankyrin type 1, calcitonin-gene-related pep-
tide, mouse brain slice.
INTRODUCTION
Migraine is a complex neurological disorder characterized
by recurrent unilateral throbbing head pain. Around 16
percent of world’s population regularly suffer debilitating
symptoms, which ranks top 6 causes of global years
lived with disability worldwide. A common component of
these headaches for many migraineurs is the aura,
which precedes migraine symptoms in up to one third of
patients (Cutrer and Huerter, 2007). Migraine aura may
include visual, sensory, language, or brainstem symp-
toms. Meanwhile, 81% of these migraines with aura are
also associated with migraine without aura (Queiroz
et al., 1997). The pathologic mechanism by which
migraine aura develops has not been fully elucidated.
Cortical spreading depression (CSD), a transient propa-
gating excitation of synaptic activity followed by depres-
sion, has been increasingly regarded as an underlying
cause of migraine aura. CSD is directly linked with the
aura phase of migraine (Lauritzen, 1994, Hadjikhani
et al., 2001; Moskowitz, 2007) and triggers migraine-like
behavior through generating neuro-inflammatory
responses (Karatas et al., 2013). CSD also activates noci-
ceptor (Zhang et al., 2010; Shatillo et al., 2013) and
induces a delayed persistent activation of central trigemi-
nal neurons (Zhang et al., 2011). Certain drugs such as
topiramate and sumatriptan that can relieve migraine pain
also suppress CSD (Unekawa et al., 2012; Wiedemann
et al., 2012; Guedes et al., 2017). Anti-CSD drugs may
be therefore related to aura suppression in migraine
patients and CSD has therefore become a useful model
for studying migraine mechanism (Pietrobon and
Moskowitz, 2013; Wang, 2013; Russo, 2015).
The transient receptor potential ankyrin type 1
(TRPA1) is a type of nonselective transmembrane
cation channel with 17 ankyrin repeats on its N-terminal.
TRPA1 is a sensor of oxidative, nitrative and
electrophilic stress (Vay et al., 2012). In peripheral
https://doi.org/10.1016/j.neuroscience.2018.04.025
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nervous system (PNS), the channel is expressed in
mouse dural afferent neurons (Story et al., 2003; Huang
et al., 2012) and axons with terminations in trigeminal
nucleus caudalis (Kim et al., 2010). While in the central
nervous system (CNS), TRPA1 expression has also
recently been reported in cortex of rats and mice (Lee
et al., 2016; Kheradpezhouh et al., 2017), as well as
hippocampal pyramidal (Story et al., 2003) neurons of
rats (Julius, 2013; Kheradpezhouh et al., 2017).
Majority studies have focused on peripheral TRPA1
channels, highlighting the involvement of TRPA1 in
migraine pain in addition to thermal and chemical
sensations (Julius, 2013; Trevisan et al., 2013). Gain-of-
function mutation of TRPA1 channels contributes to a
familial episodic pain syndrome (Kremeyer et al., 2010).
Experimental studies show that activation of TRPA1
channels increases the activation threshold of rodent
meningeal afferents (Denner et al., 2017) and triggers
migraine-like behavior in rats (Nassini et al., 2012;
Benemei et al., 2014). Supporting the role of peripheral
TRPA1 in pain pathways, a recent study further shows
an active role of TRPA1 in counteracting nitroglycerin-
induced hyperalgesia at the trigeminal level (Demartini
et al., 2017). Based on these data in the literature, TRPA1
has been proposed as an emerging target for developing
drugs to relieve migraine pain (Benemei et al., 2014;
Dussor et al., 2014). Yet, the role of central TRPA1 in
mechanism of migraine aura remains unclear.
TRPA1 is associated with key signals that are known
players in migraine pathology, of which a key signal is
calcitonin gene-related peptide (CGRP), a known target
of migraine prevention (Edvinsson, 2015; Russo, 2015;
Wang et al., 2016b). In medulla-pons, cervical spinal cord
and trigeminal ganglion, TRPA1 antagonism is associated
with a significant inhibition of nitroglycerin-induced
increase in mRNAs of c-fos and CGRP (Demartini et al.,
2017). Consistently, inhibition of TRPA1 blocks CGRP
release induced by reactive oxidative species (ROS)
(Shatillo et al., 2013) and environmental irritant-induced
TRPA1 activation stimulates CGRP release in the trigem-
inal ganglion (Nassini et al., 2012). Conversely, TRPA1
activation leads to trigeminal neuronal activation via
CGRP (Benemei et al., 2014; Dussor et al., 2014;
Kunkler et al., 2015) and releases CGRP in rodent menin-
geal afferents (Denner et al., 2017). However, the role of
central TRPA1 signaling in pain pathways has compara-
bly been unexplored. TRPA1 is also reported to be asso-
ciated with neurotransmitter release including GABA in
the hippocampus (Shigetomi et al., 2011) and glutamate
in brain stem neurons (Sun et al., 2009). A recent study
showed that activation of TRPA1 modulates activity of
pyramidal neurons in rodent cortex (Kheradpezhouh
et al., 2017), indicating a functional role of cortical TRPA1
in migraine pathology.
In this study, we hypothesized that cortical TRPA1
plays a crucial role in migraine aura pathophysiology.
We examined how modulation of cortical TRPA1
channel alters cortical susceptibility to CSD using an
in vitro CSD model. We further examined if cortical
TRPA1 signaling during CSD involves CGRP. Our
findings indicate the importance of cortical TRPA1 in
mechanism of migraine aura and the channel as a
potential target for migraine aura prevention.
EXPERIMENTAL PROCEDURES
Animal use
A total of 70 C57BL6 mice (male, 21.0 ± 2.9 g, mean ±
SD) were purchased from Shanghai SLAC Laboratory
Animal Corporation Ltd. The mice were housed in the
Experimental Animal Centre of Soochow University
under agreement with Xi’an Jiaotong-Liverpool
University (XJTLU) for at least 1 week before use with
food and water available ad libitum. Animal procedures
were approved by the Ethical Review Panels of
Soochow University and experiments were performed in
accordance with relevant national and provincial
guidelines.
Imaging of mouse brain slice CSD
In order to explore how modulation of TRPA1 alters CSD,
a mouse brain slice CSD model was applied by
referencing to the literature (Bu et al., 2017). Briefly, the
mouse brain was dissected and cerebrum was cut along
the midline. Coronal sections (400 mm) of the right brain
were prepared using a vibratome (7000 smz-2, Campden,
UK) at coordinates between 1 and 3 mm posterior to
bregma, each showing somatosensory and visual cortices
as they are highly associated with migraine pain
(Lauritzen and Fabricius, 1995; Hadjikhani et al., 2001).
Brain slices were quickly transferred into ice-cold oxy-
genated NMDG-HEPES cutting solution (93 mM NMDG,
2.5 mM KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM
HEPES, 25 mM glucose, 5 mM L-ascorbic acid, 2 mM
thiourea, 3 mM sodium pyruvate, 10 mM MgSO4, 0.5
mM CaCl2∙2H2O; bubbled with 95% O2 and 5% CO2;
pH 7.4). After 15-min stabilization at room temperature,
brain slices were transferred into Kreb’s solution (126
mM NaCl, 2.5 mM KCl, 2.4 mM CaCl2∙2H2O, 1.3 mM
MgCl2∙6H2O, 18 mM NaHCO3, 1.2 mM NaH2PO4, 10
mM Glucose; bubbled with 95% O2 and 5% CO2; pH
7.4) and maintained for at least 80 min prior to carrying
out further procedures. In order to minimize animal use,
at least two brain slices were used from each mouse
and each slice randomly received a different drug treat-
ment to ensure all data generated within each group were
from independent biological samples.
CSD induction and intrinsic optical imaging
Intrinsic optical signal (IOS) has been used for studying
CSD, which offers good spatial and temporal resolution
simultaneously, making it reliable for studying
pathophysiological events occurring at the cortical level
(Tozzi et al., 2012; Tang et al., 2014; Bu et al., 2017).
Each mouse brain slice was placed in a recording cham-
ber and submerged in Kreb’s solution with a perfusion
rate of 3 ml/minute using a peristaltic pump (Reglo ICC,
Ismatec; Wertheim, Germany). Unless otherwise stated,
CSD was induced by ejection of 33 ml of 260 mM KCl at
25 ml/minute using a high-precision syringe pump
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(CMA/400, CMA/Microdialysis; Solna, Sweden). The
coronal slice was illuminated for 50 ms, starting at the
same time when CSD was elicited, using a high-power
LED spotlight (625-nm peak wavelength, SLS-0307-A,
Mightex, Pleasanton, USA) driven by a computer con-
trolled power supply (LED controller, SLC-SA04-US;
Mightex, Pleasanton, USA). For each KCl application,
changes in the reflected IOS in each cortical slice were
recorded for 15 min at 2 Hz with a charge-coupled device
monochrome camera (Rolera-XR, Qimaging, Surrey,
Canada) at the maximum spatial resolution using Image
Pro Plus software (IPP7; Media Cybernetics, UK). Cam-
era exposure and illumination were synchronized using
an external trigger (TG1006, TTI, Cambridgeshire, UK).
Experimental design
A total of five series of experiments were designed.
Series 1: The mouse brain slice CSD model in our
laboratory was previously used for studying the
functional link between NMDA receptor and sarcoma
family kinase (SFK) in CSD (Bu et al., 2017). However,
it has not been used for studying the function of TRPA1
signaling. Therefore, prior to exploring the role of TRPA1
in CSD, the mouse brain slice CSD model was validated
using a potent CGRP receptor antagonist, BIBN4096,
preferably selective for calcitonin-receptor-like receptor
and receptor activity modifying protein 1 binding pocket
of CGRP receptors (Doods et al., 2000). BIBN4096 was
chosen because this drug was previously shown to sup-
press CSD in the rat brain slice (Tozzi et al., 2012) and
CGRP, the ligand of CGRP-receptor can be released in
response to TRPA1 activation induced by environmental
irritants (Nassini et al., 2012). The three groups were: (i)
Kreb’s control (n= 6); (ii) DMSO at 0.003% as the vehi-
cle control (n= 6); and (iii) BIBN4096 (Tocris, 4561, Bris-
tol, UK) at 1 mM (n = 6). Two CSD episodes were elicited
in each experiment with a 45-min interval for tissue recov-
ery. The drug or vehicle was perfused 45 min prior to the
2nd CSD induction for 1 h, i.e., the first CSD was under
Kreb’s perfusion in both control and drug group. However,
the drug replaced Kreb’s solution in the drug group prior to
the 2nd CSD. In order to minimize animal use, Kreb’s con-
trol group was also used as the control for the following
groups, i.e., series 2 group (viii) and series 4 group (xiii).
Series 2: In order to examine how modulation of
TRPA1 alters CSD, we firstly tested if TRPA1 activation
could promote the propagation of CSD induced by 260
mM KCl in the mouse brain slice using a TRPA1
agonist, umbellulone (083M4714V, Sigma) acting on the
cysteine residues of N-terminus of TRPA1 (Zhong et al.,
2011; Mihara and Shibamoto, 2015). This drug was cho-
sen as it is capable of activating trigeminal system and
inducing headache (Nassini et al., 2012). Submaximal
CSD was also induced by KCl at lower concentrations
(5 and 50 mM) in order to uncover a possible TRPA1-
induced amplification in this phenomenon. The following
six groups were designed: (iv, v) Kreb’s control (n = 6)
and 15 mM of umbellulone (n= 5) respectively with
CSD induced by 5 mM KCl; (vi, vii) Kreb’s control (n =
8) and 15 mM of umbellulone (n = 5) respectively with
CSD induced by 50 mM KCl; (viii, ix) Kreb’s control (n
= 6) and 15 mM of umbellulone (n= 4) respectively with
CSD induced by 260 mM KCl. The concentration of
umbellulone was chosen at 15 mM, at which is selective
for TRPA1 (Zhong et al., 2011; Nassini et al., 2012). Sim-
ilar to series 1, two CSD episodes were elicited in each
experiment at a 45-min interval for tissue recovery. The
drug or vehicle was perfused 45 min prior to the 2nd
CSD induction for 1 h.
Series 3: We then examined whether TRPA1
inhibition by an anti-TRPA1 antibody could prevent the
occurrence of CSD. The three groups were: (x) Kreb’s
control (n= 6); (xi) 0.025 mM of the unconjugated rabbit
IgG (H+L) (anti-IgG antibody, Sangon, D110502, n =
7) and (xii) 0.015 mM of the anti-TRPA1 antibody that
conjugates to N-terminal of human TRPA1 (Merck
Millipore, ABN1009, n= 6). In this series, two CSD
episodes were elicited in each experiment with a 2-h
interval for sufficient antibody–antigen binding. The
antibody was incubated with the brain slice for 1 h
starting as soon as the 1st CSD recording was
completed. In order to minimize the animal use, the
anti-IgG antibody group was also used for series 5
group (xxiii).
Series 4: In order to confirm the inhibitory effects of
the anti-TRPA1 antibody on CSD, we further examined
if deactivation of TRPA1 could prevent the occurrence
of CSD by two TRPA1 antagonists: HC-030031
(SIGMA, H4415), which has unknown binding site of
TRPA1 and A967079 (Tocris, Bristol, UK), a selective
TRPA1 antagonist (Chen et al., 2011) that targets the
pore-forming region between S5 and S6 and the first pore
helix of the channel (Paulsen et al., 2015), in the absence
or presence of a commonly used TRPA1 agonist, allyl-
isothiocyanate (AITC, Sigma–Aldrich, 36682) that targets
both the N-terminal domain (Cys-415/422/622 in
mTRPA1) (Andrade et al., 2012) and the S6 region
(Benedikt et al., 2009). The following groups were
designed: (xiii) Kreb’s control (n = 6); (xiv) DMSO at
0.03% (n= 6) as the vehicle control; (xv) HC-030031 at
6 mM (n = 6); (xvi) co-application of HC-030031 at 6 mM
with AITC (Sigma–Aldrich, 36682) at 50 mM (n= 7); (xvii)
A967079 at 1 mM (n = 7); (xviii) co-application of
A967079 at 1 mM with AITC at 50 mM (n = 6). In the same
series, we further explored a possible involvement of
CGRP in TRPA1-mediated CSD by co-application of
A967079 at 1 mM with exogenous CGRP peptide
(sequence: SCNTATCVTH RLAGLLSRSG
GVVKDNFVPT NVGSEAF-NH2, disulfide bridge
between 2 and 7, A-peptide Ltd, Shanghai) at 0.5 mM (n
= 7) in group (xiv). The protocol was the same as that
in series 1 and 2, i.e., two CSD episodes were elicited
in each experiment with a 45-min interval. Corresponding
drugs or vehicles were perfused 45 min prior to the 2nd
CSD induction for 1 h.
Series 5: We then extended the study to confirm the
involvement of CGRP in CSD by testing whether an
anti-CGRP antibody would alter CSD. The three groups
were: (xxiii) 0.025 mM of the anti-IgG antibody (n= 7);
(xxiv) an anti-CGRP antibody that recognizes
endogenous levels of total CGRP proteins (CST,
L. Jiang et al. / Neuroscience 382 (2018) 23–34 25
14959S, n= 6) at 0.4 mM; (xxv) CGRP at 10.5 mM pre-
incubated with the anti-CGRP antibody at 0.4 mM
overnight at 4 !C before their co-application as the
control (n = 6). The protocol was the same as that in
series 3, i.e., two CSD episodes were elicited in each
experiment with a 2-h interval for sufficient antibody–
antigen binding. The antibody was incubated with the
brain slice for 1 h starting as soon as the 1st CSD
recording was completed.
IOS image and statistical analysis
For each 1800-frame sequence, an area of interest (AOI)
parallel to the CSD wave front was delineated manually in
layers 4 to 6 of somatosensory cortex that was distant
from the site of KCl application (Fig. 1A). For each
picture within the sequence, gray levels of the pixel
constituting the AOI were corrected by the subtracting
the respective dark background. Changes in this value
were plotted against time (i.e., 1800 data points over
15-min recording), providing the dynamic changes in
IOS within the AOI. This signal was synchronous of the
sudden cellular depolarization that characterizes the
excitation phase of CSD.
As reported earlier (Wang et al., 2012), for each CSD
wave, latency (the time interval between the starting point
of KCl ejection and that of CSD elicitation) was calculated
to reflect cortical susceptibility to CSD. A prolonged CSD
latency would indicate reduced cortical susceptibility to
CSD. The area under the curve (AUC, gray levels ! min
ute) was used as an index of CSD magnitude. In the case
where CSD was abolished by drug (s), CSD latency was
counted as 15 min, i.e., the maximal recording period of
each CSD wave, and the AUC was counted as zero. In
order to eliminate the variations of AOI chosen in each
individual experiment, CSD latency and magnitude within
each different test were given as mean ± SEM in per-
centages relative to that of the 1st CSD wave (i.e., initial
control) respectively. The difference in distance that
CSD propagated before (1st CSD episode) and after drug
application (2nd CSD episode) in each submaximal CSD
experiment was calculated to observe if the TRPA1 acti-
vator could exacerbate CSD. Mann–Whitney’s U test,
one-tailed, was used for comparison of each parameter
between each two independent groups. *p < 0.05 was
considered as significance.
RESULTS
Validation of mouse brain slice CSD model
Each KCl application at 260 mM ejected on the mouse
brain slice led to changes in the optical signals as
indicated as a dark gray wave front slowly propagating
from the KCl application site across the cortex (Lower
image, Fig. 1A). The resulting changes in optical signal
indicate observable CSD wave and the pattern was
biphasic (Fig. 1B), which is consistent with what was
observed previously (Bu et al., 2017).
We validated this mouse brain slice CSD model using
BIBN4096. In Kreb’s control group, there was no
difference in CSD latency (128.7% ± 27.5% relative to
initial baseline) and magnitude (104.2% ± 11.9%
relative to initial control) (Fig. 1C,D). DMSO at 0.003%
did not alter CSD latency (150.6% ± 25.5%) and
magnitude (95.1%± 7.8%) (Fig. 1C,D, n= 6 for both
groups). As expected, BIBN4096 at 1 mM markedly
prolonged CSD latency to 16.4 folds, which was
significant when compared to that of the DMSO group
(Fig. 1C, p= 0.0206). The drug also slightly reduced
the CSD magnitude, but the reduction did not reach
significance (Fig. 1D). It was noted that at 1 mM, the
drug completely abolished CSD wave in 2/6 brain slices.
The inhibitory effect of BIBN4096 on cortical
susceptibility to CSD under study is consistent with that
reported previously in the rat cortical slice (Tozzi et al.,
2012) and chick retina (Wang et al., 2016a), indicating
the validity of the mouse brain slice migraine model under
study.
Umbellulone facilitates CSD propagation
In order to explore if TRPA1 channel activation would
promote CSD propagation, we firstly examined if
umbellulone could exacerbate CSD induced by KCl at
different concentrations to uncover a possible TRPA1
activation-induced amplification. In the control group,
when KCl at 5 mM was applied, CSD was detected in
all 6 mouse slices after the 1st KCl ejection and 4 out of
6 after the 2nd KCl ejection (data not shown),
suggesting KCl at 5 mM did not induce reproducible
CSD. During the 2nd CSD induction, umbellulone at 15
mM was unable to sufficiently amplify either the sub-
threshold CSD induced by 5 mM KCl or alter CSD that
was successfully induced in 3 out of 5 slices in the
presence of the drug (data not shown).
When the concentration of KCl was applied at 50 mM,
CSD was successfully elicited in all cortical slices in the
1st episode of Kreb’s control group; and CSD were
observed in 7 out of 8 slices in the 2nd CSD episode.
These data suggest that 50 mM was an optimal
concentration for eliciting submaximal CSD. The CSD
latency and magnitude in the 2nd CSD episode were 23
2.9% ± 30.4% and 81.7% ± 21.8% relative to
respective values of the 1st CSD episode (Fig. 2A,B). In
the presence of umbellulone at 15 mM, CSD
depolarization waves were found in 4 out of 5 slices
with CSD latency and magnitude with ratio of 387.2%
± 157.0% and 79.5% ± 41.2% in respective order,
which was not significant when compared to Kreb’s
group (Fig. 2A,B). The distance difference that CSD
propagated between the 1st and 2nd CSD episode in
the umbellulone group increased 9.6-fold relative to
Kreb’s control group (Fig. 2C, p = 0.0079), suggesting
TRPA1 activation facilitates CSD to propagate a longer
distance than control.
When KCl was applied at 260 mM, CSD was elicited
in all brain slices throughout the experiment in both
groups. In Kreb’s control group, the CSD latency and
magnitude in the 2nd CSD episode were 128.7% ±
27.5% and 104.2% ± 11.9% respectively (Fig. 2A,B).
In the umbellulone group, the CSD latency and
magnitude were 149.6% ± 24.3% and 107.2% ± 8.0%
respectively in the 2nd CSD episode (Fig. 2A,B),
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which was not different from that of control. The reason
the drug at 15 mM did not alter these parameters is
unknown but it may result from that TRPA1 channels
being fully opened during CSD induced by 260 mM KCl.
The difference in CSD propagating distance could not
be measured in this condition as




We examined whether TRPA1
inhibition by the anti-TRPA1 antibody
would suppress CSD. The results
showed that in Kreb’s control group,
CSD latency for the 2nd CSD
episode was 170.1% ± 38.9% of
initial baseline, and CSD magnitude
was 72.4% ± 7.1% (Fig. 3A,B).
These parameters were not
significantly different in the anti-IgG
antibody group (Fig. 3A,B).
Differently, when the brain slice was
pre-incubated with the anti-TRPA1
antibody at 0.015 mM, CSD latency
was prolonged 3.6-fold relative to
that of the 1st CSD wave, which was
significant different (p= 0.0087,
Fig. 3A) compared to that in the anti-
IgG antibody group. Conversely, the
anti-TRPA1 antibody reduced the
CSD magnitude in the 2nd CSD
episode to 40.7% ± 10.1%, and this
was significant when compared to
that of the anti-IgG antibody control
(p = 0.0325, Fig. 3B).
Both HC-030031 and A967079
suppress CSD
We further confirmed that TRPA1
deactivation suppresses CSD under
the application of the TRPA1
inhibitors, HC-030031 and A967079.
In the DMSO vehicle group, CSD
latency and magnitude in the 2nd
CSD episode were similar to that of
the 1st CSD episode (Fig. 4A,B).
Similar to the anti-TRPA1 antibody,
HC-030031 markedly prolonged
CSD latency with 5.6-fold increase
relative to that of the 1st CSD wave,
which was significant when
compared with 0.03% DMSO group
(p = 0.002, Fig. 4A). Corresponding
to this, the reduction in CSD
magnitude by 6 mM of HC-030031
was also observed when compared
with DMSO group (Fig. 4B, p =
0.02). Consistently, A967079 at 1 mM
also markedly prolonged CSD
latency with 28.3-fold increase
(Fig. 4A, p= 0.01) when compared with 0.03% DMSO
group. Correspondingly, A967079 at 1 mM reduced the
CSD magnitude to 44.8 %± 17.0% (Fig. 4B, p= 0.01).
The suppression of A967079 at 1 mM was pronounced
Fig. 1. This figure shows representative images and traces of CSD as well as validation of the
mouse brain slice CSD model. Representative images of the mouse cortical slice before (A, upper)
and after (A, lower) CSD induced by 260 mM KCl ejection in the mouse coronal slice and plot of
CSD wave, i.e., kinetic changes in gray level intensity within the selected area of interest (AOI,
right). The same AOI (A, rectangle within left picture) along CSD wave front (pointed by the short
arrow) was selected and used for all images of the sequence under study. All the averaged gray
levels within the AOI were plotted against time to generate the CSD wave showing a biphasic
pattern (B). From these plots, CSD latency (second), i.e., time interval required for eliciting
depolarization from the starting point of KCl application, was used for reflecting cortical
susceptibility to CSD. The area under the curve (AUC, gray level ! minute) of CSD wave was
determined by image analysis for reflecting CSD magnitude. Validation of the mouse brain slice
migraine model is shown in the lower and right panel. The bar charts show effects of BIBN4096 on
CSD latency (C) and magnitude (D) during the 2nd CSD episode (relative to respective value in the
1st CSD). The corresponding representative traces of CSD in control, vehicle control and the drug
groups are shown in (E). Data were presented as percentage of their initial levels. All data were
indicated as mean ± SEM. Data were analyzed by Mann–Whitney’s U test, one-tailed, for
comparison between 1 mM of BIBN4096 (n = 6) and 0.003% DMSO control (n = 6), *p < 0.05.
L. Jiang et al. / Neuroscience 382 (2018) 23–34 27
and this drug completely abolished CSD wave in 3/7 brain
slices.
AITC abrogates CSD inhibition by HC-030031
We further examined if TRPA1 deactivation suppresses
CSD could be reversed by co-application with the
TRPA1 agonist, AITC. In the presence of AITC at 50
mM, the prolongation of CSD latency and reduction in
CSD magnitude by HC-030031 at 6 mM was no longer
observed (Fig. 4A) and significance between HC-
030031 at 6 mM in the absence and presence of AITC
group was seen in both CSD latency (p= 0.001) and
CSD magnitude (p = 0.007). While the inhibitory effects
of A967079 on CSD was slightly restored by AITC,
insignificant differences were observed between
A967079 at 1 mM in the absence and presence of AITC
in both CSD latency (p = 0.27, Fig. 4A) and CSD
magnitude (p= 0.22, Fig. 4B). The insignificance may
be related to the large variation of the data resulting in
complete blockade of CSD in 3 out 7 brain slices. When
compared with DMSO group, co-application of A967079
and AITC maintains the significant
differences in both CSD latency (p
= 0.03, Fig. 4A) and CSD
magnitude (p = 0.046, Fig. 4B).
CGRP abrogates CSD inhibition by
A967079
Given that there is a link between
TRPA1 and CGRP (Shatillo et al.,
2013; Demartini et al., 2017) and
deactivation of cortical TRPA1 sup-
presses CSD (Fig. 4), we further
examined if cortical TRPA1 signaling
in regulating CSD involves CGRP in
the mouse brain slice. In the presence
of CGRP at 0.5 mM, the prolonged
CSD latency by A967079 at 1 mM
was no longer observed in the mouse
brain slice. However, insignificance
between A967079 at 1 mM in the
absence and presence of CGRP
group was seen (Fig. 4A). This may
be due to that 3/7 CSD waves being
completely abolished by A967079 at
1 mM in the absence of CGRP; while
no CSD was abolished in the pres-
ence of CGRP, leading to large varia-
tions in the data generated (p =
0.159, Fig. 4A). Correspondingly,
CGRP also reversed the reduced
CSD magnitude by A967079 at 1 mM
to 101.1% ± 8.9% (Fig. 4B), and this
was significant when compared to
that in 1 mM A967079 alone group
only (p = 0.01, Fig. 4B). Collectively,
our results show that exogenous
CGRP abrogated the suppressive
effect of A967079 on CSD (Fig. 4A–
C), indicating the involvement of
CGRP in TRPA1 signaling in CSD.
Suppression of CSD by anti-CGRP antibody
In order to confirm the involvement of CGRP in CSD, we
examined if the anti-CGRP antibody would also prevents
the occurrence of CSD and if these effects could be
reversed by exogenous CGRP. As expected, pre-
incubation of the anti-CGRP antibody at 0.4 mM
markedly increased the latency to 7.1-fold relative to
that of the 1st CSD (Fig. 5A), which is consistent to the
results under TRPA1 deactivation. This increase in CSD
latency was significant when compared with the anti-IgG
antibody group (p= 0.0022, Fig. 5A). Unlike TRPA1
inhibition under both anti-TRPA1 antibody and A967079
application, this antibody did not exhibit any significant
effect on CSD magnitude (Fig. 5B). When exogenous
CGRP at 10.5 mM was co-incubated with the anti-CGRP
antibody, the prolonged CSD latency by the anti-CGRP
antibody was completely reversed (Fig. 5A, p =
0.0011). These data support a key role of CGRP in
regulating CSD. Unlike CSD latency, there was no
Fig. 2. Effects of umbellulone on the latency (A), magnitude (B) and propagation distance (C) of
CSD induced by KCl at 50 mM or 260 mM respectively. There were two groups under 50 mM KCl
ejection for submaximal CSD induction: Kreb’s (n = 6) as control and 15 mM of umbellulone (n=
4), and another two groups for CSD induction under 260 mM KCl application: Kreb’s (n= 6) as
control and 15 mM of umbellulone (n = 4). The data show that umbellulone facilitated submaximal
CSD to propagate in the mouse brain slice. Mann–Whitney’s U test, one-tailed, for significance
between respective control and umbellulone group (**p < 0.01). Representative traces showing
CSD induction elicited by KCl at 50 mM or 260 mM respectively in the absence and presence of
umbellulone (D).
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difference in CSD magnitude in the presence and
absence of the peptide under CGRP blockade (Fig. 5B).
DISCUSSION
In this study, we applied a mouse brain slice CSD model
to study the role of cortical TRPA1 channels in the
mechanism of migraine aura. Our results show that
cortical TRPA1 is critical in regulating cortical
susceptibility to CSD and the channel signaling during
CSD involves CGRP. The data strongly suggest cortical
TRPA1 channels as a potential target for preventing
migraine aura.
One of key findings of this study is that cortical TRPA1
activation plays a pivotal role in CSD propagation. First,
TRPA1 activation by umbellulone facilitated submaximal
CSD to propagate longer distance in the mouse brain
slice (Fig. 2). These data are consistent with that
TRPA1 activation triggers nociceptive-like behavior in
mice (Nassini et al., 2012) and are in
line with the clinical evidence that
TRPA1 channel agonists cause
migraine or non-migraine headaches
(Kelman, 2007; Benemei et al.,
2014) as well as gain of function with
a point mutation of TRPA1 channels
causes a familial episodic pain syn-
drome (Kremeyer et al., 2010). Sec-
ond, Deactivation of TRPA1 channel
by both the anti-TRPA1 antibody and
two TRPA1 antagonists prevented
the occurrence of CSD as indicated
by the prolonged CSD latency and
reduced CSD magnitude (Figs. 3
and 4), suggesting desensitization of
TRPA1 could form a therapeutic strat-
egy for preventing migraine aura.
Third, the ability of the TRPA1 activa-
tor, AITC, in reversing the HC-
030031-suppressed CSD further sup-
ports the role of cortical TRPA1 in
CSD. These data complement those
findings in the peripheral that func-
tional desensitization of the channel
by parthenolide attenuates
headache-like responses to dural
application of AITC (Materazzi et al.,
2013). These findings also extend
the known action of cortical TRPA1
in CNS that the channel activation
modulates pyramidal neuron activity
in the cortex of rodents
(Kheradpezhouh et al., 2017), and is
associated with hippocampal
cannabinoid receptors (Storozhuk
and Zholos, 2017) as well as pro-
motes release of glutamate in brain
stem (Sun et al., 2009). Collectively,
the data support TRPA1 channel as
a potential target for preventing
migraine aura.
In this study, a complete blockade
of CSD by A967079 was observed in 3 out 7 mouse brain
slice, while this was not observed with the anti-TRPA1
antibody and HC-030031 (Fig. 4). The reason to
account for this difference is not known. One possibility
is that these drugs have different binding properties to
TRPA1 channels. While HC-030031 has uncertain
binding site (Gupta et al., 2016), the antagonist
A967079 targets the pocket between S5 and S6 that
are involved in ion conduction and pore forming of the
channel (Klement et al., 2013; Paulsen et al., 2015), while
the antibody conjugates to the N-terminal domain of the
channel (Millipore) that is associated with sensing stimu-
lators such as ROS and oxygen (Kadkova et al., 2017).
These data suggest that both the pore forming region
and N-terminal regions of the channel are involved in
CSD. It was also noted that AITC reversed CSD sup-
pressed by A967079 to a smaller extent (insignificant,
Fig. 4) than that by HC-030031, which may be due to that
Fig. 3. Deactivation of TRPA1 channels by the anti-TRPA1 antibody suppresses CSD. Panels A
and B show that the anti-TRPA1 antibody reduced cortical susceptibility to CSD as indicated by the
prolonged CSD latency (A) and reduced magnitude (B). Three groups were designed: Kreb’s (n=
6) as control, 0.025 mM of the anti-IgG antibody (n= 6) negative control and 0.015 mM of the anti-
TRPA1 antibody (n = 6). (C) Representative traces of CSD in each group. All values given are
means ± SEM. Mann–Whitney’s U test, one-tailed, for significance between anti-IgG and anti-
TRPA1 antibodies (A,B, *p < 0.05, **p< 0.01).
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they act on different binding regions of TRPA1, i.e., N-
terminal domain (Andrade et al., 2012) and S6 region of
TRPA1 for AITC (Benedikt et al., 2009), while pore-
forming region between S5 and S6 of TRPA1 for
A967079 (Klement et al., 2013). The fact that the inhibi-
tory effects of HC-030031 were reversed by AITC further
suggests a possible involvement of N-terminal and/or
pore-forming regions of TRPA1 in CSD.
We propose that the action of TRPA1 on CSD
observed under study occurs through those channels
located in the cortex rather than indirectly through
peripheral TRPA1. The cortical
action of these channels on CSD
can be supported by that TRPA1 is
expressed in mouse cortex
(Kheradpezhouh et al., 2017) and
TRPA1 expression in rat cortical neu-
rons are [Sun et al., 2009 #902]
[Yazgan and Naziroglu, 2016 #685]
increased under pathologies condi-
tions associated with Alzheimer’s dis-
ease (Lee et al., 2016). However, it
remains to be further investigated
whether the action of cortical TRPA1
during CSD is neuronal or glial.
The molecular mechanism by
which cortical TRPA1 channel
regulates cortical susceptibility to
CSD has not been reported
previously, but TRPA1 signal
pathways are divergent involving
multiple signals such as Ca2+
(Yazgan and Naziroglu, 2016), gluta-
mate (Sun et al., 2009), SFK
(Katsura et al., 2006), GABA
(Shigetomi et al., 2011) and CGRP
(Kunkler et al., 2011). One plausible
explanation is that the function of
TRPA1 on CSD may attribute to its
highly permeable property to Ca2+
(Shigetomi et al., 2011). Increased
cytosolic Ca2+ concentration is often
used as an indicator of TRPA1 chan-
nel activation in neurons of the rat hip-
pocampus and dorsal root ganglion
(Yazgan and Naziroglu, 2016); Impor-
tantly, elevation of Ca2+ influx accel-
erates CSD propagation velocity in
rats (Torrente et al., 2014).
Secondly, the function of TRPA1
channels regulating CSD may also
be associated with ROS as TRPA1
is a sensor of different external
stimuli, such as oxidative stress or
noxious impacts (Vay et al., 2012;
Shatillo et al., 2013; Benemei et al.,
2014; Yamamoto and Shimizu,
2016). This is possible because
umbellulone, AITC and the anti-
TRPA1 antibody, all of which have
putative binding domain at the N-
terminal of TRPA1 that is sensitive
to external stimuli, were capable of regulating CSD in this
study (Figs. 2–4). Additionally, these channels can be
activated by ovariectomy-induced mitochondrial oxidative
stress as indicated by increased cytosolic Ca2+ concen-
tration in neurons of the rat hippocampus and dorsal root
ganglion (Yazgan and Naziroglu, 2016). Supporting this
notion is that ROS release is elevated after CSD induction
not only in the ipsilateral cerebral cortex but also in
meninges and trigeminal ganglia of rats (Shatillo et al.,
2013). The antioxidant, ascorbate, in turn, can reduce
Fig. 4. The role of TRPA1 in CSD in the mouse brain slice involving CGRP. Effects of the TRPA1
antagonists A967079 and HC-030031 with or without AITC and exogenous CGRP on CSD latency
(A) and magnitude (B) in the mouse brain slice. Seven groups were designed: Kreb’s (n = 6) as
control, 0.03% DMSO (n = 6) vehicle control, 6 mM of HC-030031 (n= 6), 6 mM of HC-030031
with 50 mM of AITC (n = 7), 1 mM of A967079 (n = 7), 1 mM of A967079 with 50 mM of AITC (n=
6) and 1 mM of A967079 with 0.5 mM of CGRP (n = 7). The data showed reduction in cortical
susceptibility to CSD by both A967079 and HC-030031, and the inhibitory effect of HC-030031 was
reversed by AITC, and to a lesser extent those of A967079. The suppression of A967079 was
reversed by exogenous CGRP, suggesting the involvement of CGRP in TRPA1 regulated CSD.
Representative traces of CSD wave in each group are shown in C. Of which, CSD was completed
blocked by A967079 in 3 out 7 slices. All values given are means ± SEM. Mann–Whitney’s U test,
one-tailed, for significance between each group (A,B, *p< 0.05, **p < 0.01).
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cortical susceptibility to CSD in the rat hippocampal slice
(Grinberg et al., 2013).
Another promising explanation on cortical TRPA1 in
regulating CSD can be linked to CGRP. This notion can
be well supported by that peripheral evidence. In the
trigeminal nociceptive system, TRPA1 inhibition can
block ROS-triggered CGRP release (Kunkler et al.,
2011; Shatillo et al., 2013). In rat trigeminal ganglia neu-
rons, TRPA1 activation by environmental irritants stimu-
lates CGRP release (Kunkler et al., 2011) and in the
dural blood flow, both TRPA1 and CGRP receptor antag-
onists can block TRPA1 activation-triggered increase
(Kunkler et al., 2011). Further, in CNS, CSD induction
promotes CGRP release in brain slices (Shi et al., 2010;
Tozzi et al., 2012) and cerebral cortex of rats (Wang
et al., 2016b). Moreover, the ability of exogenous CGRP
in abrogating the suppressive effect of A967079 on CSD
in the mouse brain slice (Fig. 4), suggests the involve-
ment of CGRP in cortical TRPA1 signaling in CSD. This
was supported by that reduction in cortical susceptibility
to CSD was observed by the anti-CGRP antibody, which
action was also reversed by exogenous CGRP (Fig. 3).
Consistently, prolongation of CSD latency was seen by
the CGRP receptor antagonist (Fig. 1). Collectively, we
propose that there may be a positive loop during CSD that
Ca2+ influx resulting from the opening of TRPA1 chan-
nels leads to CGRP release, acting on CGRP receptors,
which in turn regulates cortical susceptibility to CSD.
It was noted that reduction in CSD magnitude was
only observed by application of the anti-CGRP receptor
antibody but not the receptor antagonist. The reason to
account for this difference is not known, but it may be
related to that there are more than one CGRP
responsive receptors (Walker and Hay, 2013). CGRP
and CGRP receptor monoclonal antibodies are capable
of preventing migraine (Dodick et al., 2014; Bigal et al.,
2015; Walter and Bigal, 2015; Giamberardino et al.,
2017). So far, there is no clinical data available demon-
strating the effect of monoclonal anti-CGRP antibodies
on aura. Interestingly, a recent paper showed that Fre-
manezumab, a monoclonal anti-CGRP antibodies
(CGRP-mAb), can prevent the activation and sensitiza-
tion of high-threshold trigeminovascular neurons induced
by CSD (Melo-Carrillo et al., 2017), suggesting a potential
explanation for selectivity to migraine headache. While
anti-CGRP antibodies are thought to be of predominantly
peripheral site of action, our data on the anti-CGRP anti-
body in preventing CSD support the important role of
Fig. 5. Effects of the anti-CGRP antibody on CSD latency (A) and
magnitude (B) in the mouse brain slice. Three groups were designed:
the anti-IgG antibody at 0.025 mM (n= 6) as the control, the anti-
CGRP antibody at 0.4 mM in the absence (n = 6) or presence of 10.5
mM of CGRP peptide (n = 6). The data showed marked reduction in
cortical susceptibility to CSD by the anti-CGRP antibody. Data were
plotted as percentage of their initial levels and indicated as mean ±
SEM. Mann–Whitney’s U test, one-tailed, for significance between
control and antibody groups. **p< 0.01 was considered significant.
Representative traces of CSD wave in each group are shown in C.
(Unekawa et al., 2012; Guedes et al., 2017).
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CGRP in migraine with aura, which may have a central
site of action.
One limitation of this study is the large variation of the
image data within each group, which may be partly due to
each coronal section being prepared from slightly different
coordinates (between 1 and 3 mm posterior to bregma).
Another limitation of this study is that the conclusion
drawn largely replies the use of a group of agonists and
antagonists that are selectively binding to TRPA1,
further in vivo studies are necessary using TRPA1
knockout mice to clarify the role specific regions of
TRPA1 in CSD. Further, as TRPA1 is a sensor of
oxidative stress (Benemei et al., 2014; Yazgan and
Naziroglu, 2016) and the cysteine residues of TRPA1
channels are target of nitric oxide (NO) and NO nitrosyla-
tion (Yoshida et al., 2006), it remains to be further inves-
tigated how cortical TRPA1 channels interact with ROS
and NO during CSD.
In summary, we conclude that TRPA1 plays a critical
role in regulating cortical susceptibility to CSD involving
CGRP. These data suggest cortical functions of TRPA1
are involved in the mechanism of migraine aura.
Desensitization of TRPA1 channels and blockade of
CGRP would have therapeutic benefits in preventing
migraine with aura.
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